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Evidence exists which suggests that the expression of
certain genes is associated with the development of human
malignancy.
The aims of the work reported in this thesis were:
(i) to quantitate accurately the expression (ie
transcription) of selected important genes in human
breast cancer, to relate this to clinical and
pathological factors and to other genetic changes in the
tumours and
(ii) to develop a xenograft model in which to study the
effect of an anticancer agent on breast tumour gene
expression in vivo and thus to establish whether these
approaches might have therapeutic implications.
The particular approach used to achieve these objectives
was the development of molecular techniques to measure
gene expression and loss of genetic material at the
nucleic acid level.
Gene expression was measured in primary breast cancers
from 80 female patients and compared to that in normal
control tissues from other patients who had surgical
removal of normal breast tissue. Ribonucleic acid (RNA)
was extracted from the tumours and probed with
radiolabelled gene probes. Gene expression (messenger
RNA) was then quantified using laser densitometry on the
resultant Northern blots. Increased expression of three
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oncogenes (p53, c-myc, c-erbB-2), a growth factor gene
(TGF-fi) and an oestrogen regulated mRNA (pS2) was
detected in varying proportions of the tumours.
Overexpression of individual genes was found to correlate
significantly with different clinical and pathological
parameters.
Since the loss of specific regions of deoxyribonucleic
acid (DNA) is associated with oncogenesis, DNA was also
extracted from the paired venous blood and tumour tissue
of each patient. Allele loss specific to the tumour DNA
was then determined using Southern blots probed with
radiolabelled DNA. The p53 gene is located near the tip
of the short arm of chromosome 17 at 17pl3 and so this
region was examined for loss of genetic material.
Specific DNA loss in this region was demonstrated in 64%
of tumours. Loss close to, but not including, the p53
locus correlated with p53 overexpression. Using the
polymerase chain reaction, exons 5 and 6 of the p53 gene
were selectively amplified and subsequent sequencing
suggested the overexpressed p53 may be mutant and
oncogenic in at least some tumours. These results suggest
that chromosome 17p is important in breast cancer. Lack
of normal p53 tumour suppressor gene expression or
deletion of a nearby regulatory locus resulting in
overexpression of mutant p53 are proposed as key events
in the pathogenesis of breast cancer.
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A mouse xenograft model, based upon the oestrogen
dependent human breast cancer cell line MCF-7, was
established. Changes in specific gene expression measured
by mRNA production were demonstrated following oestrogen
stimulated growth of the xenograft tumours. Treatment
with the endocrine agent tamoxifen resulted in a high
level of TGF-J3 expression and a reduction in tumour size.
To examine the clinical relevance of these findings, the
level of TGF-B expression was determined in a subgroup of
11 patients treated with tamoxifen prior to surgery.
Tumours which increased in size despite tamoxifen
treatment were found to have high levels of TGF-B mRNA.
This suggests that such tumours have escaped the
growth inhibitory effect of TGF-B that may be
demonstrated in vitro and in the MCF-7 xenograft model
system.
It is concluded that the use of molecular approaches,
such as those employed in this work, will help not only
to elucidate the pathogenesis of breast cancer, but also
to clarify the mechanisms by which some forms of
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General considerations
Breast cancer is common. In the United Kingdom, one in
twelve women are affected (Fentiman, 1989), with breast
cancer cited as the cause of death in 15,073 women in
1985 (Forrest, 1986). World-wide, there were an estimated
572,100 new cases of breast cancer in 1980 (Parkin et
al. , 1988), the disease accounting for 15-20% of cancer
deaths and 2-5% of all deaths (Boyle, 1989) .
Due to the complex, dynamic nature of cancer and the
interactions between tumour and host, many factors have
been implicated in the dynamic process of carcinogenesis.
A number of epidemiological factors have been suggested
as risk factors for breast cancer. The incidence of
breast cancer is much higher in women than men, increases
with age (Doll, 1975), is higher in social classes I and
II (Kelsey, 1979) in urban than rural populations (Boyle,
1989) and in western compared to third world women
(Waterhouse et al., 1976) although migrating populations
acquire the cancer pattern of the new home in time.
Dietary factors (Kalsouyanni et al., 1987, Holm et al.,
1989) including alcohol (Longnecker et al., 1988),
vitamin D intake and high body mass (Rose, 1986) have
also been implicated, but little progress has been made
recently in our understanding of the epidemiology of
breast cancer and its relationship to the biology of the
disease (Boyle and Leake, 1988).
In recent years considerable attention has been paid to
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hormonal influences on the breast. Identified
environmental risk factors appear to relate mainly to
duration and periodicity of oestrogen exposure
(Aldercreutz, 1989). These influences can be considered
under three main headings: ovarian factors, external
hormonal influences and previous breast disease.
The role of ovarian function on the development of human
breast cancer relates to the menstrual cycle and child
bearing, with risk factors for breast cancer highest in
early reproductive life (Pike, 1987). Early menarche and
late menopause increase the risk of developing breast
cancer (Kelsey and Hildreth, 1983, Miller and Bulbrook,
1986), suggesting the cumulative number of cycles may be
important (Olsson et al., 1983) particularly as
oophorectomy is protective, with a greater reduction in
risk the earlier it is performed (Feinlib, 1969).
Late age at first full-term pregnancy or nulliparity
increases the risk of developing breast cancer (Miller
and Bulbrook, 1986); the protective effect of parity,
once thought to be explained by early maternal age at
first birth (MacMahon et al. , 1970), is in fact
independent of maternal age at first birth (Ewertz and
Lund, 1989). Lactation may cause hormonal changes (via
modulation of pituitary and/or ovarian activity),
resulting in a negative relationship between lactation
and breast cancer (Byers et al. , 1985). This is
independent of parity (Byers et al., 1985) with 5 or more
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children actually increasing the risk (Duffy et al. ,
1983). The effect of other reproductive factors (early
terminated pregnancies, spacing of childbirths and age at
last pregnancy) have not yet been defined.
A substantial proportion of British women are exposed to
external hormonal influences, particularly the oral
contraceptive pill and hormone replacement therapy.
Early suggestions of increased risk from oral
contraceptive pill use, particularly the early use of an
oral contraceptive pill (Pike et al., 1983) and increased
duration of total use have not been confirmed in large
studies with a high proportion of young women (Stadel et
al. , 1985, Paul et al., 1986).
The situation remains uncertain (Chilvers & Deacon,
1990) but even if one assumes one additional breast
cancer before the age of 35 years per 7,000 years of oral
contraceptive pill use , this effect is outweighed by the
reduction in risk of ovarian and endometrial cancer (Kay
and Hannaford, 1989).
Similarly, although studies of hormone replacement
therapy have shown a minimal association with the
development of breast cancer (Kelsey & Berkowitz, 1988),
evidence from prospective studies suggests an association
with long-term hormone replacement therapy is likely
(Hunt et al., 1987).
Nevertheless, there is no clear evidence that an
excessive oestrogenic stimulus is a determinant in the
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initiation and promotion of breast cancer (Bulbrook et
al., 1989). However, both oestrogen and progesterone may
be involved in breast carcinogenesis as evidenced by the
antitumour effects of the oestrogen antagonist tamoxifen
(Stewart et al., 1989) and the use of progestins in the
treatment of breast cancer (Chamness, 1989).
Some women with a past history of benign breast disease
have an increased risk of breast cancer (Roberts et al.,
1984) probably confined to epithelial proliferation
lesions (Page et al., 1987, Tavassoli & Norris, 1990),
with benign breast disease, hyperplasia and hyperplasia
with cellular atypia progressively increasing the
relative risk of breast cancer by factors of 1.5, 1.9 and
3.0 respectively (Carter et al., 1988).
The only direct cause and effect relationship for breast
cancer is with ionising radiation. Studies of radiogenic
breast cancer in female survivors of the Japanese A-bomb
(Takunaga et al. , 1982), breast cancer mortality in
tuberculosis patients who had multiple fluoroscopies
(Howe, 1984), patients who received radiotherapy for
benign breast conditions (Baral et al., 1977) or for
intrathoracic lymphoma (Anderson & Lokich, 1990)
demonstrate an increased risk with increasing dose,
decreased risk with increasing age at exposure and
latency of at least 10 years (Hindreth et al. , 1989,
Miller et al., 1989). Ionising radiation damages cells by
disrupting, by whatever means, the genetic material of a
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cell.
In addition, evidence for a genetic (familial)
predisposition to breast cancer has been recognised since
Roman times (reviewed in Lynch et al., 1984).
It is claimed that at least 5% of breast cancers have a
hereditary basis, rising to 11.5% of cancers diagnosed
before the age of 50 (Lynch et al., 1984). Such
patients, according to Lynch, characteristically have an
early age of onset, excess of bilaterality and multiple
primaries, vertical transmission (mother to daughter)
within the family and impaired survival compared to
sporadic breast cancer (Lynch et al., 1984). The issue of
early age of onset in familial cases is still contentious
and the findings may be influenced by biased
ascertainment of cancer families (Tulinius, 1989).
However, there is certainly an increase in incidence of
breast cancer in the close female relatives of breast
cancer patients compared to the general population
(Kelsey, 1979) rising to a 9 fold increase in age-
specific risk in the first degree female relatives of a
premenopausal breast cancer patient with bilateral
disease (Anderson, 1971).
Although little recent progress has been made in our
understanding of the epidemiology of breast cancer (Boyle
and Leake, 1988), the cumulative body of evidence from
the epidemiology, biology, particularly the radiobiology,
and family studies of breast cancer suggests that the
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fundamental abnormalities in breast tumorigenesis lie at
the molecular level of nucleic acids which comprise the
genetic material of the cell.
To understand the molecular mechanisms which underlie
breast cancer it is helpful first to review the multistep
theory of carcinogenesis which encompasses the concepts
of tumour suppressor genes and oncogenes. This leads to
consideration of nucleic acid studies (DNA and mRNA) in
relation to specific genes.
Multistep theory of carcinogenesis
The evidence for a clonal origin of tumours, even of
those in which the progeny of a single cell have
diversified to heterogeneous cell phenotypes, is
compelling (Bishop, 1987) . Tumour cells therefore become
increasingly different from the host with derangement of
functions controlling growth and differentiation (Vile,
1989), metabolism of precarcinogens to carcinogens,
impaired DNA repair mechanisms, or altered immune
surveillance (Friend et al., 1988).
The thesis that carcinogensis is the cumulative effect of
a series of discrete genetic lesions (Friend et al.,
1988) was first proposed by Nordling (1953). The
epidemiology of the age specific incidence of several
common cancers suggested 6 or 7 events were required
(Armitage & Doll, 1954). The requirement for cumulative
events in the evolution of a single tumour to explain the
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limited penetrance of any one cancer gene was
subsequently modified to suggest as few as 2 mutations
were required for carcinogenesis where an external factor
(such as hormonal influences in the breast) might confer
a slight growth advantage on the altered cells (Armitage
& Doll, 1957). While an autonomously oncogenic single
mutation in the germ line would probably be lethal (any
target cell would be malignant), a non-lethal
constitutional abnormality is conceivable. It would
necessarily be less severe and probably require another
event to produce cancer, one step perhaps involving
immortalisation and the other involving transformation.
Further evidence for at least 2 hits (Knudson, 1971) came
from observations on 48 cases of the ocular childhood
tumour, retinoblastoma and subsequently from a few other
rare heritable tumours with high penetrance.
Precancerous lesions in the hereditary form of a cancer
are multicellular in origin (resulting from local
phenomena that affect numerous cells) but malignant
tumours arising from these are clonal in origin resulting
from a rare event that affects a single cell (Knudson,
1985).
Molecular analysis of common tumours such as colorectal
cancer (Vogelstein et al., 1989) points increasingly to
the presence of multiple abnormalities at the DNA level;
however malignant cells tend to accumulate multiple
aberrations in their DNA including gene deletions (Povey
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et al.( 1980, Sondberg, 1980) and it is unlikely that all
of these contribute to the malignant state.
Genetic loci may be important in either the initiation or
progression of tumours (Bishop, 1987, Vile, 1989), with
cells already capable of abnormal proliferation becoming
more aggressive (Bishop, 1987). There may be genetic
variation in the pathways of tumour progression (Hall et
al., 1989), with sequential selection of subclones, on
the basis of accumulated oncogenic events that alter
sensitivity to external signals and hence confer a
proliferative advantage (Cline et al., 1987, Steel,
1989). Such events may involve oncogene activation
(c-k-ras), loss of oncogene expression (v-abl) or no
discernable change in oncogenes (reviewed in Nicholson,
1987), loss of tumour suppressor function, the emergence
of drug resistance or loss of intimate intercellular
contacts (Steel, 1989). The propensity for metastasis
may be linked to disordered function of oncogenes
encoding cytoskeletal elements (reviewed in Waxman and
Sikora, 1988). Indeed, oncogene expression (for example
of the protein p21 - Ohuchi et al. , 1986) may be a
feature of earlier rather than later stages of mammary
carcinogenesis, so oncogene expression may contribute to
carcinogenesis rather than determine metastatic
progression (Nicholson, 1987). Conversely, in breast
cancer families, it has been suggested that oncogenes may
be involved in tumour progression rather than as primary
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alterations leading to breast cancer (Hall et al., 1989).
The hypothesis that somatic mutations lead to cancer
implies that there are critical genetic loci the mutation
of which leads to cancer (Knudson, 1985). The isolation
of candidate genes involved in the aetiology of human
cancer has resulted from 3 main approaches: transfection
studies using DNA from human tumours and immortalised
cell lines, the study of tumour-producing viruses and
molecular comparisons of malignant and non-malignant
tissues. This has led to the identification of 2 groups
of important genes: tumour suppressor genes and
oncogenes.
Tumour Suppressor Genes
Tumour suppressor genes (also variously termed
oncosuppressor genes, anti-oncogenes, recessive
oncogenes, orthogenes, emergenes or plato-genes) are
defined as genes the deletion, reduced expression or
inactivation of which contributes to carcinogenesis.
Tumour suppressor genes were originally recognised when
cancer cells, fused with normal cells resulted in non-
tumorigenic hybrids (Harris et al., 1969, Harris,
1988) although expression of the transforming gene was
not down-regulated. Some cells subsequently shed
specific chromosonal material resulting in reversion to
the tumorgenic phenotype of transformed morphology, low
serum requirements and lack of contact inhibition
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(Harris, 1988, Stanbridge, 1988). As a refinement of
this early work, specific DNA fragments introduced into
a cell were found to suppress the tumorigenic phenotype
(reviewed in Hansen and Cavenee, 1988) the clearest
example of which remains the effect of the normal
retinoblastoma gene introduced into a retinoblastoma
derived cell line (Huang et al., 1988).
Tumour suppressor genes may also play a role in
terminating embryogenesis where genes active during
embryogenesis (transforming genes) are suppressed at
differentation by dominant suppressor genes.
In Drosophila, 25 or more recessive genes have been
implicated in developmental tumours. Reintroduction of
the missing gene fragment into the germline (mutant lava)
prevents tumorigenesis and unblocks differentiation
arrest (reviewed in Anderson and Spandidos, 1988) .
In mammalian cells, loss of growth suppressor genes from
a cell removes the cell from normal growth constraints
(Weinberg, 1988) . Such genes are regarded as recessive
since both copies of the gene must show loss of function
to allow neoplastic development (Vile, 1989) . Moreover,
it has long been held (Knudson, 1985), that if genes are
important in the origin of common tumours, it is
improbable that only one dominantly expressed genetic
locus is involved.
The concept of tumour suppressor genes was shown to be
directly relevant to human malignancy following studies
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of retinoblastoma, a paradigm for hereditary cancer in
humans (reviewed in Murphree Sc Benedict, 1984). Knudson
(1971) first proposed an explanation for the familial and
sporadic forms of retinoblastoma, a childhood tumour of
the retina of the eye, based on mathematical analysis of
the disease.
In the familial form, one retinoblastoma locus or gene on
13ql4 (Yunis, 1978) is inherited in a defective,
nonfunctional form as a germ line event. Only a single
further somatic lesion of the retinoblastoma gene is
required to cause a tumour and this may be a
submicroscopic mutation, deletion, genetic recombination
- with or without duplication - or chromosome loss
(Cavenee et al., 1983, Knudson, 1985). Thus multiple
tumours can occur. In the sporadic form, both
retinoblastoma loci are intact and so 2 "hits" or somatic
mutations/deletions in the same cell are required to
inactivate the tumour suppressor function of the
retinoblastoma protein and thus sporadic tumours are
invariably single.
This may be explained on biochemical grounds. The
retinoblastoma gene encodes a protein that binds to other
proteins in the nucleus, possibly forming a complex that
regulates cellular differentiation (Friend et al., 1986).
The retinoblastoma protein also binds to DNA tumour virus
proteins (Whyte et al., 1988, De Capiro et al. , 1988)
suggesting that some oncogenic viruses may act by
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sequestering tumour suppressor gene products (Windle et
al. , 1990) thereby blocking cell differentiation
(Vile,1989). Functional inactivation of the
retinoblastoma tumour suppressor genes (by whatever
means) therefore removes a barrier to cell proliferation,
allowing inappropriate expansion of a cell clone (Friend
et al., 1988). Conversely, reintroduction of the normal
retinoblastoma gene renders a retinoblastoma-derived cell
line non-tumorigenic (Huang et al., 1988).
Similar strong evidence for tumour suppressor genes in
familial tumours has emerged in particular from studies
of Wilm's tumour (the gene for which is located on llpl3,
Franke et al., 1990) and familial adenomatous polyposis
(FAP; Bodmer et al., 1987). Familial tumours in general
seem to be associated with inactivated or deleted loci,
compatible with loss of tumour suppressor gene function.
Tumour suppressor genes may act pleiotropically in the
differentiation programs of several cell types (Vile,
1989): for example, such functions have been suggested
for the retinoblastoma gene in small cell lung cancer
(Harbour et al., 1988) and in breast cancer (T'Ang et
al., 1988). Overall, the case for tumour suppressor gene
malfunction in human cancer is strong.
Oncogenes
Oncogenes can be defined as any gene, the activation
overexpression or amplification of which contributes to
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turaorigenesis and disordered proliferation or
differentiation.
The evidence for oncogenes came initially from viral and
gene transfection studies. Acutely transforming
oncogenic viruses contain not only the "gag" (core
antigen) "pol" (reverse transcriptase) and "env"
(envelope protein) found in slowly transforming viruses
but also an "one" gene specific to each virus and
responsible for the induction of malignancy in infected
cells (Bister and Duesberg, 1982). These oncogenes are
homologous to human DNA sequences "proto-oncogenes",
(Stehelin et al., 1976, review in Slamon et al., 1987)
and probably arose from the DNA of higher organisms
including man (Stehelin et al., 1976, Bishop, 1981). In
their new setting of retrovirus DNA, these cellular genes
may be oncogenic (Bishop, 1987), particulary when viral
DNA is reintegrated into chromosomal DNA (Bishop, 1987).
Although over 20 oncogenes have been identified among
DNA and RNA tumour viruses (Bishop, 1983 ), and the
central role of certain oncogenes in tumorigenesis due to
chronic transforming retroviruses such as avian leukosis
virus has been established (Hayward et al., 1981) there
remain few examples in humans. Burkitt's lymphoma
(Epstein-Barr virus), hepatocellular carcinoma (hepatitis
B) , cervical and laryngeal carcinoma (human papilloma
virus) are generally attributed to DNA viruses and AIDS
related malignancies to the Human immunodeficiency RNA
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virus. However, a viral "one" gene has not been
unequivocally implicated in any of these instances and
other, less direct mechanisms may be at work.
Gene transfection, that is the experimental uptake of DNA
from human tumours or tumour cell lines into cells (such
as the immortal NIH3T3 or C127 mouse fibroblasts) in
vitro. can transform the cells (Shih and Weinberg, 1982).
These transformed cells are tumorigenic in
immunosuppressed mice, suggesting that the DNA
responsible for the original tumour has been integrated
into the transformed cell DNA (Krontiris and Cooper,
1981, Porteous et al., 1986).
However, the mere process of DNA uptake may itself induce
genetic instability (Kerbel et al., 1987) and normal
cells (as opposed to the immortal NIH3T3 or C127 cells)
may require co-transfection with at least two different
oncogenes (Land et al., 1983) for transformation to occur.
Out of some 50,000 human genes, fewer than 100 may be
oncogenes (Weber and McClure, 1987) . Proto-oncogenes are
normal componants of cellular DNA, their scheduled
expression being necessary for the proper growth and
differentiation of cells (Nicholson, 1987, Anderson and
Spandidos, 1988) as supported by the homology between the
proto-oncogene c-sis and platelet derived growth factor
(Heldin and Westermark, 1984) with adjacent sequences
serving to prevent unscheduled activation (Anderson and
Spandidos, 1988). Proto-oncogenes behave as oncogenes
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when activated, giving cells a continuous signal to
proliferate and thus blocking specific steps in cellular
differentiation (Vile, 1989).
Oncogenes may be classified according to the mechanism by
which they arise from the normal proto-oncogene DNA. The
transition from normal proto-oncogene DNA to oncogene may
be due to mutation for example ras point mutation at
codons 12 or 61; (Reddy et al. , 1982, Goldfarb et al.,
1982) resulting in the production of an abnormal protein
product, truncation (src, fms) or fusion (abl/bcr).
Translocation of a gene may affect the expression or
biochemical function of that gene (Bishop, 1987) - for
example chromosome 8 to 14 translocation of c-myc in
Burkitt's lymphoma results in inappropriate production of
c-myc as a consequence of disruption of exon 1 of the
gene (Klein et al., 1981, Taub et al. , 1984, Leder et
al., 1986, Bishop, 1987) and failure to terminate c-myc
expression with B-cell differentiation (Curran et al.,
1984, Gonda et al., 1984).
While normal levels of proto-oncogenes may be adequate
for cell division, supra-normal expression may be of
significance (James et al., 1988). Overexpression may
result from multiple gene copies (amplification) (Semba
et al., 1985), a feature which frequently affects proto-
oncogenes that regulate cell proliferation and may
persist in dividing cells if it provides a selective
advantage (reviewed in Bishop, 1987). Thus,
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overexpression of a gene product such as c-erbB-2 (Slamon
et al. , 1989) or normal H-ras protein p21 (Pulciani et
al., 1985) may be an important pathogenic event in some
tumours. In addition, rearrangements or deletions may
influence the activity of such genes.
Alternatively, oncogenes can be grouped according to the
type of their product action rather than how they
arise (James et al., 1988) (figure 1). For example,
growth factors (platelet derived growth factor,
transforming growth factors), growth factor receptors
(epidermal growth factor receptor, c-erbB-2), G proteins
(Ras), intracellular transducers (abl) or nuclear acting
oncogenes affecting gene expression (myc).
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Figure 1 : A classification of oncogenes according to the
site of action.
TGF-a
A diagraraatic representation of genes
potentially involved in carcinogenesis. Examples include
growth factors such as platelet derived growth factor
(PDGF) , transforming growth factors (TGF-a and TGF-J3) ,
epidermal growth factor (EGF), colony stimulating factor
(CSF1) and insulin-like growth factors I and II (IGF I
and IGF II); growth factor receptors including epidermal
growth factor receptor (EGFR), growth factor receptor¬
like genes c-erbB-2, sis and fms; G proteins (H-ras,
N-ras, K-ras) and nuclear acting genes (c-myc, N-myc,
L-myc, myb, fos and p53).
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In addition, while oncogenes may be involved in the
pathogenesis of cancer, in certain situations they may
play a role in tumour progression (N-myc in
neuroblastoma; Brodeur et al., 1984) or the organisation
of a different phenotype for example v-H-ras transfection
of hormone dependent MCF-7 cells can confer hormone
independence (Kasid et al., 1987).
The distinction between dominant oncogene expression and
recessive tumour suppressor genes expression is
essentially functional. Indeed, one gene may act as
a tumour suppressor gene or an oncogene under different
circumstances; for example the oncogenic effect of mutant
ras is enhanced by deletion of the residual normal gene
(Anderson and Spandidos, 1988). Oncogenes appear to play
a major role in cell proliferation during histogenesis
(Knudson, 1985) . The normal proto-oncogene and tumour
suppressor genes are thus involved in growth and
differentiation signalling (Bishop, 1988) with the
inactivation of tumour suppressor genes as important as
the activation of oncogenes (Friend et al., 1988). It is
not surprising therefore that the activation of one or
more oncogenes occurs as cumulative steps on the route to
colonic cancer (Vogelstein et al., 1988) and this model
may be valid for other human malignancies.
A third key factor in tumorigene sis, with tumour
suppressor genes and oncogenes, may be the influence of
growth factors in the promotion of carcinogenesis.
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Growth Factors
Transformed cells have relaxed cell cycle control and may
traverse the cell cycle in the absence of exogenous
growth factors (Heldin & Westermark, 1984). Growth factor
independence and autonomous growth of transformed cells
may be due to autocrine growth factor production,
enhanced receptor expression or subversion of the
intracellular signal system that ultimately leads to the
initiation of DNA synthesis (Heldin & Westermark, 1984).
Alternatively, it may be due to loss of responsiveness to
growth inhibitory signals, or to any combination of these
mechanisms.
The ability of many oncogenes to confer growth factor
independence on cancer cells usually seems to be related
to their alteration of a receptor or of a post receptor
signalling pathway (making activation of the receptor
independent of the effector), rather than to a primary
alteration in the synthesis and release of a specific
growth factor (Sporn & Roberts, 1985). Enhanced cell
response to a growth factor may result form a change in
the number or affinity of receptors for the growth factor
(Sporn & Roberts, 1985) or to a change in the sensitivity
of the post-receptor signal pathway.
Many types of tumour cells release polypeptide growth
factors (eg transforming growth factor-alpha, platelet
derived growth factor, transforming growth factor-B) into
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their conditioned medium when grown in cell culture and
these same tumour cells often possess functional
receptors for the released peptide (Sporn & Roberts,
1985) .
Just as homology between the oncogene c-sis and platelet
derived growth factor suggest that an oncogene may code
for a growth factor, expression of a viral oncogene may
turn on the production of a cellular growth factor that
results in the transformation of a cell (reviewed in
Heldin & Westermark, 1984).
Another feature of the relationship between growth and
oncogenes is illustrated by the functional similarities
between some oncogene proteins and growth factor
receptors (for example epidermal growth factor and
c-erbB-2; Semba et al., 1985). This is consistent with
the observation that the inner aspect of the cell
membrane is the major site of action of the tyrosine
kinases associated both with oncogene products and with
growth factor receptors (reviewed in Heldin & Westermark,
1984) .
Growth factors often function in a localised manner,
acting either on the cells which themselves have produced
the growth factor (autocrine action) or on neighbouring
cells (paracrine action). Stimulation of cells by an
abnormal growth factor could result in a polyclonal
proliferation of pre-neoplastic cells, mutation within
which would lead to an apparently monoclonal tumour
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(Editorial, Lancet, 1986). In addition, growth factors
may have important roles in tumour promotion (James et al
1988), with the response of a cell to a given growth
factor changing from enhanced proliferation at one stage
to growth arrest later on (Steel, 1989). The tumour
promoting effects of growth factors may sometimes be
secondary to an inability of the cells to progress to an
advanced state of differentiation (Steel, 1989).
Negative autocrine growth factors may themselves control
aberrant cell growth and malignant transformation or
promotion may be due to failure of cells to synthesis,
express or respond to negative growth factors (Sporn &
Roberts, 1985). Thus loss of normal inhibitory signals
may be at least as important as growth promoting factors
in tumorigenesis (Editorial, Lancet, 1986).
Modifications of the extracellular matrix and stroma can
lead to alterations in gene expression and cell phenotype
(reviewed in Nicholson, 1987). The final growth rate is
the net result of the joint effect of positive and
negative factors and separate mechanisms account for
these individual effects.
In the MCF-7 breast cancer cell line, studies of growth
associated polypeptides show that insulin like growth
factor-I, transforming growth factor-alpha and platelet
derived growth factor may be induced by oestrogen (Kasid
& Lippman, 1987). Thus, aberrant production of growth
factors, triggered either by activated oncogenes and
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oestrogen stimulation in hormone dependent cells, or by-
increased constitutive production in hormone-independent
cells may be associated with the neoplastic growth of
breast cancer in an autocrine, paracrine or endocrine
manner (Kasid & Lippman, 1987).
Cell to cell interactions are also be important as highly
metastatic mammary epithelial cells often fail to
communicate via cell junctions, while counterpart benign
or normal epithelial cells are tightly coupled
(Nicholson, 1987).
The Molecular biology of breast cancer
Evidence from familial, epidemiological, cytogenetic
and molecular genetic studies support the notion that
cancer is a profoundly genetic disease (Hansen and
Cavenee, 1987) . The molecular approach to cancer based on
these concepts of multistep carcinogenesis involving
tumour suppressor genes, oncogenes and growth factors has
been applied to breast cancer in cytogenetic,
deoxyribonucleic acid (DNA) and messenger ribonuceic acid
(mRNA) studies.
Cytogenetics
Despite the technical difficulties of cytogenetic
analysis of solid tumours, studies of direct tumour
preparations using Giemsa-banding techniques have
demonstrated aberrations of chromosomes 1, 3, 5, 6, 9,
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10, 11, 12, 15, 16, 17, 18, 21 (Pathak and Goodacre,
1985, Ferti-Passantonopoulou and Panani, 1987) with
chromosone lq most frequently involved. Such cytogenetic
studies alone are relatively crude but do suggest
possible loci for further, more detailed examination.
DNA Studies
Cancer family studies
Cancer families may be defined as families in which 2 or
more relatives, including the proband, are affected
within the modified nuclear pedigree - that is including
grandparents, aunts and uncles (Lynch et al., 1984).
Three important concepts of familial cancers have been
established (Knudson, 1989).
1. In familial cases, an inactive/physically deleted
gene is inherited.
2. The inherited defect alone is insufficient to cause
the cancer, one or more further somatic events are
required.
3. Genetic loci of familial cancer may also be the
sites of somatic mutation/deletion or chromosonal
translocation in sporadic tumours of the same
histological type. Hence, analysis of molecular lesions
in sporadic tumours may identify candidate loci for
cancer susceptibility genes in cancer families.
In familial breast cancer (reviewed in Schneider et al. ,
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1986), analysis of such families suggests that breast
cancer may be transmitted as an autosomal dominant trait
with high penetrance (Newman et al., 1988). A disease
allele frequency of 0.7% and penetrance varying with age
has been suggested (Williams and Anderson, 1984) .
A candidate locus, identified by the glutamate-pyruvate
transaminase (GPT) gene on chromosome 16 was suggested
(King et al. , 1980) but not subsequently confirmed
(King et al., 1983). More recently, exclusion of genetic
linkage to oncogenes (including H-ras, myc and int 2)
in breast cancer families has been demonstrated (Hall et
al., 1990). A recent review of segregation analysis
concludes that the existence of a single major gene is
not sufficient to explain familial distribution of breast
cancer, suggesting the genetic basis is heterogeneous and
complex (Andrieu et al., 1989). Thus, the genes involved
in familial breast cancer remain obscure. However, the
concept that the same region of the genome is involved in
familial and sporadic cancers is now well established,
for example in retinoblastoma (Cavenee et al., 1983) and
for familial polyposis coli (FAP) (which invariably
progresses to colon cancer) and sporadic colorectal
cancer (Solomon et al., 1987, Ashton-Rickart et al.,
1989). These studies suggest that advancing knowledge of
sporadic breast cancer may yet yield dividends for breast
cancer families.
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DNA changes in sporadic breast cancer.
The possibility of developing a blood lymphocyte DNA
marker for breast cancer, in the form of rare alleles at
the Harvey ras locus on chromosome lip (Krontiris et al.,
1985, Lidereau et al. , 1986, Saglio et al., 1988) no
longer seems viable (Corell and Zoll, 1988, Sheng et
al., 1988, White et al., 1988, Mackay et al. , 1988a)
particularly as a test of the familial susceptibility to
breast cancer (Hall et al. , 1990). However, somatic
changes in the tumour DNA fingerprint were identified
using mini-satellite probes in 2 out of 4 breast cancers
studied (Thein et al., 1988). Further studies of allele
losses from specific chromosomal loci (consistent with
possible tumour suppressor gene deletion or loss of
function) and other genetic abnormalities in breast
cancer implicate loci on chromosones 1, 11, 13 and 17 in
sporadic breast cancer.
A common region of deletion of 26 centimorgans on lq 23-
32 has been demonstrated in a quarter of 48 breast
cancers with allele loss (Chen et al., 1989) compatible
with cytogenetic studies (Pathak and Goodacre, 1985,
Ferti-Passantonopoulou and Panani, 1987) .
Allele loss for H-ras (llpl.4) has been demonstrated in
8.6% to 27% of breast cancers (Theillet et al. , 1986,
Yokota et al., 1986a, Mackay et al., 1988a, Biunno et al.,
1988, Lidereau, 1988), correlating with various poor
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prognostic tumour features. Several loci on lip may be
involved (Ali et al., 1987) and 39% (19/49) tumours show
allele loss of informative loci on chromosone 11 (Mackay
et al., 1988a) but no consistent region of deletion.
Turning to the long arm of chromosome 11, heterozygous
female carriers for the ataxia-telangiectasia gene on
chromosone llq22-23 (Gatti et al. , 1988) have increased
risk of breast cancer (Swift et al., 1987).
On chromosome 13, allele loss from 13q was found in human
ductal breast cancers (Lundberg et al., 1987). Specific
studies of the retinoblastoma locus on 13q demonstrated
rearrangements in 19% of primary breast tumours (Varley
et al., 1989).
Allele loss from the tip of 17p (at 17p 13.1) has
recently been demonstrated (Mackay et al., 1988b, Devilee
et al., 1989a, 1989b) in about 2/3 of breast tumours
which bears comparison with 17p allele loss in 80% of
colorectal cancers (Fearon et al.,1987). Loci already
yielding significant frequencies of allele loss in other
tumours such as chromosomes 5, 6, 8 and 18 (Vogelstein
et al. , 1989, Ashton-Rickart et al., 1989, Ehlen & Dubeau,
1990) may also merit further study.
Just as allele loss or gene mutation may represent loss
of tumour suppressor gene function, the contribution of
oncogenes to breast carcinogenesis may be deduced from
the observed amplification of myc and erbB-2 oncogenes in
breast cancers, discussed in a later section. Similarly,
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a combination of allele deletions and oncogene
amplification was demonstrated in 58% of 53 primary
breast cancers (Cline et al. , 1987). However, doubt
continues to be expressed as to whether, in the germline,
loss of a single allele at any of the loci listed above
will lead to an increased risk of developing cancer
(Vile, 1989) or whether the altered sequences observed in
primary breast cancer are merely epiphenomena (Hall et
al., 1989). One further consideration is that epigenetic
mechanisms such as DNA methylation, may play a role in
phenotypic expression (Nicholson, 1987).
Indeed, the function of cancer cells may be more
important than structural modifications. For example,
transcriptional activation of the erbB-2 gene may precede
amplification of erbB-2 in early tumours (Borg et al.,
1989, Slamon et al., 1989) and some genes amplified in
breast cancer are not expressed (for example erbA, van de
Vijver et al.,1987). Hence, the expression of genes
merits considerable attention. While measurements of
gene protein products can be informative, some tumours
produce mRNA but no protein can be detected (Yokota et
al . , 1988). Moreover, messenger RNA transcription
(synthesis) is the most common and immediate focal point
of genetic regulation in eukaryotic cells (Johnson and
McKnight, 1989). Therefore, detection and quantitation
of mRNA will give direct evidence for functional genetic
changes which may be important in carcinogenesis.
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Messenger RNA
Messenger RNA (single stranded) is faithfully transcribed
from double stranded DNA (figure 2), with the possibility
of alternative sites of transcription initiation, to form
precursor mRNA comprising exons (coding sequences) and
intervening introns (non-coding).
Introns are removed from mammalian RNA precursors (pre-
mRNA's) by two successive cleavage and splicing
reactions; this involves formation of a "lariat" with
subsequent release of the intron mediated by
spliceosomes, which are ribonucleoprotein particles
(snRNPs) (reviewed in Robertson, 1988). Indeed, an intron
has recently been identified within a gene that encodes a
spliceosomal RNA (Tani & Ohshima, 1989). Transcripts can
be differentially spliced (and in Drosophila this may
determine the organism's sex; Robertson, 1988).
Thereafter there is addition of a 5'cap and variable
polyadenylation at the 3' end to form a 3'tail.
Subsequent translation of the nucleotide sequence occurs,
with AUG acting as a signal to start protein synthesis
(translation) from the mRNA; three triplets (UAA,UAG,UGA)
act as termination signals (reviewed in Kingston, 1989).
The resultant protein may subsequently undergo
considerable post translational modification.
From a given gene, different mRNA products may be formed
in the same tissue, in different tissues and at different
stages of development.
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A diagramatic representation of messenger RNA formation
and function. From double stranded DNA, precursor single
stranded mRNA is transcribed, introns are removed by
formation of a lariat and release of the exons which are
spliced together. Following addition of a 5' cap and 3'
tail, the mRNA is translated to the protein product.
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Formation of the precursor mRNA by transcription may be
regulated by non-coding regions in the DNA - in the 5'
flanking region the TATA box and the CAT box - by other
enhancer sequences and by variation in the extent of
cytosine methylation. Transcription may also be
influenced by more distant regulatory elements on the
same or on other chromosomes. One aspect of this is the
concept of imprinting (Monk, 1987), the selective
inactivation of a locus, without loss, dependent on
passage through male or female gametogenesis. In Wilms'
tumour, there is evidence that the paternal chromosome
11 allele is retained but inactive due to imprinting
(Wilkins, 1989). Allele losses in a few cases of Wilms
tumour show a bias towards retention of the paternally
derived chromosome in the tumour (Schroder et al., 1987)
supporting this concept of epigenetic effects caused by
imprinting (Ponder, 1988). Gene expression can be
differentially regulated by use of distinct promotors
and mRNA alternatively spliced to create numerous
isoforms (Feener et al., 1989). Interaction of cis acting
negative regulatory elements (on the same chromosome)
with proteins may be important for control of gene
expression (Anderson & Spandidos, 1988).
Interactions between sequences within each mRNA can
contribute to the stability of the mRNA (Kabnick &
Housman, 1988) . One example of this is the way in which
disruption of the non protein coding exon 1 of the c-myc
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gene increases the mRNA stability (Klein et al. , 1981,
Taub et al. , 1984, Leder et al., 1986, Bishop., 1987)
allowing post-transcriptional regulation of c-myc gene
expression through control of mRNA degradation.
Alternatively, a protein such as c-fos may regulate its
own synthesis by binding to its own mRNA (reviewed in
Anderson & Spandidos, 1988).
Thus, transcription of genes from DNA to mRNA and the
subsequent fate of the genetic message is a complex
matter. It is, however, amenable to investigation in
malignancy. Initial studies of human tumours suggested
that several oncogenes were overexpressed in some breast
cancers (for example myc, ras, fes, fms, Slamon et al. ,
1984, Whittaker et al., 1986). The oncogenes implicated
in breast tumorigenesis include c-myc, c-erbB-2,
H-ras, int 1 and int 2, c-fos, and c-mos. Each one of
these oncogenes merits some individual consideration.
q-myq
c-myc is the cellular human homologue of the principle
oncogenic sequence carried by the avian
myelocytomatosis acute retrovirus MC29 (Morse et al. ,
1988). Located on chromosone 8q24 (Dalla-Favera et al.,
1982) and expressed in a wide variety of mammalian cell
types (Marcu, 1987), the c-myc gene comprises 3 exons
(the first non-coding) and 2 introns (Watt et al., 1983,
Croce, 1986), encodes a 2.2 to 2.5 kb mRNA (Ar-Rushdi et
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al., 1983, Alitalo et al., 1983, Erisman et al. , 1985,
Guerin et al. , 1985, Escot et al., 1986, Dubik et al.,
1987) that is translated to a 62 kd nuclear
phosphoprotein (Stone et al., 1987). c-myc is involved in
cell cycle regulation promoting G0/G1 transition (Parkin
& Sonenberg, 1989), shortening G1 phase (Karn et al.,
1989) and inhibiting terminal differentiation (Dmitrovsky
et al., 1986). It has recently been suggested that c-myc
may promote cellular DNA replication by binding to the
origin of DNA replication (Iguchi-Ariga et al., 1987).
Activation of c-myc has been demonstrated in a wide range
of human malignancies (reviewed in Escot et al., 1986)
and expression of the myc gene in transgenic mice results
in mammary cancers (Stewart et al., 1984)
However, recent evidence suggests that aberrant
expression rather than mutation is the method of
oncogenic conversion (Lang et al., 1988).
Amplification of c-myc by 2-15 fold has been identified
in up to 35% of breast tumours (Guerin et al. , 1985,
Escot et al., 1986, Yokota et al., 1986a, Varley et al.,
1987b, Adnane et al., 1989, Nikiforova, 1988, Sheshadri
et al . , 1989, Tavassoli et al., 1989 ). Although
amplification is more frequently found in recurrent and
metastatic tumours (Lidereau et al., 1988) it has been
identified in benign lesions (Varley et al. , 1987a,
Bonilla et al., 1988).
Rearrangements of the c-myc gene have been demonstrated
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in a small proportion of breast tumours (Escot et al.,
1986) may result in increased disease aggression (Varley
et al. , 1987a) and in one study 27/48 (56%) of breast
tumours showed c-myc amplification and/or rearrangement
(Bonilla et al., 1988). c-myc amplification has been
correlated with large tumour size (Seshadri et al.,
1989), tumour aggression (Yokota et al., 1986a), poor
short term prognosis (Varley et al., 1987a), age over 50
years and tumour type (Escot et al., 1986).
However, overexpression of c-myc may occur in the
absence of c-myc amplification (Escot et al. , 1986) and
early studies suggested myc expression could be detected
in a high proportion of breast cancers (Whittaker et al.,
1986). Furthermore, increased c-myc expression was
associated with a high degree of malignancy in breast
tumours (Guerin et al., 1985) and the antiproliferative
effects of transforming growth factors have been
associated in some target cells with selective reduction
in the expression of c-myc (Kimchi et al., 1988).
c-erbB-2
The erbB-2 oncogene was initially identified in a series
of ethylnitrosourea induced rat neuroblastomas (Shih
et al., 1981). c-erbB-2 has also been termed neu (Shih et
al., 1981), HER-2 (Coussens et al., 1985), MAC 117 (King
et al., 1985) and NGL (Kokai et al., 1988), although
sequence homology of c-erbB-2, neu and HER-2 has been
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confirmed (Coussens et al., 1985, Schecter et al., 1985).
Located on 17q 12-22 (Coussens et al., 1985, Schecter et
al., 1985, Fukushiga et al., 1986, Popescu et al., 1989)
the gene encodes a 4.4 to 4.8 kb mRNA ( King et al. ,
1985, Semba et al., 1985, Kraus et al., 1987, Slamon et
al. , 1987, van de Vijver et al., 1987) that is
translated into a 185kd protein (Schecter et al., 1985)
with 74% to 78% homology to, but distinct from, the
transmembrane and cytoplasmic domains of the epidermal
growth factor receptor (Semba et al., 1985, Coussens et
al. , 1985). The ligand that binds to this putative
receptor (the extra cellular domain) remains obscure but
presumably activates the intracellular domain with
tyrosine kinase activity (Yamamoto et al., 1986).
c-erbB-2 can induce transformation (Shih et al., 1981, Di
Fiore et al., 1987, Hudziak et al., 1987) in NIH 3T3
cells. Mutant rat erbB-2 in transgenic mice resulted in
all the mice expressing the transgene developing breast
tumours (Muller et al., 1988). However, over expression
of the normal erbB-2 rather than gene amplification may
be an important pathogenic event in some tumours (Slamon
et al., 1989), since 26% to 48% of breast tumours had
moderately increased erbB-2 protein levels in the absence
of gene amplification (Berger et al., 1988, Slamon et
al. , 1989). Tumours that do show c-erbB-2 amplification
can express the c-erbB-2 gene product at high levels (Di
Fiore et al., 1987). Up to 30 fold amplification of
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c-erbB-2 has been demonstrated in as many as 33% of
breast tumours (Yokota et al., 1986b, Venter et al.,
1987, Slamon et al., 1987 and 1989, Zhou et al., 1987,
Berger et al. , 1988, Zeillinger et al., 1989, Zhou et
al., 1989, Lacroix et al., 1989, Slamon et al., 1989).
Expression of the c-erbB-2 gene does appear to delineate
a poor prognostic group as an independent predictive
factor (Varley et al., 1987a, Slamon et al., 1987, van de
Vijver et al., 1988, Berger et al., 1988, Wright et al.,
1989, Slamon et al. , 1989, Zeillinger et al., 1989) and
this suggests it may have a role in the biological
behaviour of breast cancer. Patients with c-erbB-2
amplification (especially with greater than 5 copies) and
lymph node involvement with tumour have a shorter time to
disease relapse and worse overall survival (Slamon et
al., 1989, Wright et al. , 1989). Amplification is more
common in tumours of advanced stage (Zhou et al. , 1987,
Berger et al., 1988, Seshadri et al., 1989).
Conversely, tumours which do not express erbB-2 but do
express oestrogen receptors may be particularly
favourable for patient survival (Hynes et al., 1988).
H-ras
The Harvery-ras (H-ras) oncogene first identified as a
transforming sequence in bladder carcinoma (Shih and
Weinberg, 1982, Goldfarb et al., 1982) and named from its
homology to the Harvey murine sarcoma virus is located on
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lip (McBride et al., 1982). The H-ras gene encodes a
1.2kb to 1.4kb mRNA (Spandidos and Agnatis, 1984 ,
Theillet et al., 1986, Biunno et al., 1988, Redmond et
al., 1988) for a 21kd 189 amino acid protein, p21 (Capon
et al., 1983, Taperowsky et al., 1983). Ras proteins
bind Guanosine tiphosphate (GTP), regulating signal
transduction from the cell membrane, with GTPase
activating protein the likely biological target for
regulation by p21 (Cales et al., 1988, Sigal 1988).
Activation of ras, particularly by mutation of codons 12
and 61 (Reddy et al. , 1982) has been demonstrated in up
to 80% of chemically induced rat mammary tumours
(Sukamar et al., 1988) but occurs infrequently in human
breast cancer (Biunno et al., 1988, Rochlitz et al.,
1989). Similarly, although ras gene amplification may
serve as an alternative mechanism to ras mutation in the
development of neoplasia (Pulciani et al. , 1985), few
tumours exhibit amplification (1/65 Biunno et al. , 1988,
4/22 Nikiforova, 1988).
Early studies suggested that ras mRNA was expressed in
16/22 invasive ductal breast carcinomas (Theillet et al.,
1986) and at higher levels in tumour than in normal
tissue (Spandidos and Agnatis, 1984), although H-ras
transcripts were detected in neither normal nor cancer
tissue in 2 later studies (Whittaker et al., 1986, Biunno
et al., 1988). H-ras may provide a competence function
(Kelekar and Cole, 1987) requiring activation of a second
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oncogene before the cell becomes strongly tumorigenic
(Clark et al., 1988). In the MCF-7 cell lines viral ras
induces oestrogen independence (Kasid et al., 1985) by
secreting mitogens which may function in an endocrine
manner (Kasid et al., 1987).
Studies of ras p21 protein show higher levels of
expression in malignant than in normal or pre-malignant
breast tissue (Horan-Hand et al., 1984, Ohuchi et al.,
1986, Whittaker et al. , 1986). It has variously been
suggested that p21 expression is important in the early
stages (Ohuchi et al. , 1986) or progression of breast
cancer (Lundy et al. , 1986) and p21 may be a useful
prognostic indicator (Clair et al., 1987).
Int 1 and int 2
From evidence of mouse mammary tumour virus integration
into the host genome initiating a tumour by specific gene
activation (Dickson et al. , 1984), human homologues of
int 1 (van-t-Veer et al., 1984) and int 2 (Casey et
al.,1986) have been mapped with the int 2 gene located on
the same chromosomal band (llq23) as the progesterone
gene (Law et al., 1987).
While int 1 and int 2 (Nusse et al. , 1984, Dickson et
al. , 1984) may act co-operatively in the genesis of 50%
of mouse mammary carcinomas (Peters et al., 1986), their
role in human breast cancer is uncertain. Int gene
amplification has been described in a small proportion of
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breast cancers (Lidereau et al., 1988, Zhou et al., 1989)
with co-amplification and mRNA expression of int 2 and
another fibroblast growth factor like gene hst identified
in 41/238 (17%) of breast cancers (Theillet et al. ,
1990) . Clinically, co-amplification of int 2 and hst 1
has been correlated with aggressive disease (Zhou et al.,
1988) . Recently, it has been suggested that a genetic
element between Hst/int 2 and a nearby gene BCL-1 could
be important in the development of a subset of mammary
tumours (Theillet et al., 1990).
Other oncogenes
Other oncogenes implicated in breast cancer include
c-mos, a rare polymorphism of which results from a point
mutation and was found more frequently in breast cancer
patients than in the normal population (Lidereau et al.,
1985, Lidereau et al. , 1987) although this finding does
not appear to be important in breast cancer families
(Hall et al., 1989) and no evidence of c-mos
amplification was found in one other study of 121 breast
cancers (Escot et al., 1986).
c-fos has been implicated in the control of cell
proliferation and differentiation and is induced by
growth factors but not by oestrogen in MCF-7 breast
cancer cells (Wilding et al., 1988). Studies of c-fos
mRNA suggest higher levels of mRNA relate to increased
metastatic ability of rat mammary tumour clones (Yuhki et
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al., 1986), but there is little evidence for a role for
c-fos in human breast cancer.
No alteration of N-myc or N-ras oncogenes was identified
in 41 breast cancers, and only 2 fold amplification of
L-myc in the same series (Varley et al. , 1987a).
No significant expression of the sis oncogene was found
in either malignant or normal breast tissue (Spandidos
and Agnatis, 1984).
Similarly, although other oncogenes such as Kirsten-ras
closely related to H-ras (Yee et al., 1989 ), c-myb
(Masuda et al., 1987a) and the dbl/mcf-2 gene isolated
from the MCF-7 cell line (Noguchi et al., 1988) have been
suggested as factors in breast carcinogenesis, there is
as yet no strong evidence for the involvement of these
genes in human breast cancer.
Tumour suppressor genes
p53, initially considered to be an oncogene has
subsequently emerged as a candidate tumour suppressor
gene and spans the oncogene/tumour suppressor gene
divide. First identified in 1979 (Lane and Crawford,
1979, Linzer and Levine, 1979) the p53 gene is located at
17pl3 (Isobe et al., 1986, Miller et al. , 1986, McBride
et al., 1986). The gene encodes a 2.8 kb mRNA (Harlow et
al., 1985) expressed in most adult tissues (Oren, 1988)
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that is translated into a short lived (Reich and Levine,
1984) 53kd nuclear phosphoprotein regulated by
phosphorylation Mihara et al., 1989). The p53 gene
comprises 20kb with 11 exons (Lamb and Crawford, 1986),
has structural features of a "housekeeping gene"
including absence of a TATA box (Reynolds et al., 1984,
Bienz-Tadmor et al., 1985) and DNAase hypersensitive
sites (Shimada and Neinhuis, 1985) indicative of a
consistently expressed gene. In addition, the open
chromatin structure in the promotor region of p53 may
allow the binding of mitogenic transcriptional regulators
(Lubbert et al., 1989).
Although the normal function of p53 is not known, it may
be involved in G1 to S transition of the cell cycle
(Mercer et al., 1982, Mercer et al. , 1984) with p53
essential for continuous cell proliferation (Milner,
1981, Shohat et al. , 1987). It may modulate
transcriptional activation by binding to DNA as does myc
protein (Donner et al. , 1982) or bypass the need for
platelet derived growth factor in the induction of
competence (Oren, 1988).
p53 is often found in high amounts in transformed cells
(De Leo et al., 1979, Linzer and Levine, 1979, Benchimol
et al., 1982, Crawford et al., 1981, Rotter et al. , 1983,
Thomas et al., 1983). Studies up to 1987 suggested p53
was an oncogene (Jenkins et al. , 1985, Eliyahu et al.,
1984, Eliyahu et al., 1985; Parada et al., 1984, Rovinski
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and Benchimol, 1988, Editorial, Oncogene, 1988, Oren
1988), largely on the basis of co-transformation of rat
fibroblasts with mutant H-ras. Subsequent studies (see
discussion) suggest that the normal gene "wild type" p53
acts as a tumour suppressor (Green, 1989, Wang et al.,
1989) in contrast to the mutant, oncogenic p53.
DNA rearrangements can alter the expression of the p53
gene leading to complete gene inactivation (Mowat et al.,
1985). Rearrangements were identified in 2
osteosarcomas, but not breast tumours (Masuda et al.,
1987b) . p5 3 activation by mutation to oncogene may
increase stability of the short lived protein (Jenkins et
al., 1985) and thus compete with wild type, tumour
suppressor gene p53 product interfering with its normal
function. A similar inactivation may result from the
formation of a complex observed between p53 and SV40
large T Antigen (Lane and Crawford, 1979, Linzer and
Levine, 1979) adenovirus Elb (Sarnow et al., 1982) and
heat shock proteins (Pinhasi-Kimhi et al., 1986, Hinds et
al., 1987).
Thus the p53 story is complex and during the course of
the work outlined in this thesis has continued to evolve.
The retinoblastoma gene
The retinoblastoma gene, the first tumour suppressor gene
characterised, has recently been examined in breast
cancer. Structural aberrations of retinoblastoma
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resulting in absence or truncation of the retinoblastoma
transcript have been observed in 25% of breast tumour
cell lines and 7% of primary tumours (T'Ang et al.,
1988). Rearrangements of the retinoblastoma gene have
also recently been thoroughly documented (Varley et al.,
1989). A substantial proportion of the retinoblastoma
gene mutations are partial or complete deletions that
extend an unknown distance beyond one or both ends of the
gene (Bookstein et al. , 1989).
Despite the undoubted interest of these findings, it must
be acknowledged that no obvious excess of breast cancer
has been recorded in survivors of familial retinoblastoma
and linkage of breast cancer susceptibility to the
retinoblastoma gene has recently been excluded (Bowcock
et al., 1990). Thus the nature of the retinoblastoma
lesions in breast cancer may be different in some way
from those occurring in retinoblastoma itself.
Growth factors
While a number of growth factors may play a role in
breast cancer, transforming growth factor alpha,
transforming growth factor B, epidermal growth factor and
the epidermal growth factor receptor and the insulin-like
growth factors I and II merit particular consideration.
However, other growth factors such as platelet derived
growth factor may also be implicated in the control of
mammary epithelial cell proliferation (Yee et al., 1989).
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Transforming growth factor aloha
Transforming growth factor alpha (TGF-alpha, Derynck et
al., 1984) is a potential autocrine growth factor in
human breast cancer cell lines. A 4.8kb transforming
growth factor alpha mRNA has been detected in the MCF-7
cell line (Imanishi et al., 1989) and as a biologically
active 30kd transforming growth factor alpha in MCF-7 and
MDA—MB—231 (Lupu et al., 1988) although regulation of
transforming growth factor alpha expression was unrelated
to the proliferative behaviour of T47-D cells (Murphy and
Dotzlow., 1989).
Transforming growth factor alpha mRNA was detected in
9/18 breast tumours (Ciardiello et al. , 1989) and using
high performance liquid chromatography, biologically
active transforming growth factor alpha sufficient to
promote cell division was found in the majority of breast
tumour extracts (Gregory et al., 1989). In addition,
oestrogen withdrawl and the anti-tumour agent tamoxifen
cause a significant reduction in tumour transforming
growth factor alpha (Gregory et al., 1989, Murphy and
Dotzlaw, 1989).
Transforming growth factor alpha is a ligand which, like
epidermal growth factor (EGF), binds to the epidermal
growth factor receptor (Todaro et al. , 1980, Ro et al.,
1988). The EGF gene maps to 4q (Brissanden et al. , 1984)
and produces a 53 amino acid, 6kD peptide which binds to
specific high affinity EGF receptors (Nicholson et al.,
1988, Waterfield, 1989).
Epidermal growth factor receptor
The EGF receptor (EGFR) gene or c-erbB-1 which encodes 3
of the 4 EGFR domains (7q 13-11.2, Meera Khan & Smith,
1984, Coussens et al., 1985), encodes mRNA variously
reported as being of 1.8kb (Lebeau & Goubin, 1987), 2 . 9kb
(Semba et al., 1985, Lebeau & Goubin, 1987), 2.7 kb (King
et al., 1985), 5 kb (Murphy et al. , 1988), 5. 8kb and 10
kb (Ullrich et al., 1984, King et al.,1985) which
produces a 170 kD receptor protein.
The EGF receptor comprises a ligand binding domain
transmembrane domain and cytoplasmic domain with tyrosine
kinase activity (reviewed in Nicholson et al., 1988a).
EGFR amplification was detected in 2-4% of tumours
(Slamon et al . , 1984 , Lacroix et al. , 1989); gene
rearrangement (Slamon et al., 1987) and occasional
overexpression have also been reported (Ro et al., 1988).
It has been suggested that, although present in normal
and cancerous breast tissue, EGFR expression is
associated with dedifferentiation of breast cancer
(Pekonen et al., 1988). In keeping with this, EGF
appears to down regulate the oestrogen receptor by 50%, a
possible mechanism of inducing oestrogen independence in
oestrogen receptor positive cells (Cormier et al., 1989).
Certainly, EGF receptor protein correlated inversely with
52
oestrogen receptor (Sainsbury et al., 1985, Nicholson et
al., 1988b, Pekonen et al., 1988) and using 10 fmol mg-1
protein as a cut off point, EGFR positive tumours are
associated with failure to respond to endocrine therapy
in primary breast cancer (Nicholson et al., 1988b) and
have a positive correlation with early disease recurrence
and early death (Nicholson et al., 1988a).
Insulin-like growth factors
The somatomedins, insulin-like growth factor I (IGF-I,
which maps to chromosome 12, Brissenden et al., 1984) and
insulin-like growth factor II (IGF-II, which maps to the
short arm of chromosome 11, Brissenden et al., 1984), are
single chain proteins of 70 and 67 amino acids
respectively. These two growth factors act on specific
receptors and may behave as autocrine regulators in
tumours (reviewed in Bell et al. , 1984, Tricoli et al. ,
1984 and Slack, 1989). Although it has been suggested
that the insulin-like growth factors may be significant
autocrine growth factors in human hormone dependent
breast cancer cells (Watson and Sikora, 1988), insulin¬
like growth factor II was not induced by oestrogen
treatment in an oestrogen sensitive line and was not
detected in an oestrogen independent cell line suggesting
insulin-like growth factor II may be produced




Transforming growth factor B
By contrast with transforming growth factor alpha,
epidermal growth factor and the somatomedins,
transforming growth factor B has an inhibitory effect on
breast epithelial cells (Sporn et al., 1987) either in an
autocrine (Sporn and Roberts, 1985) or paracrine (Knabbe
et al., 1987) fashion.
There are three major forms of transforming growth factor
B: transforming growth factor Bl, transforming growth
factor B2 and transforming growth factor B1.2 which
result from the homodimeric and heterodemeric combination
of 12.5kd Bl and B2 subunits (Cheifetz et al., 1987).
The transforming growth factor B originally described
consists of two subunits of Bl (Derynck et al., 1985)
which is more abundant than B2 (Roberts et al., 1988).
The transforming growth factor B mRNA of 2.5 kb (Derynck
et al. , 1986, Knabbe et al., 1987) which predominates
over minor species of 1.9 and 4.8 kb (Akhurst et al.,
1988, Derynck et al., 1986) is expressed in all tumour
tissues and cell lines (Derynck et al., 1987) in higher
amounts than in adjacent normal breast tissue (Derynck et
al., 1987) .
Transforming growth factor B is secreted from cells in a
precursor form and 98% remains biologically inactive,
unable to bind to the transforming growth factor B
receptors unless activated by proteolysis, or in the
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experimental setting by transient acidification
disrupting a noncovalent complex (Sporn et al., 1987).
To further complicate the autocrine loop, not only are
there 3 forms of transforming growth factor £, and an
activation step but 3 glycoprotein transforming growth
factor £ receptors of 65kd, 85kd and 280kd. The 2 smaller
receptors preferentially bind transforming growth
factor £1 (Massague, 1987). Thus there is potentially
great flexibility in regulation of tissue growth by the
transforming growth factor £ system (Chiefetz et al.,
1987).
The functions of transforming growth factor £ encompass
embryogenesis, inflammation, tissue repair and
carcinogenesis (Sporn et al. , 1986, Heine et al. , 1987,
Massague 1987, Sporn et al., 1987).
Increased secretion of transforming growth factor £
accompanies viral transformation of cells with down
regulation of the transforming growth factor £ receptor
(Anzano et al. , 1985). Conversely, transforming growth
factor £ could be oncogenic by defect, releasing cells
from their proliferative constraints (Sporn and Roberts,
1985, Roberts et al., 1985). The action of transforming
growth factor £, as inhibitor or enhancer may depend not
only on the cell type but also other growth factors
present (Roberts et al., 1985, Fernandez-pol et al.,
1987) and enhancing effects on stromal tissues and cells
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(Wrann et al., 1987, Sporn et al., 1987, Massague et al.,
1988).
Transforming growth factor B is a negative growth factor
for mammary epithelial cells (Sporn et al., 1987) and
secretion of transforming growth factor B is induced from
MCF-7 cells treated with growth inhibiting concentrations
of antioestrogens (Knabbe et al., 1987); the transforming
growth factor B thus produced also inhibiting oestrogen
insensitive MDA MB 231 cells. Thus, transforming growth
factor B may play an important role in breast
carcinogenesis and in vitro studies have suggested there




The oestrogen receptor gene, which maps to chromosone 6,
produces a Mr 65000 oestrogen receptor protein homologous
to the erbA protein of oncogenic avian erythroblastosis
virus and the human glucocorticoid receptor (Green et
al., 1986). Since cDNA for the oestrogen receptor gene
was cloned and sequenced (Walter et al., 1985, Green et
al., 1986) much of the molecular work has studied the
mRNA, although at the DNA level absence of an RFLP
allele for oestrogen receptor was found in breast cancer
cells which fail to express the oestrogen receptor (Hill
et al., 1989).
56
The oestrogen receptor gene generates mRNA species
variously described as 3.7kb to 6.3kb (Green et al. ,
1986, Rio et al., 1987, Barrett-Lee et al., 1987, Pari et
al . , 1987, Henry et al. , 1988) with all oestrogen
receptor positive tumours having detectable oestrogen
receptor mRNA (Henry et al. , 1988) and 15 of 21 tumours
with no detectable oestrogen receptor protein expressing
mRNA for the oestrogen receptor (Henry et al., 1988).
Therefore, many tumours may not be able to translate the
mRNA to receptor protein (Barrett-Lee et al., 1987).
Hormone receptor complexes are presumed to interact with
specific DNA sequences (Brown et al., 1984). Supporting
evidence for this comes from the identification of
functionless defective oestrogen receptor hormone
complexes which are unable to bind to nuclear material
(Raam et al . , 1988) and thus cannot activate
transcription. Although the oestrogen receptor protein
is of considerable clinical importance, neither oestrogen
dependence of the tumour nor clinical response to
hormonal therapy is guaranteed by the presence of
oestrogen receptors (Raam et al., 1988). Interest has
therefore grown in the pS2 gene, the mRNA for which is
oestrogen regulated (Masiakowski et al., 1982).
oS2
Expression of the pS2 gene in mRNA increases in response
to oestrogenic stimulus (Masiakowski et al., 1982, Brown
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et al. , 1984) but is not influenced by progestins,
glucocorticoids or androgens (Brown et al., 1984). pS2
transcription coincides with the appearance of highly
associated oestrogen-receptor complexes in the nucleus
(Brown et al., 1984).
The 600 bp mRNA (Masiakowski et al., 1982) encodes for an
84 amino acid protein which is cystene rich (Rio et al.,
1987) and has structural similarities to IGF-I (Rio et
al., 1987) but does not stimulate DNA synthesis (Kida et
al., 1989). Thus, although the significance of oestrogen
receptor protein and the oestrogen inducible pS2 requires
to be more closely defined, subclassification of breast
tumours on the basis of molecular studies of oestrogen
receptor and pS2 may define patients with tumours more
likely to respond to endocrine therapy (Raam et al.,
1988, Henry et al. , 1988) and those likely to have a
short time to disease relapse (May et al., 1989).
Multiple drug resistance gene
Among the other genes considered for study was the
multiple drug resistance gene, MDR1, responsible for
multiple drug resistance, which maps to 7q 21.1
(Fairchild et al., 1987). This gene encodes a 4.8 kb mRNA
and 170 kd membrane glycoprotein that exports drugs,
subverting their intracellular cytotoxic activity. The
degree of MCF-7 resistance to adriamycin correlated with
overexpression of MDR1 mRNA (Fairchild et al. , 1987) and
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MDR1 overexpression may precede MDR1 gene amplification
(Shen et al., 1986). While the study of MDR1 in breast
tumours has been limited, 15% of breast tumours show low
levels of MDR1 and 2/2 post chemotherapy resistant breast
tumours expressed MDR1 (Goldstein et al., 1989).
It is evident that in order to seek evidence for the
multistep theory of carcinogenesis and the involvement of
tumour suppressor genes and oncogenes in human breast
cancer, one must select key genes to study. On the basis
of the work published up to the commencement of the work
encompassed in this thesis (October 1987) it was elected
to pursue the lines of enquiry outlined below.
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AIMS
The first aim of the work reported here was to quantitate
accurately the expression of the oncogenes c-myc, erbB2,
H-ras, the tumour suppressor gene/oncogene p53, the
growth factor gene transforming growth factor B and
the oestrogen regulated gene pS2 in human breast tumour
tissue. These genes were selected on the basis of the
published evidence outlined above. To quantitate
expression it was elected to study gene transcription
(mRNA), the most sensitive measure of gene activity
(Johnson and McKnight, 1989).
The expression of the genes under study would then be
related to clinical and pathological factors of
significance in patient management, and one gene would be
chosen for further molecular studies at the genetic (DNA)
level.
While it is desirable to examine tumours from patients,
there remained a need to examine the dynamic changes in
gene expression occurring within a breast tumour in
response to oestrogen stimulation or a therapeutic agent.
Such studies are not generally possible in human
subjects, therefore the second aim of this thesis was to
develop a xenograft model in which to observe the changes
in gene expression (mRNA) occuring in vivo, particularly
in response to the commonly used anti-tumour agent,
tamoxifen.
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At the conclusion of this molecular approach to breast
cancer, the intention was to integrate the findings from
human material and the xenograft system to contribute
towards greater understanding of the pathogenesis of
breast cancer, clarify the mechanisms by which the































-selection of polyA+ RNA
-RNA electrophoresis
-Northern blotting
-hybridisation and washing conditions






























































Mixed bed resin AG 501-X8
Boehrinaer Mannheim





Enzyme buffer B : lOmM Tris HC1, 5 mM MgC^, lOOmM NaCl,
ImM 2-mercaptoethanol, pH 8.0.
Enzyme buffer H : 50mM Tris HC1, 10 mM MgCl2, lOOmM NaCl,
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ImM 1-dithiothreitol, pH 7.5.
Enzyme buffer L : lOmM Tris HC1, 10 mM MgCl2,
ImM 1-dithiothreitol, pH 7.5.
Proteinase K















Dulbecco modified eagle medium (DMEM).
Foetal calf serum (FCS).
Imperial Chemical Industries
Tamoxifen (Nolvadex, ICI 46,474)
Innovative Research
1.25mg slow release pellet of 17B oestradiol benzoate
Intervet
17J3 oestradiol benzoate in arachis oil
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Kodak

























































Sequenase DNA sequencing kit
Solutions
Denaturing solution : 5g NaOH (0.5M), 219.15g NaCl (1.5M)
in 2.5 litres.
Denhart's solution : 5g Ficoll, 5g polyvinyl pyrrolidine,
5mg bovine serum albumin.
Lysis buffer : 0.1M Tris HC1, 20mM NaCl, ImM EDTA.
Neutralising solution : 292.9g NaCl (2M), 394g Tris base
(1M) in 2.5 litres. Add HC1 to pH 5.5.
Phosphate buffer : 23g KH2P04, 125g K2HP04 in 1 litre.
Resuspension buffer : lOmM Tris HC1, 150mM NaCl, lOmM
EDTA.
Running buffer (DNA) : 30% sucrose, 0.4% bromophenol
blue.
20x SSC : 876.6g NaCl, 441.2g Na3citrate in 5 litres.
20x TAE gel buffer : 484g Tris base, 114.2ml acetic acid,
200ml 0.5M EDTA in 5 litres.
lOx TBE : 1M tris borate 20mM EDTA pH 8.3
TE Buffer : lOmM Tris HC1 pH7.5, 0.5mM EDTA.
T-broth : 6g tryptone, 5g yeast extract, 5g NaCl, 1ml IN
NaOH in 1 litre. Add 50ml phosphate buffer before use
Wash buffer O.lx SSC : 50ml 10% sodium pyrophosphate,
25ml 20% SDS, 25ml 20x SSC in 5 litres.
69
Wash buffer 0.5x SSC : 50ml 10% sodium pyrophosphate,
25ml 20% SDS, 125ml 20x SSC in 5 litres.
Hardware
Aloha Lab
Plastic disposable 'S' transfer pipette
Becton Dickinson
50ml Falcon tubes
96 well Falcon 3072 microtitre plate
FACScan flow cytometer
Bio-Rad
Gel drier model 583.














EC 105 power source
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Flow Laboratories
IR 1500 Automatic C02 incubator.
Fui i
















Microprobe part No. 38121-114
Microcentaur 13000 eppendorf microcentrifuge
Soniprep 150 ultrasonic disintegrator
Nuclear Enterprises
Farmer dosemeter 2570 probe
Nunc
















X ray source - Stabilpan II TH250 therapy tube housing,
gigma























Human breast tumour cell lines MCF-7 ( Soule et al.,
1973) T-47D (Keydar et al., 1979), MDA-MB-231 (Cailleau
et al. , 1974) were obtained from Dr. W.R. Miller,
Department of Surgery, Royal Infirmary, Edinburgh.
All lines were cultured in 75 cm2 Nunclon flasks, fed
regularly with Dulbecco Modified Eagle Medium (DMEM)
(Dulbecco et al.,1959) supplemented with 12% foetal calf
serum (FCS) and maintained in an incubator in an
atmosphere containing 5% CO2 at 37®C. Medium was
changed twice each week or more frequently if the phenol
red indicator in the DMEM became yellow. The cells were
harvested in the logarithmic (80% confluent) phase of
growth (Kelekar & Cole, 1987), by pouring off the DMEM
and washing the cells gently with warm phosphate buffered
saline (PBS) to remove the residual medium. The cells
were bathed in 10ml of a cold 50:50 mixture of 0.04% EDTA
and 0.2% trypsin for 5 minutes to remove the cells from
the flask wall. The cell suspensions were transferred to
50ml Falcon tubes and pelleted in a swingout rotor in a
Wifug 500E benchtop centrifuge centrifuge at 2500 rpm
(lOOOg) for 5 minutes, resuspended in PBS and pelleted in
the same way. The resultant pellet was either taken up in
lml freezing mix (95%FCS with 5% Dimethyl sulphoxide,
DMSO) in a 1.5ml polypropylene tube and stored frozen in
liquid nitrogen tanks or used to reseed further flasks,
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used for nucleic acid extraction or injected into mice.
Culture Contamination
Any culture flask where yeast or bacterial contamination
was suspected or evident was destroyed.
All cultures were tested for mycoplasma using
conventional immunofluoresence techniques which
frequently provides the first evidence of contamination.
The supernatant was tested according to standard methods




A long established breeding colony of CBA/Ca strain mice
(Festing, 1979) held at the Institute of Animal
Technology, Western General Hospital, Edinburgh were used
to establish a human breast tumour model in
thymectomised, irradiated mice (Steel et al. , 1978) under
Home Office Licence CMS313. Maintained as described by
Hay and collegues (1985), they undergo normal growth and
development. Immediately after weaning at age 21 days,
each mouse was anaesthetised with ether in a glass
dessicator and fixed in the supine position using
elasticated clips. Following skin preparation with 70%
ethanol, a standard procedure of thoracotomy and removal
by suction of the bilobed thymus, with one stage closure
of the skin using michel clips was used. The mice
recovered in a warmed cage. Three weeks following
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thymectomy, the mice were irradiated to a total body dose
of 7.50 Gy recorded using a dosememter probe placed in
the centre of a perspex jig within which the animals were
contained but could move freely. Radiation was delivered
from a stabilpan II TH250 X ray source (250v : 0.3-0.4
Gy/min ) with a Thoreus II filter over approximately 20
minutes. The mice were protected from this otherwise
_ 1
lethal dose of irradiation by 200mg kg cytosme
arabinoside injected by the intraperitoneal route 48
hours prior to irradiation.
Twenty homozygous nu/nu mice (Fogh & Hajdu, 1978) of
mixed background from the Imperial Cancer Research Fund,
London, which are congenitally athymic, were also used in
these studies. The nu/nu mice were maintained in sterile
incubators by skilled technical staff who performed all
injections and tumour cell or tumour fragment implants in
these nu/nu mice.
Oestrogen Supplementation
Oestrogen supplementation was administered in the form of
17B oestradiol benzoate dissolved in and diluted with
arachis oil and administered by subcutaneous injection
into the nape of the neck at dose regimes lug/day,
lug/2days, 2ug/day, 5ug/day, 5ug/week, lOug/week, 30ug/2
weeks, 50ug/3 weeks.
The regime used for serum oestradiol measurement and
tumour studies for the CBA strain mice was 50ug 17B
oestradiol in 50ug arachis oil administered every 3
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weeks. This regime was chosen since it did not kill the
mice but did allow tumour growth.
Twenty homozygous nu/nu mice were also used for tumour
studies with oestrogen supplement of 1.25mg slow release
subcutaneously placed pellet replaced every 6 weeks.
Serum Oestradiol
Oestradiol was measured in 50ul of serum from individual
samples of 0.3 to 0.8 ml blood extracted by cardiac
puncture from each of 30 mice at specified times
following injection of 50ug 17B oestradiol benzoate in
50ul arachis oil. The radioimmunoassay used oestradiol-6-
carboxymethyloxime^^-l-iodohistamine as radiolabel and
rabbit antiserum against oestradiol-6-carboxymethyloxime-
bovine serum albumin. Separation of free from bound label
was achieved by means of a solid phase second antibody.
Organic solvent extraction of samples prior to assay was
not necessary; oestradiol is displaced from its serum
binding protein by an excess of blocking agent. Within
assay CV was 5% and between assay CV was 6%. The serum
oestradiol measurements were performed by S. Barnes and
V. Sweeting, Department of Clinical Chemistry, Royal
Infirmary, Edinburgh.
Tumour Growth
In vivo growth of breast cancer cell lines was studied in
groups of 20 CBA mice which had been thymectomised and
irradiated in the same batch. A known number of MCF-7
c o
cells (10 up to 10° cells checked for viability by dye
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exclusion ) were suspended in 50 - 100 ul PBS and were
injected into the right 4th mammary fat pad of healthy
mice one to 3 weeks after irradiation. Some mice
received oestrogen supplementation which commenced at the
same time, by subcutaneous injection into the nape of the
neck. This injection was repeated every three weeks to
the same site.
Mice were checked daily and the animals examined for
signs of disease or debility, including the cell line
injection site and the oestrogen injection site. Tumours
were measured in 2 dimensions (maximum and minimum
diameters) by the author twice each week using 0.1mm
graduated calipers. The volume of the tumour was
calculated using the formula pi/12 x (mean diameter)0.
Tumour bearing mice were killed at specific times
following injection of oestrogen; 6, 12, 18, 24, 36, 48,
or 72 hours or 3, 7, 10, 14, or 21 days after oestrogen
injection. The excised tumours were frozen immediately in
liquid nitrogen or fragments fixed for pathologial
examination or analysed for oestrogen recptor protein
content Those mice which did not develop tumours were
killed 90 days from the start of the experiment. Mice
which died in the interim or were generally debilitated
and therefore killed, were examined by post mortem and
histopathological examination of organs in detail for
evidence of disease including metastasis.
78
Tumour Transplantation and Re-culture.
A number of tumours arising from inoculum of MCF-7 cells
were transplanted into further thymectomised irradiated
mice. Tumour from a freshly killed mouse was cut into
fragments of less than 3mm3. A mouse was anaesthetised
with ether and one tumour fragment placed in each flank
by tunnelling subcutaneously with the tumour bearing
forceps through a single small incision in the mid
dorsum. The wound was closed with a single steel clip and
the oestrogen supplement injection administered as the
mouse awoke. Thereafter the transplant bearing mice were
treated as above, with oestrogen supplements every 3
weeks. Remaining tumour fragments were macerated and
added to DMEM containing 12% FCS and tumour cells
returned to culture in Nunclon flasks at 37°C in an
atmosphere of 5% C02, for 8 weeks before re-injection
into mice or extraction of nucleic acid.
Tumour Therapeutic Manipulation
Two effects of tumour manipulation were examined in
batches of 20 mice which had undergone thymectomy on the
same day, received the same irradiation and been injected
with the same preparation of cells on the same day and
received the same oestrogen supplement.
1. Oestrogen withdrawal. Tumours were established to 100
mmJ; oestrogen supplementation was not replenished and
the effects of oestrogen withdrawal on the tumours
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observed by serial tumour measurement.
2. Antioestrogen treatment. The antioestrogen tamoxifen
(Nolvadex, ICI 46,474) was dissolved in arachis oil and
1.25mg in 50ul arachis oil was injected daily,
subcutaneously, into the hindquarters commencing on the
same day as oestrogen supplementation to observe the
effects in vivo of tamoxifen on tumours receiving the
standard oestrogen supplementation. Tumours were measured
as before, mice killed and tumours excised for study at
2, 4, 7, 14, and 21 days after commencing anti-oestrogen
therapy. The dose of tamoxifen was estimated on mg
tamoxifen per kg body weight from the human dose and
tested for toxicity at 125mg/day on mice which had or
had not received exogenous oestrogen.
Histooathology
Tumour material and tissue removed at post mortem was
fixed in methacarn (60% methanol, 10% glacial acetic
acid, 30% chloroform) for 1 hour then 95% ethanol and
processed routinely to paraffin blocks by the Department
of Pathology, University of Edinburgh and the Department
of Pathology, Western General Hospital, Edinburgh. lOum
sections were stained with haematoxylin and eosin and
were examined for pathological features including tumour
type, necrosis, lymphocyte infiltration, vascular
invasion or metastasis. The mitotic index for each tumour
was calculated from the mean number of mitoses in 50
randomly chosen high power fields (x400) by a single
80
pathologist (Dr David Patterson) examining the sections
without knowledge of which mouse they had been excised
from.
Cell DNA Synthesis
A monoclonal antibody BR9 directed against the
halogenated nucleotide 5-Bromodeoxyuridine (BrdU),
raised by Dr. D. Deane, MRC Human Genetics Unit, Western
General Hospital, Edinburgh, was used for rapid S-phase
measurements (Gonchoroff et al., 1985).
The BrdU (200ul of 6mg ml-^) was injected into the
peritoneal cavity of each mouse under examination at 0,
6, 12, 18, 24, 36, or 48 hours after injection of 50ug
17B oestradiol.
Each mouse was killed 1 hour after administration of the
BrdU, the tumours excised and finely minced in DMEM
_ I
containing lmg ml dispase (neutral protease). Cells
released by this digestion were fixed in 70% ethanol. For
the simultaneous differentiation of human MCF-7 cells
from invading host (mouse) tissues, a double staining
procedure was used. Fixed cells were washed with PBS,
then incubated with lOug of an antihuman class I
monoclonal antibody PE25 (Made by Dr. D. Deane) washed in
PBS and 2ug of phycoerythin labelled anti-mouse conjugate
added. To prevent cross-reactivity between this antibody
and the BR9, the cells were then incubated in PBS
containing lOug ml1- mouse IgG for 30 minutes. After a
wash in PBS, lOug of the monoclonal antibody BR9 was
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added to the cell pellet of approximately 10 cells and
incubated at room temperature for 40 minutes. The cells
were washed in PBS and incubated for a further 40 minutes
in the presence of 2ug Fluoroscein isothiocyanate (FITC)-
labelled goat anti-mouse conjugate. After a further wash
in PBS the cells were analysed on a FACScan flow
cytometer for absolute number and proportion of tumour
cells in S-phase.
Thymidine uptake was also used to determine DNA synthesis
by isolated tumour cells. For each time point, intact
cells were separated from the dispase/DMEM digests by
density centrifugation over 5%-30% Ficoll 400 gradient
and 150ul of cell suspension (10^ cells per ml DMEM with
5% added FCS) added per well of a 96 well microtitre
plate. luCi 3H thymidine was added to each well and the
cells harvested 5 hours later onto glass fibre discs. The
radioactivity emitted from each disc was counted in 5ml
of scintillant in a Packard analyser.
Human Material
Patient Selection
Material for this study was obtained from female patients
who attended the breast clinic, Department of Surgery,
Royal Infirmary, Edinburgh. Criteria for patient
selection were patients with untreated tumours (or
treated with tamoxifen only) with a primary breast
carcinoma proven by fine needle aspiration cytological
examination, from whom sufficient quantities of very
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fresh tumour material could be obtained. Small tumours
(less than 1cm on mammography ) and those lesions
requiring needle localisation biopsy (where it is
critical to determine all the calcified suspicious lesion
has been excised) and patients who had previously
received radiotherapy or chemotherapy for a breast lesion
were excluded from the study. Consent was obtained from
all patients approached and 20ml venous blood withdrawn
prior to surgery.
Tumour Collection
Tumour material was obtained intra-operatively when the
patient underwent tumour biopsy, local excision of the
tumour or mastectomy by standard surgical procedures at
Longmore Hospital, Edinburgh between August 1987 and July
1989.
The tumour size and method of resection for each tumour
dictated the quantity of tissue removed and length of
time for each tumour to be cut into 5 mm to 10mm blocks
by the pathologist, placed in eppendorf tubes and frozen
in liquid nitrogen. The time from excision to freezing
ranged from 2 minutes to 10 minutes and was noted. Tumour
material removed for the purposes of this work was taken
adjacent to tissue processed for pathological examination
and material sent to the Lister Surgical Laboratories,
Department of Surgery, Royal Infirmary, Edinburgh for
oestrogen receptor protein and other measurements.
Tumour tissue was transferred for long term storage to
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two independent -70°C freezers and material retrieved as
required.
Tumour material was obtained from three groups of
patients:
1. Primary untreated tumours.
2. Primary tumours from whom tissue was available before
treatment was commenced and following endocrine or
chemotherapy.
3. Patients who had received a course of tamoxifen only




Detailed patient data (full personal, family and clinical
history and examination prior to therapeutic
intervention) was obtained for every patient in this
study. This included clinical staging of the disease
according to the TNM tumour classification system
(Hermanek and Sobin, 1987), tumour size on pathological
examination of the excised breast or on radiological
evidence where tumour biopsy rather than excision was
performed, nodal involvement with tumour (pathological
evidence) and biochemical parameters ( such as oestrogen
receptor protein).
Patient Follow-up
All patients studied were closely monitored in the
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routine follow up clinic at Longmore Hospital, Edinburgh
every 3 months post operatively, at which time a full
clinical examination was performed, supplemented by
annual mammography, chest and pelvic radiographs. The
site and timing of tumour recurrence or metastasis (and
consequently disease free interval, subsequent treatment
and cause of death) was noted. This follow up will
continue on an annual basis following the second
anniversary of the patient's surgery.
Normal Tissue
Normal breast tissue was obtained from ten patients who
underwent cosmetic reduction mammoplasty under the care
of Mr. A.C.H. Watson, Consultant Plastic Surgeon, Bangour
General Hospital, Broxburn, West Lothian. These patients
had no personal or family history of breast carcinoma. A
limited clinical history including age and menopausal
status was obtained from each patient.
Normal uterine and ovarian tissue was obtained fresh from
a single premenopausal women who underwent hysterectomy
and oophorectomy for menorrhagia under the care of Dr. G.
Smart, Consultant Gynaecologist, Royal Infirmary,
Edinburgh.
Tonsils free from acute disease were obtained from 5
female patients who underwent tonsillectomy at the Royal
Hospital for Sick Children, Edinburgh.
Breast tissue adjacent to cancer tissue was not examined
since it has been established that breast tissue which
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appears to be grossly normal may even so contain
substantial amounts of tumour (Whittaker et al., 1986).
Pathology
Pathological examination of each tumour, surrounding
breast tissue and axillary nodes was carried out by
several different pathologists at the time of surgery who
noted the size of the tumour (measured in 3 dimensions).
The histological features of each tumour were noted by a
single pathologist (Dr D. Patterson, Department of
Pathology, University of Edinburgh, Edinburgh) who
reviewed all the tumour material at a later date. The
features noted included the tumour type, the presence of
in situ disease, invasion into vessels, histological
grade (Bloom & Richardson, 1957), degree of lymphocyte
infiltration, extent of tumour necrosis and spread of
tumour within the breast and/or to the lymph nodes.
Oestrogen Receptors
The cytoplasmic oestrogen receptor protein content was
measured by Dr R A Hawkins and his collegues, Lister
Surgical Laboratories, Royal Infirmary, Edinburgh, using
the Dextran coated Charcoal method (DCC method; Hawkins
et al., 1975) or for patients who had received hormonal
therapy (and in whom the DCC method would therefore not
accurately assess oestrogen receptor protein) and for
mouse tumour material and cell line pellets, the Enzyme
Immunosorbent Assay (EIA; Hawkins et al . , 1987) and
expressed in fmol mg protein-^-.
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Tumour material was considered to be oestrogen receptor
moderate or rich at 20 fmol mg protein-1 or greater, but
oestrogen receptor poor or negative at less than 20 fmol
1
mg protein , these being the cut-off levels used in




Throughout the RNA extraction procedures strenuous
efforts were made to avoid ribonuclease contamination and
consequent RNA degradation. The recommendations of
Maniatis and collegues (1982) were followed. Ribonuclease
activity during the initial stages of extraction was
minimised and subsequent introduction of trace amounts of
ribonuclease were avoided. A designated laboratory area
was devoted to RNA work. Gloves were worn at all times to
avoid skin contamination of sterile disposable plastic
ware which is free of ribonuclease (Maniatis et al.,
1982) or laboratory glassware which was autoclaved,
washed in 0.1% diethylpyrocarbonate (DEPC), a strong
inhibitor of ribonuclease, then in distilled water and
baked in an oven for one hour at 80°C to remove traces of
DEPC (Maniatis et al., 1982). All solutions were made up
with high grade chemicals reserved for RNA work and
autoclaved DEPC-treated distilled water, using baked
sterilised glassware and bottles.
No exogenous inhibitors of ribonuclease (vanadyl-
ribonucleoside complexes or RNasin; Maniatis et al. ,
1982) were used.
Total ribonucleic acid (RNA) was extracted from frozen
tumour using a modification of the method described by
Auffrey & Rougeon (1980) which disrupts cells,
inactivates ribonuclease and extracts RNA by differential
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precipitation. A frozen tumour fragment was weighed on a
balance, cut into thin slices, placed in liquid nitrogen
in the teflon capsule of a mikrodi smembrator and
pulverised within 10 seconds. The resulting tumour powder
was finely disrupted in 13ml polypropylene tubes using a
disposable plastic pipette in the presence of 2ml
3M Lithium chloride / 6M urea for every lOOmg tumour and
left at 4°C overnight. Cells cultured in vitro were
washed in PBS and 10® cells disrupted in 8ml 3M Lithium
chloride / 6M Urea with a disposable plastic pipette and
left to precipitate nucleic acid at 4°C overnight. The
DNA was sheared using a microprobe in an ultrasonic
disintegrator with an ice jacket around the sample tube.
The RNA was recovered by centrifugation at 12000 rpm
(5000g) in a Sorval 3MK centrifuge, the pellet collected
and resuspended in 8ml 3M lithium chloride/6M urea and
spun again at 12,000 rpm.
The pellet was taken up in 6ml 10 mMol Tris buffer pH 7.0
/0.5% sodium dodecyl sulphate (SDS), and incubated with
300ug proteinase K at 37°C for 20 minutes.
Proteins were extracted from the aqueous phase by
vigorous mixing with an equal volume of glass distilled
grade phenol equilibrated with 0.1M Tris pH7.0 and
separated by centrifugation at 3000rpm (lOOOg) for 5
minutes in the swing out rotor of a Wifug 500E
centrifuge. Two further extractions with 24:1 chloroform
: isoamyl alcohol were performed using the same
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centrifugation. The aqueous phase was then divided into
two 13ml polypropylene tubes, 2 volumes of 100% ethanol
added to each and the RNA precipitated at -20°C for 24
hours. The RNA was recovered by centrifugation at 12,000
rpm (5000g) for 30 minutes, air dried for 10 minutes and
taken up in 20 to 500 ul of DEPC treated sterile water
and, following spectrophotometry, stored in aliquots at
-70°C in sterile eppendorf tubes.
Poly A+ RNA Purification
Poly A+ RNA was purified from total MCF-7 RNA by a
protocol derived from Maniatis and colleagues (1982) and
Aviv & Leder (1972). A 1cm column of oligo(dT) cellulose
equilibrated in sterile loading buffer (lx loading buffer
comprises 20mM Tris hydrochloride pH7.6, 0.5M sodium
chloride, ImM EDTA, 0.1% SDS) was poured in a pasteur
pipette.
The column was washed in 3 column volumes each of sterile
DEPC-treated water then 0.1M sodium hydroxide then
sterile DEPC-treated water such that the pH of the column
effluent was less than pH 8 and further flushed through
with 5 volumes of sterile loading buffer.
lmg of total RNA extracted from MCF-7 cells in 400ul
DEPC-treated water was heated to 65°C for 5 minutes and
an equal volume of 2xloading buffer, the sample cooled to
room temperature and applied to the olig(dT) cellulose
column. The eluent was collected, heated to 65°C for 5
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minutes, cooled to room temperature and reapplied to the
column. The column was washed with 5 volumes of loading
buffer then washed with 4 column volumes of low salt
buffer (20mM Tris pH7.6, 0.1M sodium chloride, ImM EDTA,
0.1% SDS).
The poly A+ RNA was eluted from the column with 3 volumes
of sterile elution buffer (lOmM Tris hydrochloride pH7.5,
ImM EDTA and 0.05% SDS).
The poly A+ RNA was precipitated by adding 3M sodium
acetate pH 5.2 to the elute to a final concentration of
0.3M and 2.5 volumes of 100% ethanol and cooling to -70®C
for 15 minutes. The precipitate was collected by 15
minutes spinning in a eppendorf centrifuge, rinsed in
70% ethanol and the pellet dissolved in 20ul sterile
DEPC-treated water.
Electrophoresis of RNA.
The method of electrophoresis and Northern blot transfer
of RNA was modified from Southern, 1975, Maniatis et
al., 1982 and Fourney et al., 1988.
Electrophoresis was used to separate RNA species by
molecular weight since the migration of fully denatured
RNA is in linear proportion to the Log10 molecular weight
(Lehrach et al., 1977).
20ug of total RNA (up to lOul volume with DEPC-treated
water) was denatured with lOul formamide deionised by
mixing with mixed bed resin pH7 for 30 minutes, filtered
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and stored in aliquots in tightly capped tubes at -20°C)
and 2.5ul 37% (12.2M) formaldehyde (pH>4.0) in the
presence of 2.5ul lOx MOPS buffer (0.2M
morpholinopropanesulphonic acid (MOPS) pH 7.0, 50mM
sodium acetate pH7.0, 5mM EDTA) at 55®C for 20 minutes in
a waterbath, 2ul loading buffer (50% glycerol, ImM EDTA
0.4% bromophenol blue, 0.4% xylene cyanol) and lul
lug/ul ethidium bromide were added to each sample (total
volume 28ul). The denatured specimens were loaded onto a
0.66M formaldehyde , 1.1% high purity agar gel which
allowed accurate RNA molecular weight determinations in a
20cm x 30cm gel tank, submerged beneath lx MOPS buffer
and the RNA species separated by electrophoresis at 60v,
0.4amps from an EC 105 power source until the dye fronts
Were 4cm ( Xylene ) and 10cm (Bromophenol blue) from the
loading pit. The MOPS buffer was circulated through ice
using a lOrpm Crouzet pump.
At least six standard RNA specimens were run on each gel
to allow comparison by densitometry at a later date.
Northern Blotting
The gel was washed in 2 changes of lOx standard saline
citrate with gentle shaking on a Luckham skaker and
photographed.
To blot the RNA, a blotting tank made from a seed tray,
sheet of plate glass, 17mm Whatman chromatographic paper
dipped in the lOx SSC to act as a wick. The gel was
inverted such that the RNA lay uppermost in the gel and
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the a Hybond-N nylon filter placed on top with care taken
to exclude bubbles. The assembly was completed with 2
sheets of 3mm Whatman chromatographic paper and 30 paper
towels on top as the salt wick. Blotting proceded for 8-
12 hours, the Hybond was rinsed in 2x SSC, air dried and
the RNA covalently fixed to the Hybond membrane using 3
minutes and 45 seconds exposure to ultra-violet light
from a UV transilluminator. The Hybond and remaining gel
were photographed to check for adequate transfer of
ethidium stained material (Denis et al., 1988) and to
mark the position of the ribosomal RNA bands.
Hybond filters were labelled and stored in sealed plastic
bags at 4°C.
Hybridisation and washing conditions
Filters sealed in a heavy duty plastic bag were
prehybridised in 7% SDS, 0.5M disodium hydrogen phosphate
pH 7.2 and ImMol EDTA pH7.0 (modified from Church &
Gilbert, 1984) for 30 minutes at 65°C in a shaking water
bath. To this was added 32P cytidine triphosphate (CTP)
labelled cDNA probe labelled to 1 x 107cpm ml-1 using
the Randomprime DNA labelling kit (Feinberg &
? 9
Vogelstein, 1983). P CTP incorporated probe was
separated from unincorporated radionucleotide by passage
down a sephadex G-50 column to give incorporated probe in
400ul lOmM Tris hydrochloride pH7.5 containing ImM EDTA
and denatured by heating to 98°C for 2 minutes and then
put on ice before addition to the hybridisation solution.
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Hybridisation proceded at 65°C for 24 hours in a shaking
water bath.
Following hybridisation, filters were stringently washed
to remove nonspecifically attached probe in 2 changes of
500ml of 0.1% SDS lOmMol disodium hydrogen phosphate wash
buffer at 65°C with gentle agitation in a Gallenkamp
Orbital Shaker for 5 minutes then, with the second change
of buffer, for 30 minutes. Filters were blotted dry,
wrapped in cling film and autoradiographed. The size of
mRNA species was calculated from the position of
ribosomal RNA markers. Filters were reprobed upto six
times with different cDNA probes; before reprobing,
filters were stripped of residual probe by washing at
80°C for 60 minutes in 0.1% SDS in a Grant SS40-2
waterbath and the filter checked by autoradiography for
48 hours. Care was taken not to allow the filter to dry
out.
DNA Extraction from blood and tumour
Each patient from whom tumour tissue was to be obtained
consented to donating 20ml of venous blood prior to
surgery or therapy other than tamoxifen. The blood was
spun in a swing out rotor of a Wifug 500E centrifuge at
3000 rpm (lOOOg) for 5 minutes and the plasma aspirated.
DMEM was added to the blood to total 20 ml, gently mixed,
19ml of lysis buffer and 1ml 20%SDS added, the blood
mixed and placed at 4°C for 30 minutes. The lysed blood
was gently mixed with an equal volume of glass distilled
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grade phenol and spun at 3000rpm for 10 minutes. The
supernatant was saved and a half volume of ammonium
acetate and two volumes of isopropylalcohol added, mixed
and allowed to stand for 12 hours at 4°C. The DNA strands
were spooled out using hooked glass rods made in house
from glass pipettes and allowed to air dry for 20
minutes. The blood DNA was redissolved in 10ml
1
resuspension buffer lOug ml x RNAase was added to the
resuspended DNA and incubated at 37°C for 30 minutes.
Tumour DNA was extracted from frozen tissue by placing
finely chopped tumour tissue in lysis buffer containing
1% SDS and lysis allowed to occur at 4°C over 12 hours.
_ 1
To this tumour DNA in lysis buffer, lOug ml RNAase was
added and the mixture incubated at 37°C for 30 minutes.
To blood DNA or tumour DNA incubated at 37°C with RNAase
1for 30 minutes, 50ug ml ± freshly dissolved proteinase K
was added and the mixture further incubated in a
waterbath at 37°C for 60 minutes. An equal volume of
phenol was mixed with the aqueous DNA containing solution
and left to stand for 20 minutes on ice. The
phenol/resuspension buffer were separated by
centrifugation at 3000 rpm (lOOOg) for 5 minutes, the
supernatant was aspirated and mixed with 24:1
chloroform/isoamylalcohol and again centrifuged at 3000
rpm for 5 minutes. The supernatant was aspirated and a
half volume of ammonium acetate and 2 volumes 100%
ethanol gently mixed in and left at -20°C for 12 hours.
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The DNA was then spun out on hooked glass rods, air dried
for 30 minutes, and redissolved in 500ul TE buffer. The
smaller fragments of DNA were not recovered. Following
spectrophotometry, DNA was stored in screw top eppendorf
tubes at 4°C or in aliquots at -70°C for long term
storage.
DNA Digestion
5ug DNA was digested with 5 units per ug DNA of the
restriction endonuclease appropriate for the probe to be
used. Digestion was carried out in total volume 40ul or
60ul made up with distilled water in eppendorph tubes
with the appropriate buffer. Spermidine was routinely
added to all digestions and triton X added, in addition,
to Msp 1 digests. Digestions were carried out at 37°C
(except for Taq 1, 75°C) in a water bath over 4 hours and
further enzyme (2 units per ug DNA) added and allowed to
digest for a further 2 hours. 4ul orange G was added to
the digested DNA and the DNA was immediately used for
electrophoresis.
DNA Electrophoresis
A 0.8% agarose gel (2.4g agar in 300ml lx TAE buffer) a
20 x 40cm gel tank was loaded with up to 22 samples (11
tumour/blood pairs ) and digested lambda markers, lx TAE
buffer was used to submerge the gel and the gel run for a
suitable time to ensure separation of the DNA species of
interest (18 hours for 2 kb species), at 60v 0.2 amperes
from a E-C power pack. Buffer was circulated through ice
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using a Crouzet lOrpm pump to ensure the temperature and
pH of the buffer remained satisfactory.
On completion of the electrophoresis, the gel was placed
in a plastic tray, 1 litre of the TAE buffer used in the
electrophoresis poured into the tray and the DNA in the
_ -I
gel stained with 20ul ethidium bromide lOug ul for 30
minutes. The gel was destained in distilled water for 10
minutes and photographed under ultraviolet light. The
resulting photograph was studied to ensure that the gel
had run correctly (gel tracks straight),to determine
whether adequate samples had been loaded and whether or
not digestion of the samples had occurred.
DNA Blotting
The DNA fragments were transferred to a hybond-N by an
alkali blot modification of the Southern Blotting
technique (Southern, 1975). A photographed gel was placed
in denaturing solution for 10 minutes, placed on a single
layer of denaturing solution soaked 17mm Whatman
chromatography paper, itself on cling film on a benchtop.
Hybond was placed on top of the gel followed by two
layers of denaturing solution moistened 3mm Whatman
chromatography paper and 30 dry paper towels, maintained
in place with a 7mm thick perspex sheet.
Blotting proceded over 6 hours, after which the Hybond
was removed and placed in neutralising solution for 30
minutes, air dried and the DNA bonded to the Hybond
membrane by exposure to ultra-violet light from a UV
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transillurainator for 4 minutes followed by baking at 80°C
under vacuum in an oven for 1 hour.
Hybridisation and washing conditions
The membrane was prehybridised in 30ml hybridisation
buffer in a sealed polythene bag in a 65°C shaking water
bath for 45 minutes. To this, 107 cpm ml-1 32P CTP-
labelled probe insert was added and allowed to hybridise
for 24 hours. Probes were labelled by the randomprime
labelling method (Feinberg & Vogelstein, 1983) using a
kit and unincorporated probe removed by ethanol
precipitation. To 20ul of labelling reaction, 7.5ul 3M
-I
sodium acetate, 25ul lOmg ml sonicated salmon sperm
(carrier) DNA and 250ul ethanol were added and left at
-20°C for 15 minutes. The precipitated random primed
probe was collected by centrifugation at 4°C, 13000rpm
(2000g) for 15 minutes in an eppendorf centrifuge and
redissolved in 200ul lOmg ml--*" sonicated salmon sperm DNA
in TE, heated to 98°C for 2 minutes and placed on ice for
5 minutes then added to the prehybridisation solution.
Following precipitation, the pMCT 35.1 and pBHp53 probes
_ -I
were taken up in 180ul 1.5mg ml sonicated tonsil (total
human) DNA, boiled for 10 minutes and the probe
reannealed to total human DNA at 66°C for 45 minutes to
reduce nonspecific hybridisation to the digested genomic
DNA (modified from Sealey et al., 1985).
Excess probe was washed from the membrane using 3
successive 30 minute washes of 0.1% SDS with 0.5, 0.2 or
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O.lxSSC and 0.1% sodium pyrophosphate at 65°C and the DNA
fragments of interest were detected by autoradiography.
DNA Sequencing
DNA from selected patients in whom there were allelic
losses on the short arm of chromosome 17 and/or increased
expression of p53 mRNA was examined in detail for DNA
base changes. The published literature gives the sequence
for p53 exons but only to a very limited extent for p53
introns (Mowat et al., 1985, Zakut-Houri et al. , 1985,
Lamb & Crawford, 1986, , Tan et al. , 1986, Buchman et
al. , 1988, Finlay et al., 1988 ). Evidence in other
malignancies such as colon cancer (Baker et al., 1989)
indicates that mutations in exon 5 and exon 6 may cause
functional change from tumour suppressor gene to
oncogene. Therefore, oligonucleotide primers were
synthesised by the Oswell DNA Service, Department of
Chemistry, University of Edinburgh, West Mains Road,
Edinburgh to the 20 nucleotide 5'end of exon 5 (primer 1)
and the 20 nucleotide end of the 3' end of exon 6 (primer
2) . The DNA amplification and sequencing techniques were
adapted from published techniques by Dr J Prosser, MRC
Human Genetics Unit, Western General Hospital, Edinburgh.
From lug DNA extracted from a tumour or from the
patient's blood, exons 5 and 6 were selectively amplified
using the polymerase chain reaction (Saiki et al., 1985a,
Saiki et al., 1985b, Erlich et al. , 1988), and DNA
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purified from this reaction sequenced using dideoxy
labelling (McGraw et al. , 1988).
Polymerase Chain Reaction
lug DNA from each patient's blood or tumour was incubated
with primer 1 (5'TTCCTCTTCCTGCAGTACTC), primer 2
(5'AGTTGCAAACCAGACCTCAG) buffer (1.5mM MgCl2, 0 . ImM
dNTP's) with water added to lOOul and 0.5ul Taq
polymerase. The mixture was submerged beneath 90ul
paraffin to prevent evaporation and placed in the heat
block of a Techne PHC-1 Dri-block.
Twenty five cycles of 94°C for 2 minutes (to separate the
double strands of the DNA), 55°C for 2 minutes (to
reanneal) then 72°C for 3 minutes (to allow
polymerisation) were used with a final 5 minutes at 72°C
after the 25 cycles (total time approximately 5 hours).
lOul from the aqueous phase was then run on a 1% agarose
TE gel, stained with ethidium bromide and photographed to
check DNA had been amplified and the resultant fragment
size of 408 base pairs was as expected. Up to 20
individual samples were amplified in this way at one
time.
DNA Purification
The remaining 90ul of polymerised DNA was loaded onto a
1.0% low melting point agarose gel and run at 60v for 4
hours.
The gel was again stained with ethidium bromide and
photographed under ultraviolet light. The agarose bearing
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the single band of interest for each specimen was excised
under ultraviolet light control and placed in a labelled
eppendorf tube.
The DNA was purified from the low melting point agarose
with a Geneclean kit, which uses a method described by
Vogelstein and Gillespie (1979). The weight of the DNA-
bearing agarose was calculated by subtracting the weight
of an empty eppendorf tube from that containing a sample.
Two volumes of 6 M sodium iodide Solution were added to
the agarose and the tube placed in a 45°C water bath for
5 minutes to melt the agar.
To the resulting approximately lOOOul of sodium iodide
and agar, 8ul of glassmilk suspension was added, the
eppendorf contents vortexed and replaced in the 45°C
water bath for 5 minutes. The sample was then placed on
ice for 5 minutes with vortex mixing every minute. The
glass milk (silica pellets to which the DNA is bound) was
pelleted by a 5 second spin in a microcentrifuge and the
supernatant poured off.
The pellet was washed 3 times in ice cold NEW wash
(sodium chloride, tris, EDTA in water/ethanol mixture).
After each wash the glass milk was pelleted by 5 second
centrifugation and the supernatant discarded, with the
final few microlitres aspirated from the eppendorf tube
with a micro pipette.
The DNA was then eluted from the silica by the addition
of lOul lx TE buffer (pH 7.5), incubated at 45°C and the
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supernatant containing the DNA aspirated from the glass
milk and transferred to a labelled eppendorf tube. This
was repeated with a fresh lOul of lxTE buffer to remove
the remaining DNA from the glass milk to a total 20ul
sample. 3 ul of this sample were run on a check 1%
agarose gel, the gel stained with ethidium and
photographed to confirm good recovery of DNA without
contaminants. The remaining sample was stored frozen at
-20°C until used for sequencing.
DNA Sequencing
Both alpha 35S and gamma 32P were utilised with the
sequenase DNA sequencing kit using dideoxynucleotide
labelling (modified from Winship et al., 1989).
Annealing Reaction
DNA obtained by use of the polymerase chain reaction was
annealed to either primer 1 or primer 2. To 50ng DNA,
sequencing buffer (2ul), primer 250ng (lul), lul 10% DMSO
made up to total lOul with distilled water was placed in
a hot block at 100°C for 2 minutes and then chilled on
ice.
Sequencing Reaction
To the lOul annealed DNA was added 0.1m DTT (lul) 1:15
diluted appropriate labelling mix (2ul), 1:6 diluted
sequenase enzyme (1.5ul), 35S or 32P labelled ATP or CTP
(0.5ul) and the mixture incubated at room temperature
(20°C) for 1 to 5 minutes
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Termination Reaction
3.0 ul of sequencing reaction mixture was added to each
of four stop reactions in separate labelled eppendorf
tubes containing 2ul of ddGTP, ddATP, ddTTP or ddCTP
diluted with 1 in 10 parts 10% DMSO. The termination
reaction was allowed to proceed for 5 to 10 minutes at
37°C, 4ul stop solution was added to each tube and the
samples stored frozen until loaded on a sequencing gel.
Sequencing Gels
Sequencing was performed on Sequi-Gen nucleic acid
sequencing cells using a Sequigel sequencing system. A
gradient gel of 0. 5x to 5x Tris borate EDTA (TBE) of
uniform 0.4 ram thickness was used, which gives good
resolution of sequences up to 150 nucleotides long
(Maniatis et al., 1982).
A plug of 40% bi s/acrylamide (38g acrylamide, 2g
bisacrlyamide in lOOmls) was made by adding 9.5 ml 40%
bis/acrylamide and 0.5ml 20x TBE. To this 125ul ammonium
persulphate and 50ul TEMED were added and the quick
setting gel drawn up to form a plug between the two glass
plates in the bottom of the gel apparatus. The gradient
gel was made from:
0.5X TBE 5X TBE
40% bis/acrylamide 6ml 1. 5ml
20x TBE 1ml 2 . 5ml
urea 17g 4 . 25g
sucrose nil 2g
distilled water to 40ml 10ml
ammonium persulphate 240ul 60ul
(10%)
TEMED 35ul 7ul
Bromophenol blue nil few grains
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To pour the gel, 19ml 0.5 TBE was drawn up into a 50 ml
syringe, then a further 6 ml of the blue 5xTBE drawn up
into the same syringe and the two mixed. The gel was then
poured taking care not to incorporate any bubbles to
form a gradient gel with the 5xTBE (blue) at the lower
part of the gel. A sharks tooth comb was introduced into
the top of the gel and the gel left to solidify for at
least 30 minutes at an angle of 30 degrees above the
horizontal.
Loading Gels
Gels were prerun at 25 watts (with amperage and voltage
non limiting) for 30 minutes. Sequenced samples were
denatured by heating to 100°C for 2 minutes and then
placed on ice until loaded. 1.0 to 1.5 ul per sample were
loaded using a lOul Hamilton syringe and the tip (made
from a plastic tip drawn out in a flame) flushed with
water between loadings. The samples were then run in
until the dye front was 1 cm above the bottom of the gel.
The gel was then carefully lifted on one glass plate and
placed in 1 litre of gel fixative (10% methanol, 10%
acetic acid in water) for 30 minutes then dried in a
vacuum gel drier and autoradiographed.
Probes
Probe Growing
cDNA probes were used for the identification of
complementary RNA sequences in the total or poly(A+) RNA
bound to Hybond filters. Individual probes were grown
104
with the assistance of Mrs. I McKenzie, from stocks held
at the MRC Human Genetics Unit, Western General Hospital
Edinburgh and stored in glycerol in -70°C or as stabs in
agar maintained at 4°C.
Plasmid DNA (O.lug) was used to transform competent E.
coli DH1.
10ml T-broth was inoculated with a single colony, and
incubated with shaking at 37°C overnight. From this
preculture, 0.1ml was inoculated into 4x25ml T-broth
until the optical density at 600nm reached 0.6 and
4x250ml prewarmed T-broth innoculated with 12.5ml of this
late log phase culture and incubated at 37°C vigorously
shaking in an orbital shaker for 150 minutes, 1.875ml of
_ 1
20mg ml chloramphenicol added to each flask and shaking
continued overnight.
From 500ml of this culture, the cells were harvested at
6, 000 rpm (3000g) for 10 minutes at 4°C and the pellet
resuspended in 2 ml of glucose mix (50mM glucose, 25mM
tris pH 8.0, lOmM EDTA, filtered and autoclaved) and lOmg
lysozyme dissolved in 18ml glucose mix added and placed
on ice for 30 minutes. 40ml of alkaline-SDS (0.2M sodium
hydroxide, 1% SDS) was added and the mixture gently mixed
on ice until the homogenate was clear then left to stand
on ice for 10 minutes.
30ml 5M potassium acetate pH 4.8 was added, the mixture
stirred and incubated on ice for 30 minutes while a
course white precipitate formed. The supernatant was
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collected after 10 minutes centrifugation at 12000 rpm
(5000g) and 4°C, transferred to a clean bottle and 2
volumes (10ml) ethanol at -20°C added and the precipitate
formed at -20°C for 30 minutes. The precipitate was
collected by centrifugation at 10000 rpm (4500g) for 10
minutes and resuspended in 10ml TE.
5ml of 7. 5M ammonium acetate was added and the mixture
left for 20 minutes on ice, the precipitate separated by
centrifugation at 12000 rpm (5000g) for 20 minutes, 2
volumes of ethanol at -20°C added, the precipitate
collected by centrifugation at 12000rpm for 30 minutes
and the pellet taken up in a total 4ml TE.
lOug ml-1 RNase was added and incubated at 37°C for 15
minutes; 200ul 20% SDS then lOOug ml-1 proteinase K added
and the mixture incubated for at least 1 hour at the same
temperature.
Following phenol/chloroform (1:1) then chloroform
extraction, 1/10 volume of 3M sodium acetate then 2
volumes of ethanol were added and the plasmid DNA
precipitated at -20°C overnight. The precipitate was
collected by centrifugation at 12000rpm (5000g) for 30
minutes and the pellet finally dissolved in 1 ml lOmM
Tris/lmM EDTA.
A small aliquot of plasmid DNA was run on a 1% agarose in
TAE gel alongside Hindlll/EcoRl digested lamda DNA as a
marker, stained with ethidium and photographed to ensure
it was of the expected size and that there was no
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remaining protein or RNA.
Half the plasmid DNA was digested with a suitable
restriction enzyme to cut out the probe insert and lOul
of the resultant digest run on a 1% agarose in TAE buffer
gel alongside lamda DNA digested with Hindlll and
Hindlll/EcoRl, stained with ethidium and photographed.
The correct digestion of the plasmid / cDNA was
confirmed. The remaining digested plasmid was run on a 1%
low melting point agarose gel, and following ethidium
staining the appropriate band excised from the gel. The
agarose bearing the desired fragment was placed in the
upper chamber of a Spinex column and the insert DNA
collected following centrifugation at 13000rpm (2000g)
for 10 minutes in a eppendorf centrifuge. The collected
solution was extracted with phenol/chloroform (1:1) and
Chloroform and precipitated by the addition of a half
volume of 3M sodium acetate and 2 volumes of ethanol. The
probe was redissolved in lOOul TE and the concentration
of cDNA probe insert estimated by running an aliquot of
the purified insert alogside lug Hindlll lamda DNA on an
agarose gel and ethidium staining the resultant gel. A
dilution of the insert was then made up such that 25-50ng




Probes used for Northern blots:
c-erbB2 : Semba et al., (1985)
pEJ : Shih & Weinberg, (1982)
c-myc : Land et al., (1983)
p53 : Zakut-Houri et al., (1985)
TGF-a : Derynck et al., (1984)
TGF-B : Derynck et al., (1985)
Epidermal growth factor receptor : Ullrich et al., (1984)
OR3 : Walter et al., (1985)
pS2 : Masiakowski et al. , (1982)
Actin : Minty et al. , (1981)
Probes used tQ. examine 17p allele loss:
YNZ 22.1 : Nakamura et al., (1988)
pHp53Bam : Zakut-Houri et al., (1985)
pBHp53 : Hoyheim et al. , (1989)
pMCT 35.1 : Carlson et al., (1988)
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Spectrophotometry
The quantity and the purity of the extracted RNA was
assessed by spectrophotometry at 260nm and 240nm with
ultraviolet light (Maniatis et al. , 1982 ) from a
deuterium source. The quantity of RNA extracted was
calculated using a dilution of 2 to 5 ul RNA sample in
700ul water from the formula:
RNA Extracted =
optical x dilution x correction x volume of
density factor factor RNA
at 260nm (40) sample
and the purity from the 260nm/240nm ratio (Maniatis et
al., 1982).
Similarly, the quantity of DNA was calculated from:
DNA Extracted =
optical x dilution x correction x volume of
density factor factor DNA
at 260nm (50) sample
and the purity from the 260nm/280nm ratio (Maniatis et
al., 1982).
The total quantity of RNA or DNA extracted from a given
piece of tissue was calculated.
Photography
RNA and DNA gels and Northern blot Hybond membranes were
photographed under a UV transilluminator using a 15
second exposure to 4inch x 5 inch Kodak Professional Film
with a Polaroid MP4 land camera and the film developed in
an X-ray film processor.
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Autoradiography
Filters or dried sequencing gels were exposed to Kodak
XAR preflashed film for 48 hours at -70°C in a light
tight cassette using intensifying screens and the film
was developed in an X-ray film processor. A further
exposure to preflashed Kodak XAR film was then made to
obtain a radiograph of optimal definition using the same
exposure conditions, for up to 14 days exposure.
Densitometry
The extent of hybridisation of radiolabelled probe to the
mRNA species was determined from densitometry using a
laser densitometer constructed by the Medical Research
Council Human Genetics Unit and expressed with respect to
hybridisation to the actin probe.
Statistical Analysis
The appropriate statistical analyses were determined in
consultation with Dr. A Carrothers, Statistician, MRC
Human Genetics Unit, Edinburgh. Statistical analysis was
performed using the "Kwikstat" and "Epistat" IBM
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Patients
Fresh breast tumour tissue and venous blood was collected
from 80 female patients. Of the 80 patients 15 had
received tamoxifen prior to surgery and 12 yielded both
pretreatment and, following chemotherapy or endocrine
therapy, post-treatment (mastectomy) specimens. Full
patient documentation and all relevant pathological and
biochemical data were available for every specimen.
Good quality, undegraded total RNA and DNA was extracted
intact from all 92 tumours and DNA extracted from the
corresponding 80 blood samples. Total RNA was also
extracted intact from 10 reduction mammoplasty specimens,
from other normal human tissues including tonsils, ovary
and myometrium and from the human breast cancer cell
lines MCF-7, T-47D and MDA MB 231.
Gene expression
mRNA for p53, c-myc, c-erbB-2, H-ras, TGF-J3 and pS2 was
detected on Northern blots of breast tumour RNA, breast
cancer cell line RNA and normal human RNA (figures 3 &
4). Using laser densitometry, autoradiographs of Northern
blots bearing up to 48 samples were examined to
quantitate the expression of these mRNA species relative
to actin mRNA. On each Northern blot, 3 breast cancer
cell lines 4 normal human tissues and 4 tumours were used
as internal controls to standardise between the
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individual blots. Each filter was successfully reprobed
up to 5 times. Samples that gave reproducible levels of
gene expression with respect to actin (the internal
control) on laser densitometry on more than one blot
were used for analysis of mRNA levels in relation to
clinical and pathological data.
Quantitative differences were noted between different
tumours for all the probes compared with the actin
control and qualitative differences between the
tumours/normal tissues and the breast cancer cell lines
were identified using the probes for p53, c-erbB-2 and
pS2.
Gene expression (mRNA) was either undetectable,
detectable and upto 1.5 times that found in control
(reduction mammoplasty) breast tissue (if gene expression
was detected in the control tissue), or overexpressed (at
least twice the level found in control breast tissue).
Where no mRNA was detected in the control breast tissue,
then the detection of an mRNA species was considered on a
"present" or "absent" basis in the tumours.
For example, a 2.8 kilobase p53 mRNA was detected in 43
of the 76 tumour specimens (57%), in all 3 breast cancer
cell lines and in six of the ten reduction mammoplasty
specimens (figure 3) . Low levels of this p53 mRNA
(comparable to those found in the six positive
mammoplasty specimens) were also detected in normal human
tonsil, uterus and ovarian tissue (data not shown). There
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were quantitative differences between the tumour
specimens and qualitative differences between the tumours
and the cell lines. Thirty-three of the 76 patients had
no detectable p53 mRNA in their tumour tissue, 19
patients had detectable p53 mRNA of 2.8kb similar in
quantity to the reduction mammoplasty specimens that gave
a positive signal. 24 patients had increased levels of
the 2. 8kb p53 mRNA approaching those found in the cell
lines.
The 3 breast cancer cell lines each yielded four p53 mRNA
species. Three closely related species were of
approximately 2.8kb, with differences between cell lines
in the amounts of mRNA for each of these species. A
fourth (1.6kb) p53 mRNA was strongly expressed in all
three lines.
A single mRNA for c-myc of 2.5kb, a single mRNA for H-ras
of 1.4kb and one species of 2. 5kb for TGF-J3 were each
identified in a proportion of the tumours, normal tissues
and the breast cancer cell lines (figures 3 & 4) . In
breast tumours, c-erbB-2 expression was detected as a
4.8kb mRNA, although no expression was demonstrated in
normal breast tissue and mRNA species of 3.0kb, 2.8kb and
1. 8kb were noted in the MCF-7 cell line (figure 3).
Similarly, a 600 base pair single mRNA for pS2 was
identified in some of the tumours, but not in the normal
tissue and two additional mRNA species of 3kb and 1.6kb
were found in the MCF-7 cell line (figure 4).
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Figure 3 : Representative Northern blot results of
oncogene expression in human breast cancer tissue, breast
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Gene expression of p53, c-myc, c-erbB-2, H-ras and actin
control; sizes in kilobases (kb) calculated from
ribosomal RNA size markers of 4 . 7kb (28s) and 1.8kb
(18s). Autographs obtained by probing Northern blots of
total RNA with the exception of MCF-7 samples which were
polyA+ RNA.
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Figure 4 : Representative Northern blot results of growth
factor and oestrogen regulated gene expression in human
breast cancer tissue, breast cancer cell lines and normal
tissues.
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Gene expression of TGF-B, pS2 and actin control; sizes in
kilobases (kb) calculated from ribosomal RNA size markers
of 4.7kb (28s) and 1.8kb (18s). Autographs obtained by
probing Northern blots of total RNA with the exception of
MCF-7 samples which were polyA+ RNA.
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Clinical and pathological correlation
For each tumour, the quantity of mRNA expressed for each
gene under study was assessed in relation to clinical and
pathological parameters.
Overexpression of mRNA for the oncogene c-myc was
significantly associated with small tumour size (p <0.05;
table 1). There were no significant associations between
p53, c-erbB-2, H-ras, TGF-B or pS2 mRNA expression and
tumour size.
Table 1 : Gene expression compared to clinical tumour
size at time of diagnosis.
PROBE
p53 c-myc c-erbB-2 H-ras TGF-B pS2
0N + 0N+ 0 + 0 N + N + 0 +
(No.Tumours examined)
(76) (76) (71) (79) (56) (78)
TUMOUR
SIZE
<5cm 16 12 15 15 16 12 24 16 20 12 11 9 25 27 17
>5cm 17 7 9 20 4 9 26 5 19 14 3 2 20 26 8
NS p=0.028* NS NS NS NS
0, no expression detected;
N, gene expression as in normal tissue;
+, increased gene expression.
* Chi square test (Yates correction).
NS Not Significant.
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Overexpres sion of mRNA for p53 was associated with
clinically insignificant levels of oestrogen receptor
protein (p =0.049) and pS2 overexpression correlated
with tumours showing significant levels (greater than 20
fmol mg protein-1) of oestrogen receptor protein
(p=0.02) (table 2). There were no significant
association between overexpression of c-myc, c-erbB-2,
H-ras, or TGF-B and tumour oestrogen receptor protein
content.
Table 2 : Gene expression compared with tumour oestrogen
receptor protein content.
PROBE
p53 c-myc c-erbB-2 H-ras TGF-beta pS2
0N + 0N+ 0 + 0 N + N + 0 +
(No.Tumours examined)





<20 13 5 15 14 7 13 26 8 15 12 8 4 22 27 6
>20 20 14 9 21 13 8 24 13 24 14 6 7 23 26 19
p=0.049* NS NS NS NS p=0.02+
0, no expression detected;
N, gene expression as in normal tissue;
+, increased gene expression.
* Chi square test (Yates correction).
+ Fisher's exact test.
NS Not Significant.
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Overexpression of mRNA for c-myc was associated with
tumours which had not spread to the regional lymph nodes
(p=0.021) (table 3). There were no significant
relationships between mRNA p53, c-erbB-2, H-ras, TGF-B
or pS2 and the presence or absence of metastatic tumour
in the regional lymph nodes.
Table 3 : Gene expression compared with regional lymph
node involvement with tumour.
PROBE
p53 c-myc c-erbB-2 H-ras TGF-beta pS2










Nil 15 7 13 12 8 15 21 13 14 16 7 4 24 24 12
>1 18 12 11 23 12 6 29 8 25 10 7 7 21 29 13
NS p=0.021* NS NS NS NS
0, no expression detected;
N, gene expression as in normal tissue;
+, increased gene expression.
* Chi square test (Yates correction).
+ Fisher's exact test.
NS Not Significant.
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There were no significant associations between expression
of mRNA for p53, c-rayc, c-erbB-2, H-ras, TGF-B or pS2 and
the menopausal status of the patients at the time of
diagnosis.
Table 4 : Gene expression compared with menopausal status
PROBE
p53 c-myc c-erbB-2 H-ras TGF-beta pS2
0 N + 0 N + 0 + 0N + N + 0 +
(No.Tumours examined)
(76) (76) (71) (79) (56) (78)
MENOPAUSAL
STATUS
pre- 13 4 9 9 8 9 14 9 10 12 4 1 18 18 8
menopausal
post- 20 15 15 26 12 12 36 12 29 14 10 10 27 35 17
menopausal
NS NS NS NS NS NS
0, no expression detected;
N, gene expression as in normal tissue;
+, increased gene expression.
* Chi square test (Yates correction).
NS Not Significant.
There were no significant correlations between expression
of any of the genes under study and the histological
features of the tumour including pathological grade.
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c-erbB-2 mRNA expression was compared to c-erbB-2
antibody staining using the antibody 21N (Gullick et al. ,
1987) in tissue sections of 31 tumours examined by Miss
Claire Reid, Department of Pathology, University of
Edinburgh. Immunohistochemical data were recorded without
prior knowledge of c-erbB-2 mRNA findings. Protein
expression correlated strongly with mRNA expression
(p=0.0004, Fisher's exact test; table 5) although
c-erbB-2 mRNA expression was detected in some tumours in
which no antibody staining was detected .
Table 5 : Comparison of c-erbB-2 mRNA expression with







Fisher's exact test p=0.0004
Overall, these data demonstrate that quantitative
differences in gene expression were evident between
tumours compared to control tissues and the expression of




At the time these results were collated, three
publications suggested that loss of genetic material from
17p was common (over 60%) in breast tumours (Mackay et
al., 1988b, Devilee et al., 1989a Devilee et al., 1989b).
These data were obtained using a VNTR probe (YNZ 22.1,
Nakamura et al . , 1988) that maps within the same
chromosomal band (17pl3) as the gene for p53 (Isobe et
al., 1986). Since allele loss may be associated with loss
of a tumour suppressor locus, and the dispute as to the
function of p53 as oncogene (Editorial, Oncogene 1988)
or tumour suppressor gene (Green, 1989) remained
unresolved, p53 gene expression was compared with allele
loss from 17pl3.
Using the Southern blot technique, allele loss, or
diminution of an allele signal to less than 50% of the
predicted level, when the relative intensities of the
unaffected allele band were measured in tumour and blood
leukocyte DNA tracks by laser densitometry, was
determined in blood/tumour pairs of DNA. Using probes YNZ
22.1 (17pl3.3), MCT 35.1 (17pl3.1), pBHp53 (17pl3.1) and
php53Bam (17pl3), alleles were examined in the 80
untreated or tamoxifen treated tumours as far as the
limited quantity of DNA allowed (figure 5). The cDNA
probe used to detect p53 mRNA, php53Bam was not
sufficiently informative for use on the blood/tumour
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paired DNA; less than 10% of human tonsil samples were
informative (i.e. heterozygous) with this probe.
Figure 5 : Representative allele losses for chromosome
17p.
YNZ 22.1 IV!CT 35.1 pBHp53
B T B T B T
Examples of autoradiographs of DNA from 3 patients
comparing constitutional, blood leucocyte, DNA (B) with
tumour DNA (T). Two bands (alleles) are present with each
probe in the constitutional DNA and hence these patients
are constitutionally heterozygous (informative). There is
loss of an allele in the tumour DNA demonstrating loss
of genetic material from 17p for each of the 3 loci
examined. The faint second band in the tumour DNA
detected with probe MCT 35.1 almost certainly represents
heterozygous normal tissue DNA within the cancer tissue
examined (Mackay et al., 1988b)
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Overall, 72 of the 80 patients were informative for 1 or
more of these 3 probes, with 46/72 (64%) exhibiting
allelic loss from 17pl3. Four patients who were
informative for all three probes had allelic loss for all
three loci. While there was no consistent pattern of
allele loss, loss from 17pl3 for each probe was over 50%
for loci telomeric to p53 and 35% at the p53 locus (table
6) .



















Allele loss identified with each of these probes was
related to clinical and pathological features of the
tumours and to expression of the p53 gene.
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YNZ 22.1 allele loss did not correlate with with tumour
size, low level of oestrogen receptor protein, regional
lymph node involvement or menopausal status (table 7).
Table 7: Correlation between YNZ allele loss and clinical
and pathological parameters.
TUMOUR OESTROGEN NODES MENOPAUSE
SIZE RECEPTOR INVOLVED
<5cm >5cm <20 >20 nil >1 pre post
Allele
loss 17 14 20 11 12 19 13 18
No allele 14 9 8 15 11 12 8 15
loss
NS NS NS NS
pBHp53 allele loss did not correlate with tumour size,
oestrogen receptor protein, regional lymph node
involvement or menopausal status (table 8).
Table 8 : Correlation between pBHp53 allele loss and
clinical and pathological parameters.
TUMOUR OESTROGEN NODES MENOPAUSE
SIZE RECEPTOR INVOLVED
<5cm >5cm <20 >20 nil >1 pre post
Allele 96 69 96 96
Loss
No allele 13 15 13 15 12 16 7 21
loss
NS NS NS NS
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There were no correlations between MCT 35.1 allele loss
and the clinical or pathological features of the tumours
(table 9).
Table 9 : Allele loss of MCT 35.1 compared with clinical
and pathological parameters.
TUMOUR OESTROGEN NODES MENOPAUSE
SIZE RECEPTOR INVOLVED
<5cm >5cm <20 >20 nil >1 pre post
Allele 95 77 86 77
Loss
No allele 85 58 58 49
loss
NS NS NS NS
p53 gene mRNA expression was compared to allele loss
demonstrated with each of the three probes for
informative patients (table 10) . p53 mRNA overexpression
was associated with YNZ 22.1 allele loss (p = 0.042, Chi
square test) but not with pBHp53 or MCT 35.1 allele loss.
Table 10 : p53 mRNA expression compared to 17pl3 allele
loss.
p53 EXPRESSION YNZ 22.1 P53 MCT3 5 . 1
Loss No loss Loss No loss Loss No loss
Nil 11 13 6 15 8 4
Normal 6 7 6 4 1 4
Increased 14 3 3 9 5 5
Chi square test: p=0 . 042 not applicable
Fisher exact test : p=0 .017 p=0 . 32 p=0 . 16
(for Nil/Normal v increased expression)
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Four of the cancer specimens collected on histological
examination contained only in situ (pre-invasive ) breast
cancer tissue (table 11).
Table 11 : p53 mRNA expression and 17pl3 allele loss in 4
in situ 'cancer specimens •
SPECIMEN p53 mRNA ALLELE STATUS FOR PROBE
NUMBER EXPRESSION YNZ 22.1 MCT 35.1 pBHp53
11 Overexpressed no loss no loss no loss
18 No expression no loss not done no loss
77 No expression homozygous loss no loss
92 No expression homozygous homozygous loss
Thus, one of the four specimens showed increased
expression of p53 and allele loss at MCT 35.1 and pBHP53
was seen in one case each. These findings are in line
with what would be predicted from the total tumour
collection. A larger series of non-invasive cancers will
need to be studied to establish whether the frequency of




After 18 months mean clinical follow up from the
definitive surgical procedure (range 4 to 24 months), 15
of the 80 patients (19%) had recurrence of their breast
cancer and 5 of these patients (6% of the original 80)
had died , all from the effects of metastatic breast
cancer. The total number of such patients is
comparatively small and the follow up, although
meticulous, is short (18 months). However, a
statistically significant correlation between failure to
express mRNA for pS2 and disease recurrence was
identified (p=0.015, Fishers exact test; table 12). There
were no other statistical associations between expression
of the genes examined and early prognosis or between
allele losses and disease recurrence. The correlation
between lack of pS2 gene expression and poor early
prognosis was less significant than the stage of the
disease at diagnosis or node status. Nevertheless pS2
does appear to be more useful than oestrogen receptor
protein measurement for identifying patients with a very
poor short term prognosis.
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Table 12 : Tumour pS2 mRNA expression as a prognostic
feature for breast cancer in 78 patients compared with
known prognostic features in the overall group of 80
patients.
pS2 Tumour stage Nodes Oestrogen
receptor protein
0 + T2 T3/T4 + - >20 <20
Disease
recurrence 14 1 3 12 14 1 8 7
Disease
free 39 24 42 23 29 36 35 30
p=0.015+ p=0.002+ p=0.0005+ NS




The results from mRNA studies of p53 gene expression and
17pl3 allele loss demonstrate that expression of p53 mRNA
is associated with loss of an allele telomeric to the p53
gene (as demonstrated by YNZ 22.1 loss; p=0.042) but not
with allele loss in the immediate vicinity of the p53
gene (MCT 35.1 and pBHP53). A possible explanation for
this is that the YNZ 22.1 allele loss may represent loss
of a regulatory element for p53 gene expression (which
would not necessarily require to be close to the p53
gene) that allows the overexpression of p53. It was
therefore of importance to determine whether the p53
expressed was from a mutant (and hence potentially
oncogenic) p53 gene. Alternatively, the absence of
detectable p53 mRNA in 33/76 tumours may represent
failure to express the tumour suppressive normal p53
gene. To address this problem DNA sequencing of part of
the the p53 gene was used.
Four blood/tumour DNA pairs (tumour numbers 38, 43, 50
and 92) were examined to determine whether the sequence
of the p53 gene in the tumours might be mutant. Exons 5
and 6 and the intervening intron were selectively
amplified by the polymerase reaction and sequenced with
32P and 35S. A reproducable point mutation of Cytosine to
Guanosine at amino acid 175 in exon 6 was demonstrated in
the tumour of patient 43 (figure 6), but not in the
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patient's constitutional DNA. This represents a change in
the encoded protein from basic histidine to acidic
leucine.




Part of a S sequencing gel autoradiograph for blood and
tumour of patient 43 demonstrating a guanosine band
(indicated by the arrow) present in the tumour DNA (T)
but not in the constitutional DNA (B) at amino acid 175
(numbering from Zakut-Houri et al., 1985).
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No other base changes were identified in exons 5 and 6 or
in the intervening intron in the remaining three
blood/tumour pairs. However, if one considers the p53
expression, allele distribution and sequencing data for
these four tumours together (table 13) the findings still
support the thesis that either loss of normal p53 gene
expression (tumours 50 and 92) or overexpression of
mutant, oncogenic, p53 (tumour 43) may occur in breast
tumours. Further, failure to detect a mutation in tumour
38 at exons 5 and 6 does not exclude the possibility of
significant mutations elsewhere in the p53 gene.
Table 13 : p53 gene expression, 17pl3 allele loss and p53
mutation in 4 breast tumours.
Tumour p53 mRNA Allele status
Number expression YNZ MCT pBHP53
38 Overexpressed loss homo+ homo
43 Overexpressed loss loss loss
50 Nil loss loss loss









Using the regime of 50ug 17B oestradiol benzoate in 50ul
arachis oil injected subcutaneously every three weeks,
xenografts of the oestrogen responsive human breast
cancer cell line MCF-7 were established providing a
renewable source of substantial amounts of tumour
material. This could be transplanted into other mice, or
the cells regrown from the xenografts in vitro and then
reinoculated into further mice.
One hundred and forty-five CBA strain mice were injected
with MCF-7 cells in this study (table 14). Tumour
formation and growth of MCF-7 cells taken directly from
tissue culture ("primary inocula") was observed at the
site of inoculation in 30/57 (53%) mice. The take rate
of transplanted tumour material was higher than that of
primary inocula (23/32, 72%) and was significantly higher
for tumour cells that had been re-cultured in vitro and
then inoculated into fresh mice compared with primary
inocula (16/18, 89% p=0.004 by Fishers exact test).
Tumours did not grow without oestrogen supplementation.
The 50ug oestradiol benzoate in arachis oil, or the
arachis oil alone were well tolerated by the CBA mice and
the oestrogen delivered in this form promoted tumour
growth. Withdrawl of oestrogen supplementation (failure
to administer the supplement at 3 week intervals after
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the tumours had become established) resulted in a decline
in tumour volume.








NUMBER NUMBER OF MICE DEATHS
OF CBA WITH NO
MICE TUMOURS TUMOURS
20 Nil 20 Nil
Cells 50ug oestradiol 69
benzoate
Transplant 50ug oestradiol 36
xenograft benzoate







+ Number of live mice bearing tumours as a percentage of
surviving animals.
Using the same regime of 50ug oestradiol benzoate or no
oestrogen supplement, no tumour growth was obtained
following injection of T-47D or MDA-MB-231 cells into the
CBA mice.
Histopatholoav
Each MCF-7 tumour was firm, pale, solid and well
circumscribed, not showing overt local invasion or
ulceration of the overlying skin. All the tumours were
examined histologically by Dr. David Paterson, Department
of Pathology, University of Edinburgh and were compatible
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with an origin from breast , although they did not show
marked adenocarcinomatous differentiation. There were no
areas of necrosis in the smaller tumours, although the
tumours of 15mm diameter or greater did have evidence of
central necrosis. No marked lymphocyte infiltration was
noted in any tumour.
Microscopic and macroscopic examination of mice which
died and of mice which were killed to obtain tumour
showed evidence of metastasis in only one animal. In that
instance, tumour cells were evident at the site of MCF-7
cell inoculation, as peritoneal seedlings and
microscopically in the visceral pleura of the lung. No
pathological evidence of oestrogen toxicity was found at
post mortem in any animal on the 50ug oestradiol benzoate
regime although there was some hair loss at the site of
the oestradiol injection.
Serum oestradiol concentration
Oestradiol was not detected in the serum from
thymectomised and irradiated mice prior to injection.
After injection with 50ug oestradiol benzoate (figure
_ 1
6), a sharp rise to a mean 7492 pmols L x (S.D. 3374
_ 1
pmols L ) oestradiol occurred by 24 hours,
declining exponentially to undetectable levels (less
_ I
than 53 pmols L ) 2 weeks after the injection. Serum
oestradiol detection and measurement was performed by S.




The tumours became palpable during the first 3 weeks
following 17 £ oestradiol benzoate injection and
following the second and third injections of oestrogen,
the tumour was observed to grow in size, but not in a
uniform fashion (figure 7) . In particular, during the
first 14 days after injection, the tumour increased
rapidly in size, then from day 14 to 21 slowed down or
became static. By 3 to 6 weeks, all tumours were large
enough for the studies described.
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Figure 7 : Serum oestradiol and tumour volume in a mouse
xenograft model.
Serum oestradiol (mean + standard deviation) in
thymectomised and irradiated mice for 2-4 mice at each
time point following subcutaneous injection of 50ug 17J3
oestradiol benzoate. From undetectable levels (<53 pmol
L ) prior to injection of oestradiol there is a rapid
rise to a peak of 7492 pmols followed by a decline in
serum oestradiol to undetectable levels by the third week
post injection. Tumour volume (calculated from pi/12 x
mean diameter ) for a cohort of 12 mice (Mean volume +
standard deviation) measured during weeks 3 to 6
following injection of the MCF-7 cells. Only four time
points are shown for clarity. There is a rise in tumour
volume for the two weeks following injection of
oestrogen, with little change in tumour volume once serum
oestradiol becomes undetectable.
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Cellular DNA synthesis and mitosis
Increased thymidine uptake was noted by 18 hours
following the oestrogen injection (figure 8) and, in
parallel with the percentage of S-phase cells, reached a
maximum 24 hours following oestrogen injection, declining
thereafter. Both these assays were performed by Dr. D L
Deane, MRC Human Genetics Unit, Western General Hospital,
Edinburgh.
The number of mitoses per high power field (x400) by Dr.
D Paterson (figure 8) showed an increase, compared to the
baseline value of 3 per x400 field, to 24 per x400 field
demonstrable 24 hours following oestrogen stimulation of
the tumour. The level fell to 5 mitoses per x400 field
ten days later. The number of mitoses showed parallel
changes to the biochemical indices of cellular DNA
synthesis.
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Figure 8 : Three indices of cellular proliferation in
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Cell proliferation measured by radiolabelled thymidine
(jH dTr) uptake, percentage of cells in S-phase and
mitoses per x400 field showing mean value of 4 tumours
for each time point. Standard deviation was <3.5 for
thymidine uptake (except at time 24 hours, standard
deviation 13.9), <3.7 for percentage of cells in S-phase
(except at 24 hours, standard deviation 7.6) and <3.0 for
mitoses per x400 field. The same tumours were used for
all 3 indices of cell proliferation. Between 12 and 24
hours following injection of 17B oestradiol benzoate
(arrow at injection time = 0), MCF-7 cells are stimulated
to divide, DNA synthesis returning to prestimulation
levels by 48 hours and mitoses declining within days.
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Oestrogen receptors
MCF-7 cells in vitro. tumour material taken immediately
prior to oestradiol injection and cells cultured from
xenografts contained a mean 120 fmols oestrogen receptor
protein mg total protein-1. There was a rise to mean 240
fmols mg protein-1 at 30 hours, but at 7, 14 and 21 days
following injection, the level had returned to between
_ 1
120 and 150 fmol mg protein . Oestrogen receptor protein
was assayed by Dr R.A. Hawkins, Department of Surgery,
University of Edinburgh.
Xenograft tumour gene expression
Presence of mRNA species
Messenger RNA was detected in MCF-7 cells by seven of the
nine probes (figure 9). No mRNA for EGFR or TGF-alpha was
detected in the MCF-7 cells or xenografts, although both
mRNA species were detected in two other breast cancer
cell lines, MDA-MB-231 and T47-D (data not shown). mRNA
for two genes (c-erbB-2 and 0R3) detected in the MCF-7
cell line were not found in the xenograft material, but
no mRNA species was detected in the tumours which was not
present in the original cell line (figure 9). The mRNA
for c-erbB-2 was detected at 3.0kb, 2.8kb and 1.8kb in
the original cell line but not in the xenografts. Four
mRNA species for p53 (three at 2.8kb, one at 1.8kb) were
identified in the original cell line but only a single
140
mRNA for p53 was found in tumours or in re-cultured cells
even after 56 days in vitro. Similarly, 3 mRNA species
were detected with the pS2 probe in the original cell
line but only the single 0.6kb mRNA in the tumours. Other
cDNA probes such as those for TGF-B and c-myc detected
only a single mRNA (2.5kb in each case) present in both
the cell line and xenografts. There were no differences
in any mRNA species detected between xenografts,
transplanted tumours and tumour cells recultured for 56
days.
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Figure 9 : Examples of Northern blot autoradiographs of
gene expression in MCF-7 cells in vitro and in vivo
(xenografts).
GENE c-erbB-2 p53 pS2 c-myc TGF-p
u / ACTIN _
b\mRNA ••9«« •• V 19 • -1-8
Representative autoradiographs of MCF-7 cells, MCF-7
xenografts and MCF-7 cells re-cultured from the
xenografts after probing with cDNA probes for c-erbB-2,
p53, pS2, c-myc and TGF-J3. In each case the actin-probed
control for each lane is shown. Two c-erbB-2 species are
evident in the cell line but are not seen in the
xenografts. Four p53 mRNA species are demonstrated in the
cell line but only one in the xenografts and re-cultured
cells. Similarly, three species detected with the pS2
probe are seen in the cell line but only one species in
the xenografts and cells cultured from those xenografts.
The c-myc, TGF-B and H-ras probes (H-ras blots not shown)
detected identical species in both the MCF-7 cell line
and the xenograft tumours.
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Changes in gene expression after oestrogen stimulation
Densitometry permitted detection of changes in the levels
of mRNA for c-myc, p53, TGF-B and pS2 with respect to
alpha-actin mRNA, following stimulation of the xenograft
by oestrogen (figure 10). The mRNA species for c-myc and
p53 both increased within the first 24 hours then
returned towards the unstimulated level whilst that for
TGF-B was rapidly suppressed, increasing only as the
oestrogen stimulus declined after one week. pS2
expression showed a biphasic response with an initial
increase to 24 hours, then suppression for 12 hours, a
less substantial increase by 48 hours and finally a
decline as the expression of TGF-B increased, peaked at
day 7, and returned gradually to prestimulation levels by
day 21. There was no change in H-ras expression
following oestrogen stimulation.
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Figure 10 : Changes in mRNA following oestrogenic
stimulation of MCF-7 xenografts.
Host animals were injected with 17B oestradiol benzoate
at time 0 (arrow). The changes shown are for c-myc, p53,
pS2 and TGF-B mRNA species in xenografts, as detected by
densitometry of autoradiographs, with respect to that for
actin as a control. The percentage at each time point is
the mean of 6 tumours (standard deviation <11%). mRNA
expression for the same four species is shown for the
original MCF-7 cells and cells recultured from xenograft
tumours.
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Tamoxifen treatment of xenograft tumours
O
In a group of ten tumours of mean volume 250mm , due to
have the next dose of 50ug 17B oestradiol administered,
the oestrogen stimulus was administered and at the same
time and at 24 hour intervals thereafter, 1.25mg
tamoxifen in 50ul arachis oil administered subcutaneously
at a different site. Sequential tumour measurement
demonstrated tumour regression (figure 11) over the
ensuing 21 days rather than the expected tumour growth
observed following oestrogen injection alone to a mean
820 mmJ. Although no quantitative differences in tumour
c-myc, p53 or pS2 expression relative to actin mRNA were
observed during the first week compared to untreated
tumours. TGF-J3 expression, which peaked at 7 days in the
untreated xenografts (figure 11), remained at elevated
levels during the second and third weeks in the tamoxifen
treated tumours and was associated with the decline in
tumour volume.
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Figure 11 : Effect of tamoxifen treatment on MCF-7




























0 ® Tumour volume
I 1 1 1 1 1 1 1 1 1 1 1
0 2 4 6 8 10 12 14 16 18 20 22
tl7p oestradiol 50|xg DAYS
TTT TTTTTTTTTTTTTTTTTTTT
Tamoxifen 1.25mg
Regression in MCF-7 xenograft tumours following tamoxifen
administration, associated with a sustained rise in TGF-B
mRNA. Values for TGF-B mRNA (as % actin mRNA) is the mean
of densitometric measurement in 3 tumours at each time
point. 17B oestradiol benzoate 50ug administered at
time=0 (arrow); daily injection of tamoxifen 1.25mg
indicated by the letter "T".
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Tamoxifen treated patients
A subgroup of 14 patients received tamoxifen prior to
surgery. The tumour was excised at mastectomy either
because it was increasing in size (8 patients) or the
tumour was static in size despite 6 months treatment with
tamoxifen (6 patients). Little difference was noted
between the two groups for expression of p53, c-myc and
c-erbB-2 genes (table 15). However, TGF-B
overexpression, low levels of pS2 expression and pEJ
overexpression were features of the growing tumours but
normal TGF-B expression and pEJ expression and high pS2
expression features of the tumours static in size during
tamoxifen treatment (table 15) . It should be noted that
mRNA quantification was only performed where the Northern
blot autoradiographs were of good quality.
Table 15 : Gene expression in tumours from patients
treated with tamoxifen prior to surgery.
PROBE p53 c-myc c-erbB-2 pEJ TGF-B pS2
(No. (14) (13) (14) (14) (11) (14)
tumours
examined)
Tumour 074 7 2 - 7
increasing N 1 - - 2 -
in size + - 3 1 4 6 1
Tumour 013 5 3 - 2
static N 4 2 - 3 4
+ 11 1 - 1 4
0 No gene expression detected
N Gene expression similar to that found in normal breast
tissue
+ High level of gene expression
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Preoperativelv svstemicallv treated patients
In tumour samples from 12 patients, mRNA was extracted
from tissue obtained at biopsy prior to preoperative
systemic therapy and following endocrine or chemotherapy
treatment. Gene expression was compared in the paired
samples (table 16).
Patients were grouped according to gene expression or
response to therapy. No definite association was seen
when comparing the pre-treatment to the post-treatment
mRNAs detected either quantitatively or qualitatively.
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Table 16 : Gene expression in pre-trea traent and
post-treatment tumour samples.















Same levels pre and post treatment:
54/67 c-myc,TGF-B c-myc,TGF-B Chemotherapy Static
21/59 pS2 pS2 Chemotherapy Response
64/82 c-myc,TGF-B, c-myc,TGF-B, Chemotherapy Response
p53,pEJ. p53,pEJ.
Change in levels pre and post treatment:
35/71 Nil Normal p53, Endocrine Response
c-myc
52/68 High p53, No p53, Endocrine Static
pS2,pEJ Normal pS2
High pEJ,c-myc
56/70 Normal p53 No p53 Chemotherapy Response
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The work presented in this thesis examined primary breast
cancers from a consecutive group of patients in whom
there was sufficient material available both for routine
diagnostic purposes and for experimental study.
Therefore, some degree of patient and tumour selection
has occurred in that impalpable cancers detected by
mammography at breast cancer screening and tumours of
less than 0.5 cm diameter have not been examined.
However, the group of 80 patients of 240 presenting for
surgery within the 18 month study period is a
representative cross section of the disease spectrum
presenting, with palpable disease, to a specialist breast
cancer unit and is a higher proportion than in other
studies from this unit (Miller et al., 1990). The control
tissue examined for gene expression, reduction
mammoplasty breast tissue, tonsil, normal uterus and
ovary are representative of a variety of normal adult
human tissues.
The method of RNA extraction used, differential
precipitation by lithium salt, is now widely established
as an excellent technique for extracting intact, high
quality total RNA which can then be used, without further
purification to poly A+ RNA, for the detection of
messenger RNA species (Henry et al., 1988). The use of
laser densitometry to quantify mRNA species with respect
to a standard mRNA, of which actin is a well tried
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example, has now supplanted the earlier technique of dot
blotting in which serial dilutions of test RNA are probed
(Travers et al., 1988) and has the immense advantage that
the sizes and integrity of the mRNA species of interest
can be individually assessed. Furthermore, the use of
nylon filters allows more ready reprobing of northern
blots, essential for work such as this where a limited
amount of tissue and nucleic acid is available.
The DNA extraction, digestion, Southern blotting and
probing techniques are now considered to be standard
reliable methods for the detection of allele losses,
representing loss of genetic material, from the
chromosomal loci under examination (Vogelstein et al.,
1989). By contrast, the methods used to examine the
sequence of part of the p53 gene required considerable
adaptation from the techniques for the polymerase chain
reaction (Siaki et al. , 1985a) and direct sequencing of
double stranded DNA (Winship et al., 1989).
However, it should be noted that the tissues examined
using these molecular techniques may contain stromal
cells (fibroblasts, normal breast cells and adipocytes)
and haemopoietic cells (lymphocytes, monocytes,
polymorphs) in addition to breast cancer cells. It is
possible that these contaminant normal tissues can
express the genes under consideration. Given the high
proportion of breast cancer cells and the absence of
visible lymphocyte infiltrates in the tumours, the genes
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detected in this work, as in previous studies (Mariani-
Constantini et al., 1988, Travers et al., 1988), reflect
predominantly the breast cancer cell expression.
Conversely, it is conceivable that normal tissues may
"dilute" the gene expression or allele losses identified
(Slamon et al. , 1989). Two factors suggest this is
unlikely; first, the tissues from which nucleic acids
were extracted were examined by a pathologist to ensure
the predominance of tumour cells. Second, lOOg of
reduction mammoplasty (normal) breast tissue was required
to yield the same amount of nucleic acid as 0.2g of
tumour and indeed some workers have been unable to
extract adequate samples of RNA from normal breast tissue
(Mariani-Constantini et al. , 1988).
The work incorporated into this thesis has therefore
involved adaptation of the most modern molecular
approaches to the study of a common, aggressive disease,
breast cancer.
The decision to target the expression of specific genes
for detailed examination on the basis of the rapidly
evolving literature, has been justified and yielded data
of considerable interest. Each of the genes examined:





The c-myc mRNA of 2.5kb detected in this work corresponds
to that previously reported in MCF-7 cells (Zajchowski
et al., 1988), the 2.3 kb to 2.7 kb mRNA for c-myc
described in a variety of human tissues (Alitalo et al.,
1983 , Ar-Rushdi et al. , 1983 , Guerin et al . , 1985,
Erisman et al. , 1985, Escot et al., 1986, Dubik et al. ,
1987, Monnat et al., 1987 and Finley et al. , 1989) and
confirms that c-myc overexpression is a feature of breast
as well as other malignancies (Marcu, 1987).
The detection of mRNA for c-myc in 54% (41 of 76) tumours
examined, represents a somewhat lower proportion than the
10/14 (Escot et al., 1986) and 87% of 23 breast tumours
(Whittaker et al., 1986) previously described. This could
be due to the examination of small numbers and a highly
selected tumour population in the earlier studies.
Certainly the high constitutive expression of c-myc in
MCF-7 and T-47D (Escot et al., 1986) and the MDA MB 231
cell line (Dubik et al., 1987) were confirmed, the weight
of tumour and cell line evidence thus arguing against the
assertion of Kozbor & Croce (1984) that overexpression of
c-myc mRNA in breast cancer was likely to be an unusual
occurrence.
This study did not address the questions of
transcriptional control or DNA changes in the c-myc gene.
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Transcriptional control of c-myc is particularly complex,
with multiple regulatory elements involved (Lang et al.,
1988). Translocation of the c-myc gene (as in Burkitt's
Lymphoma, Dalla-Favera et al., 1982, (Croce, 1986) and
colorectal cancer, Alitalo et al., 1983) renders the gene
unresponsive to normal transcriptional control. However,
structural alterations in c-myc in small cell lung cancer
(Kok et al., 1989) are thought to be secondary events
linked to tumour progression. In any event, in breast
cancer, high levels of c-myc mRNA do not require
alterations in the c-myc gene (Escot et al., 1986) and
may (Mariani-Constantini et al., 1988) or may not (Dubik
et al., 1987) be related to amplification of the gene.
Thus the detection of c-myc gene overexpression in human
breast cancer is likely to be more important than the
possible structural mechanisms which could have brought
it about and which were not examined (Lang et al., 1988).
While it has been claimed that elevated expression of
exogenous c-myc is insufficient for transformation of
established, but not late passage fibroblasts (Zerlin et
al., 1987, Karn et al. , 1989), SWB13-5 breast cancer
cells with high c-myc expression, but not those with low
expression, are tumorigenic (Lavialle et al. , 1988) and
80% of transgenic mice with augmented mammary gland c-myc
expression develop mammary cancer as early as 2 months
after birth (Schoenenberger et al., 1988).
Just as the question of whether c-myc expression alone is
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sufficient for mammary carcinogenesis remains open, the
precise function of overexpressed c-myc remains
speculative. Cells which overexpress c-myc may continue
to proliferate despite the depletion of serum growth
factors (Mulder & Brattain, 1988) with promotion of DNA
replication (reviewed in Parkin & Sonenberg, 1989),
shortening of the cell cycle (Karn et al., 1989) and
inhibition of terminal differentiation (Dmitrovsky et
al., 1986) all key factors.
The work presented in this thesis has demonstrated that
overexpression of the c-myc gene is associated with small
rather than large tumour size and with lack of metastasis
to the regional lymph nodes. This suggests that c-myc
overexpression may be a feature of breast tumorigenesis,
perhaps being important in rapid early growth, accounting
for the association with small tumour size rather than
disease progression. In support of this, Spandidos and
collegues (1987) demonstrated that high expression of
c-myc protein could be identified in both in situ and
invasive breast cancer; in colorectal cancer, they also
identified overexpression of c-myc in both the cancer and
precancerous polyps. While no correlation between c-myc
expression and node status was found in an earlier study
(Whittaker et al., 1986), other published evidence has
suggested that c-myc expression correlates with nodal
metastasis (Guerin et al. , 1985) and the analogous n-myc
expression in neuroblastoma certainly correlates with
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poor prognosis (Grady-Leopardi et al., 1986). As already
noted, c-myc overexpression may be a primary event with
secondary amplification of the gene subsequently
occurring, as in small cell lung cancer (Kok et al.,
1989) .
The association between c-myc amplification and large
tumour size (Yokota et al., 1986a, Seshadri et al., 1989),
poor histological grade (Nikiforova, 1988), tumour
metastasis and recurrence (Lidereau et al., 1988) and
poor short term prognosis (Varley et al., 1987a)
therefore lends credence to the concept that
amplification of the gene rather than overexpression may
play a role in tumour progression. However, evidence from
this work does suggest that c-myc overexpression may play
a part in the early stages of breast tumorigenesis.
c-erbB-2
The mRNA for c-erbB-2 detected in 21/71 (30%) of tumours
was identical in size to the 4.8kb transcript identified
in previous studies (Coussens et al., 1985, Semba et al
1985, van de Vijver et al., 1987) and similar to that
noted in others (4.4kb Slamon et al . , 1989 ; 4. 6kb
Yamamoto et al., 1986, Yokota et al., 1988; 5kb King et
al., 1985, Kraus et al., 1987). The present data
confirm that c-erbB-2 protein is detected only where the
mRNA is overexpressed (Berger et al. , 1988) and that
there is a very strong correlation between detection of
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the raRNA for c-erbB-2 and imraunohistochemical detection
of the protein (Slamon et al., 1987, Slamon et al.,
1989). However, as Slamon and colleagues point out, there
may be loss of iramunoreactivity during tissue fixation
accounting for failure to detect c-erbB-2 protein at
lower levels of gene expression.
Despite the good correlation between c-erbB-2 mRNA
expression and c-erbB-2 gene amplification (van de
Vijver et al. , 1987, Kraus et al. , 1987, Yokota et al.,
1988, Slamon et al., 1989) there remains a clear group of
tumours (18 of 187, Slamon et al 1989) in which there
is overexpression of the gene at the mRNA and protein
level but no c-erbB-2 gene amplification. This
suggests that as for c-myc, amplification is not a
prerequisite for overexpression of the c-erbB-2 gene. In
addition, activating mutations in c-erbB-2 are rare in
breast cancer (Garcia et al . , 1989, Lemoine et al. ,
1990). Thus measurement of mRNA for c-erbB-2 remains the
most sensitive method of evaluating the contribution of
this gene to breast carcinogenesis.
Reports have suggested that c-erbB-2 mRNA expression
correlates with advanced disease stage (Zhou et al.,
1987, Seshadri et al., 1989) and immunohistochemica1
detection of c-erbB-2 protein with high tumour grade
(Parkes et al. , 1990) and node involvement with tumour
(Berger et al. , 1988). In this study, expression of
c-erbB-2 mRNA did not correlate with any clinical or
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pathological variable. It is interesting to note that
c-erbB-2 expression is more frequently observed in non¬
invasive than invasive breast cancer (van de Vijver et
al., 1988), perhaps providing a selective growth
advantage for the cancer cells (Yaraamoto et al., 1986).
H-ras
The 1.4 kb mRNA for H-ras detected in the breast tumours
is similar in size to that identified in previous studies
(Spandidos and Agnatis 1984, Slamon et al . , 1984,
Theillet et al. , 1986, Biunno et al., 1988). This work
confirms that a substantial proportion of breast cancers
express H-ras, whether it is detected at the mRNA level
(16/22, Theillet et al., 1986) by radioimmunoassay (66%,
Horan-Hand et al . , 1987) or using antibodies on
histological sections (30%, Walker & Wilkinson, 1988)
contrary to the findings of others (Whittaker et al.,
1986, Biunno et al., 1988) who were unable to detect mRNA
for H-ras in either normal or cancerous breast tissue.
In this work, no correlation was found between H-ras mRNA
expression and the clinical and pathological parameters
examined although immunohistochemical staining for p21,
the H-ras protein, is associated with large tumour size
and spread of the cancer to the regional lymph nodes
(Lundy et al . , 1986). Certainly, the detection of
elevated levels of p21 is associated with the malignant
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phenotype in breast cells (Horan-Hand et al. , 1984 ,
Ohuchi et al . , 1986, Whittaker et al. , 1986) and
therefore the lack of clinical or pathological
correlation in this study would fit with the concept that
H-ras may provide a competence function (Kelekar & Cole,
1987). However, in the present study, no attempt has been
made to differentiate between normal and mutant H-ras
although it has been suggested that elevated expression
of the normal H-ras allele may cause suppression of
morphologically transformed and tumorigenic phenotypes
(Spandidos & Wilkie, 1988). In addition, it has been
demonstrated that H-ras allele loss predicts a poor short
term prognosis (Garcia et al., 1989). Neither has the
work presented here examined activation or amplification
of the H-ras gene, although activation by mutation occurs
very infrequently in breast tumours (Biunno et al., 1988,
Rochlitz et al., 1989) and amplification is equally rare
(Biunno et al., 1988).
TGF-J3 and oS2
Detailed consideration of the implications of TGF-B and
pS2 gene expression is discussed below but, in brief, the
2.5kb mRNA for TGF-B was of the size previously reported
(Derynck et al., 1985, Knabbe et al., 1987, Travers et
al., 1988, King et al., 1989). However, the minor TGF-B
species reported elsewhere of 1.9 kb (Derynck et al.,
1986, Akhurst et al., 1988) or 4.8 kb (Derynck et al.,
160
1986) were not demonstrated. TGF-B mRNA expression was
found in all the tissues tested as previously described,
with higher levels in the tumours (Derynck et al., 1987)
and abundant expression of TGF-B noted in 45 of the 56
tumours examined in this study, similar to the 76% of
tumours examined by Travers et al (1988).
Similarly, the 600 base pair mRNA for pS2 confirms that
described originally (Masiakowski et al., 1982) and found
here in 33% of cancers, less than the the 46% (Luqmani et
al . , 1989) and 57% (Henry et al . , 1990) previously
reported. However, this work confirms that there is a
correlation between oestrogen receptor protein and pS2
mRNA expression but not with menopausal status or the
presence of nodal metastasis (Henry et al., 1990).
A 2.8kb mRNA for p53 was detected in 43 of the 76 breast
cancer specimens. This corresponds to the mRNA for p53
identified in previous studies of human tissue (Harlow et
al., 1985, Lamb & Crawford, 1986, Buchman et al. , 1988,
Baker et al. , 1989, Takahashi et al., 1989, Lubbert et
al., 1989, Lavigeuer et al. , 1989). The quantitative
difference between individual tumours in p53 mRNA
expression raises the possibility, discussed later in
this thesis, that the p53 gene may fulfil different
functions in different patients. The low level of p53
expression detected in normal breast, tonsil, ovary and
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uterus confirmed reports that p53 is expressed at low
levels in most adult tissues (Rotter 1983, Oren, 1988).
High expression of the mRNA for p53 in the 3 breast
cancer lines (MCF-7, T-47D, MDA MB 231) was clearly
demonstrated in accordance with the high expression noted
in other cell lines ( De Leo et al., 1979, Rotter et al.,
1981, Crawford et al., 1981, Benchimol et al., 1982).
If one considers the qualitative differences between the
tumours and cell lines, the three p53 mRNAs of circa
2. 8kb in size found in different quantities in each of
the cell lines may result from multiple transcription
initiation sites (frequently associated with the known
absence of an upstream TATA box as for the p53 gene,
Bienz-Tadmor et al., 1985), differential splicing (which
could give rise to an altered protein with different
biological properties, Reisman & Rotter, 1989) or other
post-transcriptional modification. A similar situation
has been found in lung cancer, where cell lines derived
from lung tumours express 2.3, 2.6, and 3.7kb species in
addition to the 2. 8kb mRNA also found in normal lung
tissue (Takahashi et al., 1989).
The 1.6kb mRNA (still large enough to encode a 53kd
protein) could reflect reading frame differences and is
similar in size to the single p53 mRNA species of 1. 8kb
previously described in NIH3T3 cells (Reich et al., 1983,
Reich & Levine, 1984). This 1.6kb mRNA may correspond to
the nuclear mRNA regulating translation detected by
162
Khochbin & Lawrence (1988) or the unusually stable 44kd
p53 that accumulates to high intracellular levels
(Rovinski et al., 1987).
The three cell lines examined are distinguishable on
karyotype (Mr. G. Spowart, MRC Human Genetics Unit,
Western General Hospital, Edinburgh, personal
communication) on molecular analysis (using DNA probes;
Dr J. Morten, ICI diagnostics, Macclesfield, Cheshire,
personal communication) and they have different
phenotypic characteristics; for example the MCF-7
line used in these studies had on average 120 fmol
_ i
of oestrogen receptor protein mg total protein,
T-4 7D 4 0 fmol mg-^ and MDA-MB-2 31 0 fmol mg-^".
These lines also show differing sensitivity to oestrogens
and antioestrogens. The consistently high level of p53
mRNA expressed in all three lines thus implies that, in
this in vitro setting and by contrast with the clinical
material, p53 mRNA expression is independent of oestrogen
receptor protein content of the cells and of hormone
sensitivity.
Cattoretti and colleagues (1988), using an antibody
PAbl801 specific for human p53 protein in breast cancer
specimens, noted a correlation between oestrogen
receptor-negative tumours and elevated p53 protein
expression (p<0.05). Using this antibody, no other
significant correlation was identified, but with a mouse
antibody, PAb 421, p53 staining correlated with other
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additional poor prognostic parameters. Although the
regulation of p53 expression may occur not only at the
level of mRNA abundancy but also p53 protein stability,
depending on the system under study (Rovinski et al.,
1987), in both embryonal carcinoma cells (Reich et al. ,
1983) and in several tissues in transgenic mice
(Lavigueur et al . , 1989 ) p53 mRNA and p53 protein
expression correlate.These results therefore agree with
our findings in relation to p53 mRNA: p53 both at the
protein and mRNA levels is associated with a low level of
oestrogen receptor protein. If one considers oestrogen
receptor protein to be a "luxury" protein, produced only
by biochemically well differentiated cells, then those
tumours expressing little or no oestrogen receptors,
which also tend to have high p53 mRNA expression, may be
at an early stage of differentiation.
Discussion of p53 gene expression leads on to
considerations of DNA changes in the chromosomal material
around the p53 gene on chromosome 17 in band 13.
Chromosome 17ol3
The DNA studies confirm that the loss of one YNZ 22.1
allele from the short arm of chromosome 17 occurs in over
half of the breast tumours studied (Mackay et al., 1988,
Devilee et al . , 1989a, Devilee et al . , 1989b) and
suggests for the first time that this allele loss
164
1
may be associated with low levels (under 20 fmol mg
protein) of oestrogen receptor protein. The tip of the
short arm of chromosome 17 is thus of importance in
breast as well as in colon cancer (Lothe et al. , 1989,
Vogelstein et al., 1989) where allele loss from 17p plays
a role in the development of a major subset of colorectal
tumours and also in a high proportion of other tumours
such as lung cancer (Yokota et al., 1987, Takahashi et
al., 1989), astrocytoma (James et al. , 1989, Fults et
al. , 1989) and osteosarcoma (Toguchida et al., 1989).
The increasing allele loss (of YNZ and MCT) towards the
tip of 17pl3 suggests there may be a regulatory element
for p53 in this region, p53 mRNA overexpr e s s i on
correlating as it does with YNZ allele loss. It is also
possible that there may a second tumour suppressor gene
in the region 17pl3, although in colorectal cancer this
does not appear to be the case (Baker et al., 1989). This
issue is discussed more fully after consideration of the
role of p53 itself.
The low level of polymorphism detected with the cDNA
probe for p53 (Zakut-Houri et al., 1985) was as expected.
However, although pBHp53 allele loss was not associated
with menopausal status, Devilee et al (1989a) have
suggested that patients with 17p allele loss have a high
risk of early onset, bilateral, multifocal disease of
familial type.
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The possible roles for p53 merit discussion. Evidence
from this thesis supports the proposal that p53 may
behave either as a tumour suppressor gene or as an
oncogene in breast cancer (Lane & Benchimol, 1990).
In those tumours where no p53 mRNA was detected, this may
reflect deficiency of normal (unmutated) p53 and hence a
reduced tumour suppressor function conferring a selective
advantage for the development of the tumorigenic
phenotype (Finlay et al., 1989). Supporting evidence for
this comes from the observation that in 3 of the 4 in
situ cancers, no p53 expression was detected. Thus, one
"hit" along the carcinogenic pathway may be to stop
expression of the p53 tumour suppressor gene as was found
in myeloid leukaemias (Reisman & Rotter, 1989).
p53 gene deletion has also been reported in several mouse
erythroleukaemia cell lines, and in this setting p53 has
been likened to the retinoblastoma tumour suppressor gene
(Mowat et al., 1985, Green, 1989). Indeed the
similarities between retinoblastoma and p53, which both
appear to be required for normal cellular growth, may
merit study in the same tumours (Lane & Benchimol, 1990).
Deletion of one copy of the p53 gene is also compatible
with increased function of the other (abnormal) gene,
perhaps enhancing the transformation process in concert
with another oncogene. Thus, where there is normal or
increased p53 mRNA expression, this may be of a mutated
form (for example the point mutation identified in
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patient 43) which therefore blocks the activity of any
remaining wild type tumour suppressing p53 (Green, 1989)
and/or acts as an oncogene, promoting carcinogenesis.
Certainly, mutant p53 has a dramatically increased half
life (typically 4 to 8 hours) compared to normal, wild
type p53 (6 to 20 minutes) (Reihsaus et al., 1990, Lane &
Benchimol, 1990) . Mutant p53 also has altered protein and
antibody binding characteristics with antibody binding
further increasing stability (Reihsaus et al., 1990),
rendering it less vulnerable to proteases, altered
phosphorylation and an additional (extranuclear) cellular
location (Jenkins et al., 1985, Sturzbecher et al.,
1987, Oren, 1988, Van Roy et al., 1990).
Single tumorigenic point mutations, clustered in highly
conserved regions of the p53 gene (Soussi et al., 1987,
Nigro et al., 1989), particularly between amino acids 135
and 218 (Finlay et al. , 1989, Baker et al., 1989) can
account for the differences in tumour suppressor versus
oncogene function of p53 (Matlashewski et al., 1987). In
support of this, p53 point mutations have been described
in colon cancer (Baker et al., 1989) 57% of lung cancer
cell lines (Takahashi et al., 1989) and in two breast
cancer cell lines but not in the single breast cancer
examined which was homozygous for 17p (Nigro et al. ,
1989). When these mutants are overexpressed, they may act
in a trans-dominant fashion to inactivate the endogenous
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wild type p53, possibly by the formation of nonfuctional
multimeric complexes (Rovinski & Benchimol, 1988, Eliyahu
et al. , 1988, Finlay et al., 1989) in a similar way to
SV40 large T antigen, Adenovirus E1A and Human papilloma
virus E6 protein (Lane & Benchimol, 1990) . In support of
this, wild type p53 suppresses co-transformation of REF
cells by mutant p53 and ras (Finlay et al. , 1989).
However, it has been suggested that some additional
oncogene activity of the mutant p53 may be required and
only fully manifest in the absence of normal wild type
p53 (Lane & Benchimol, 1990).
Alternatively, loss of one allele (resulting in failure
to express detectable quantities of the p53 gene as found
in three of the in situ cancers) may confer a minor
growth advantage, with subsequent mutation of the
remaining p53 required to initiate or promote
carcinogenesis.
If mutation were to occur first, loss of the normal
allele may be required to allow effective expression of
the mutant p53, by analagy with co-transfection studies
of normal and mutated H-ras (Spandidos & Wilkie, 1988).
However, in the present work, the finding that in 2 of
the 4 in situ breast cancers there was 17p deletion but
no p53 expression suggests that loss of p53 tumour
suppressor gene function (deletion) may be the first
event and p53 mutation the second on the carcinogenic
pathway.
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Nigro and collegues (1989) have suggested the converse;
they found that some tumours had mutant p53 but no allele
loss although most tumours with 17p deletions contained
mutant p53 in the allele that was retained. In the work
presented here, one cancer, but not both of the tumours
with p53 overexpression, had a mutation within exons 5
and 6 of the gene. This could be explained if there were
other sites of important mutation in the p53 gene (exons
7,8 and 9) or possibly a second tumour suppressor gene on
17pl3 or even if the p53 gene and 17p allele losses are
co-incidental to important genetic abnormalities
elsewhere (Nigro et al., 1989). However, the data
presented here for breast cancer demonstrate a parallel
with lung cancer (Takahashi et al., 1989) where 17p
deletions and p53 mutations implicate p53 as an important
tumour suppressor gene, the disruption of which is
involved in the pathogenesis of cancer.
p53 abnormalities alone are insufficient to explain the
aetiology of breast cancer as co-transformation and
immortalisation studies with mutant p53 (Parada et al. ,
1984, Eliyahu et al., 1984, Eliyahu et al., 1985, Hinds
et al., 1987) but not wild type p53 (Finlay et al., 1988)
have demonstrated.
To summarise, loss of p53 expression may represent loss
of tumour suppressor gene function (Lavigueur et al.,
1989). Expression of mutant p53, either acting directly
as an oncogene or indirectly by complexing with wild type
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p53 may occur to render the cell susceptible to
uncontrolled growth (Finlay et al., 1989).
The association between allele loss with probe YNZ 22.1
and overexpression of the p53 gene merits further
consideration in that the tip of 17pl3 may contain
regulatory elements for p53 gene expression. This
possibility is not excluded by the demonstration that the
DNA 5' to the p53 gene is a conserved promotor region
capable of negative transcriptional control (Bienz-Tadmor
et al. , 1985) and that there are 2 promotors, one
upstream of exon 1 and the second within the first intron
(Reisman & Rotter, 1989). In fact, full p53 gene promotor
activity may reside within exon 1 of the p53 gene (Tuck &
Crawford, 1989) and the DNAase I hypersensitive sites at
the transcription initiation site may represent areas
regulated by transacting proteins (Lubbert et al., 1989).
Despite this evidence for gene regulatory elements close
to the p53 gene, cis-acting or trans-acting loci near the
tip of 17pl3 or even more distant loci may be important.
Further, initial data suggest (Devilee et al., 1990) that
more detailed deletion mapping of 17p may demonstrate a
common region of deletion and target regions of 17p, in
addition to the p53 locus, worthy of further study.
Other future strategies may include screening all the
tumours for p53 mutations with the amplification mismatch
technique (Montandon et al., 1989). This may then be
followed by sequencing all the important regions of the
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p53 gene (particularly exons 5,6,7,8 and 9) either by
direct DNA sequencing as described in this work, or using
an asymetric polymerase chain reaction technique from
mRNA (Iggo et al., 1990).
Prognosis
While at a mean 18 months follow up it remains too early
to determine the full prognostic significance of the
data, three pointers merit consideration even at this
early stage.
Failure to detect pS2 mRNA expression appears to
correlate with early disease recurrence, although the
statistical significance of this finding remains less
dramatic than for conventional prognostic indices such as
tumour stage or involvement of regional lymph nodes with
tumour. However, pS2 is oestrogen regulated and it is
therefore of interest that failure to detect pS2 mRNA
appears to be a more powerful predictor of early disease
recurrence than oestrogen receptor protein content of the
tumours. If this observation is carried through to 3 and
5 years follow up, it will indicate a group of patients
with breast cancer who are unlikely to respond to
endocrine therapy (Henry et al., 1990) but who should be
offered additional systemic therapy. Eleven of 76
patients for whom p53 mRNA expression was determined had
tumours showing loss of heterozygosity for YNZ 22.1,
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increased expression of p53 mRNA and low levels of
oestrogen receptor protein. With just 18 months mean
follow up, four of these patients have already relapsed
with metastatic disease. Continued follow up of the whole
cohort will establish the prognostic significance of this
combination of findings.
One might expect those patients with detectable c-erbB-2
mRNA to have a poor prognosis since it is now well
established that c-erbB-2 amplification (which correlates
well with mRNA overexpression, Slamon et al. , 1989) and
strong antibody staining for c-erbB-2 is an independent
prognostic factor for shorter disease free interval and
shorter overall survival (Slamon et al., 1987, van de
Vijver et al., 1987, Berger et al., 1988, Slamon et al.,
1989, Wright et al., 1989, Zeillinger et al., 1989, Ro et
al., 1989, Thor et al. , 1989). However, in the present
group of patients, at 18 months follow up no prognostic
value was observed for c-erbB-2 mRNA detection. Even if
the relation between c-erbB-2 and poor prognosis is
confirmed at 3 or 5 years follow up in the present group
of patients, c-erbB-2 may prove to be less useful in
clinical practice than pS2 since the c-erbB-2 gene is
only amplified or overexpressed in a small minority of
tumours (Barnes, 1989) and, unlike pS2, gives no
indication of the most suitable adjuvant therapy.
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Mouse Xenograft System
The MCF-7 breast cancer cell line has been established
for the first time as a renewable xenograft system in CBA
mice immunocompromised by thymectomy and whole body
irradiation, a system previously used to test the
tumorigenicity of lymphoblastoid cell lines (Morten et
al. , 1984). Tissue from these tumours can be
transplanted to similar mice and cells cultured from the
xenografts can be re-implanted to grow tumours. The use
of an anatomically appropriate site for xenograft growth
does not appear to be important in this CBA mouse system,
unlike "nude" nu/nu mice (Price et al., 1990). This model
therefore yields a large renewable supply of tumour
material passaged in vivo and permits the in vivo study
of tumours during hormonal manipulation. These MCF-7
tumours were clearly adenocarcinomata, with necrosis in
only the larger tumours, as in nude mice (Osborne et al.,
1988) and metastasis, as previously noted, a rare event
(Busuttil et al., 1986).
As in nu/nu mice, oestrogen supplementation is a pre¬
requisite for MCF-7 tumour growth (Shafie & Grantham,
1981; Osborne et al., 1985; Gottardis et al., 1988). The
absence of detectable serum oestrogen in female mice
prior to injection confirmed that the mice had been
"oophorectomised" by the irradiation. The serum oestrogen
profile following a single subcutaneous injection of
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oestradiol benzoate in arachis oil gave very high serum
levels of oestradiol between 12 and 36 hours. From day 2
to day 8, levels of oestradiol were within the
physiological range for non-pregnant premenopausal women
(110-1630 pMol L-1, data from Baxter Health Care,
Newbury, U.K.) and they remained sufficient to sustain
oestrogen-dependent tumour growth for 21 days. Serum
oestradiol levels in surgically oophorectomised nude
mice which have received the implantable pellet
also fall within the same range ( Shafie & Grantham,
1981, Blumenthal et al. , 1988). There is no obvious
explanation for the intolerance of the CBA mice to the
implantable pellet, although the findings reported here
comfirm previous experience with this strain in the
Institute of Animal Technology, Western General Hospital,
Edinburgh where this work was performed.
Cell proliferation as measured by DNA synthesis and
mitotic activity of the tumour cells in response to
oestradiol was similar to that observed in nude mice
(Osborne et al., 1985) and, as expected, preceded the
increase in tumour volume.
Thus, the CBA mouse xenograft system has similarities to
the "nude" mice used previously for breast cancer
studies, but has distinct advantages of low cost and ease
of husbandry. These are important considerations where
substantial numbers of animals are involved and daily
handling for accurate measurements is a necessary part of
174
the protocol. Moreover, the characteristics of the model
allow the ready study of molecular events in an oestrogen
sensitive breast cancer system.
mRNA differences in vivo and in vitro
The original MCF-7 cells grown in vitro expressed several
mRNA species not evident in the xenografts or in
cells of these xenografts recultured for some time in
vitro. If one can exclude contamination of the in vitro
cultures, these findings suggest selection in. vivo of a
subpopulation of cells from the MCF7 culture.
The MCF-7 cells re-cultured from xenografts had an
identical pattern of gene expression to the xenografts
and did not, over an 8 week period, revert to the
original MCF-7 cell line pattern. Serious consideration
was given to the possibility that these findings could be
due to a contaminant in the original cell line (such as
mycoplasma) expressing the gene concerned or to plasmid
contamination at some point in the RNA extraction or
electrophoresis. Both these explanations are unlikely
since tests on the MCF-7 culture (Barile, 1973) were
persistently negative for mycoplasma, and no evidence of
plasmid contamination was found in these or any other
northern-blot RNA studies. Moreover, a range of different
plasmids was used as vectors for the cDNA probes.
It therefore seems most likely that passage of the MCF-7
cells through mice does indeed select for a tumorigenic
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subpopulation.
Using the oncogene probes to study the RNA from MCF-7
grown in vitro. 3 distinct mRNA species of 1.8kb, 2.8kb
and 3.Okb were identified hybridising to the c-erbB-2
probe, although these were not present in the xenografts
nor in recultured cells. These species were smaller than
the single 4.8kb mRNA species previously described (Semba
et al., 1985), detected in the human tumours and closer
to the truncated 2.3kb transcript detected in MKN-7
gastric cancer cells (Yamamoto et al., 1986, Yokota et
al., 1988). Moreover, no mRNA for erbB-2 of aberrant size
was identified in a survey of breast cancer cell lines
(Kraus et al., 1988). An amplified and rearranged
epidermal growth factor (erbB-1) has been identified in
epidermoid carcinoma cells generating a truncated 2. 8kb
mRNA that encoded only the extracellular EGF binding
domain (Ullrich et al., 1984) and multiple mRNA
transcription initiation sites have been demonstrated for
c-erbB-2 (Tal et al., 1987). Thus, although increased
expression of the c-erbB-2 gene has been found to provide
a selective advantage in the formation of or progression
of epithelial cell tumours (Yamamoto et al., 1986), this
does not appear to be the case in the MCF-7 xenograft
system developed here.
0R3, a probe for oestrogen receptor mRNA, detected two
messages of 3.0 and 1.7kb, but no larger mRNA species.
While mRNA of 6.3kb (Green et al. , 1986, Rio et al.,
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1987, Barrett-Lee et al., 1987, May et al., 1989), 6. 2kb
( Walter et al., 1985 ), 4.2kb ( Pari et al. , 1987) and
3. 7kb (Barrett-Lee et al., 1987) have been reported in
human tumour tissue and in the MCF-7 cell line, the
species identified here do not correspond to any of
these.
Henry and colleagues (1988) were unable to demonstrate
oestrogen receptor mRNA in the MCF-7 cell line using
this 0R3 cDNA clone, but demonstrated hybridisation to a
6.2kb mRNA using their radionucleotide labelled
riboprobe. The translated oestrogen receptor protein was
certainly present when assayed by enzyme immunoassay. The
slight rise in oestrogen receptor protein following
_ 1
oestrogen stimulation of the tumour, from 120 fmol mg
_ 1
protein to 240 fmol mg protein, and its subsequent
return to basal level is consistent with the view that
oestrogen can stimulate the synthesis of its own
receptor.
The pS2 probe appears to cross-hybridise to the same 3kb
and 1.7kb mRNA as the 0R3 probe but hybridises most
strongly to a small mRNA of about 600 base pairs,
corresponding to the oestrogen induced mRNA of
Masiakowski and collegues (1982).
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Changes in mRNA after stimulation with oestrogen
The choice of internal control probe, actin, allowed
demonstration of changes in transcription of the other
genes studied, It is important to note that transcription
of this standard (actin mRNA) is not influenced by
oestrogen (Saceda et al., 1988, Barton & Shapiro 1988).
Oestrogen-induced stimulation of c-myc expression,
previously noted in breast cancer cells in vitro (Dubik
et al., 1987), was confirmed. Although this probably
represents a real increase in transcription, factors such
as increased stability of the c-myc mRNA (Dubik et al.,
1987) or post-transcriptional regulation (Morello et al.,
1989) of the gene may also occur. The expression of c-myc
and also p53 at elevated levels in the xenograft tumours
in response to oestrogen confirm that i_n vivo the
expression of these two nuclear genes may be involved in
cell cycling (Kelly & Seibenlist, 1985, Lamb & Crawford,
1986). Recent evidence using conditional alleles of c-myc
and the hormone binding domain of the oestrogen receptor
gene suggests that oestrogen may act by binding to its
receptor then interact with c-myc, thus activating DNA
polymerase and DNA synthesis (Eilers et al., 1989).
Similarly, the rise in p53 expression following oestrogen
stimulation may reflect a function of p53 as a modulator
of growth factor gene expression through DNA
transcriptional activation (Braithwaite et al., 1987).
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In vitro work has previously identified an increase of
pS2 mRNA in response to oestrogen within 3 hours (Brown
et al. , 1984). The rapid rise in vivo in pS2 mRNA
transcription confirms in vitro observations that pS2 is
oestrogen regulated at the level of transcription
(Masiakowski et al., 1982, Brown et al., 1984). The
biphasic change in pS2 observed in the xenograft system
described here suggests that the role of pS2 as a marker
for oestrogen action in vivo may not be as simple as
originally proposed on the basis of in vitro studies,
with the very high peak of serum oestradiol perhaps
causing transient inhibition of pS2 transcription. While
pS2 behaves as an epidermal growth factor-like
immunoreactive factor when secreted by MCF-7 cells (Kida
et al., 1989), purified pS2 protein does not stimulate
cellular DNA synthesis and hence may not be crucial to
the effect of oestrogen on MCF-7 cells (Kida et al.,
1989) .
The initial decrease in TGF-B transcription demonstrated
in the xenografts confirmed the original in, vi tro
studies of the TGF-B response to oestrogen treatment of
MCF-7 cells (Dickson et al., 1986). In the present
xenograft system, TGF-B transcription increased as the
mitogenic stimulus of oestrogen declined, confirming in
vitro studies (Knabbe et al., 1987) and compatible with
the antiproliferative effects of TGF-B noted on oestrogen
receptor-positive breast cancer cell lines in vitro (Kerr
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et al., 1989, Arrick et al., 1990)
While H-ras was expressed by the MCF-7 xenografts, no
change in H-ras transcription was demonstrated,
confirming that ras transcription is insensitive to the
effects of oestrogen on MCF-7 (Dubik et al., 1987).
Clinical implications
Gene expression in the breast cancer cells, as detected
by mRNA analysis, obviously changes when cells cultured
in vitro grow as tumours in. vivo. The physiological and
clinical significance of in. vitro observations have on
occasion been controversial and may be difficult to
interpret due to lack of host-related determinants that
affect tumour behaviour in vivo (Shafie & Grantham,
1981). Certainly, different effects on cell kinetics have
been observed using MCF-7 cells in vitro compared to nude
mouse xenografts (Brunner et al., 1989).
The model described here provides information
complementary to that obtained from in vitro work and
from clinical studies, particularly in examining host -
tumour cell interactions and in determining the role of
gene expression in oestrogen-dependent breast tumour
growth.
The MCF-7 xenografts in thymectomised and irradiated CBA
strain mice therefore present a useful model for
examining the in vivo behaviour of oestrogen-dependent
breast cancer and has considerable potential to study the
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mechanisms of action or failure of action of therapeutic
agents i_n vivo. An illustration of this comes from
studies of the effect on xenograft gene expression of the
anti-tumour agent tamoxifen.
Changes in mRNA with tamoxifen administration
The sensitivity of MCF-7 cells grown as xenograft tumours
to the antitumour effects of tamoxifen was independent of
c-myc expression (Katsaros et al., 1988, Liu et al.,
1989) or of p53 expression. The induction of pS2 in the
xenografts by oestrogen was not antagonised by tamoxifen
contrary to in vitro findings (May & Westley, 1987),
possibly due to the excess of serum oestradiol during the
first 24 hours. However, the effects of tamoxifen on
breast cells are complex and other factors may well be
involved (May & Westley, 1987, Johnson et al. , 1989,
Berry et al., 1989).
TGF-B and tamoxifen
The MCF-7 oestrogen sensitive xenografts confirm the
effect of tamoxifen on MCF-7 cells in vitro (Knabbe et
al., 1987): oestrogen withdrawal leads to an increase in
TGF-J3 and decreased growth while tamoxifen treatment of
the xenograft tumours results in a sustained rise in
TGF-B mRNA, associated with a reduction in tumour volume.
Therefore, one might expect to find low levels of TGF-B
gene transcription in tumours growing despite tamoxifen
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therapy, releasing the cells from proliferative
constraints (Sporn & Roberts, 1985). However, high levels
of TGF-B mRNA and low levels of oestrogen receptor
protein (Anderson et al., 1989) were found in this group
of human breast tumours. By contrast, patients in whom
tamoxifen therapy had induced tumour stasis (but not
regression) had low levels of TGF-B mRNA but oestrogen
1
receptor protein of greater than 20 fmol mg total
protein. The association between high TGF-B mRNA
expression and failure of tamoxifen therapy may be
coincidental given that these were oestrogen poor
tumours. However, the lack of correlation between TGF-B
mRNA and oestrogen receptor protein, confirming a
previous study (Travers et al., 1988), and the inhibitory
effect of TGF-B on oestrogen receptor poor MDA MB 231
cells (Knabbe et al., 1987) suggests that the association
is not due purely to chance and in this situation TGF-B
induction is clearly not mediated through oestrogen
receptors (Knabbe et al., 1987). The data are also
unlikely to be due to a direct effect of tamoxifen
on TGF-B or due to TGF-B degradation (Knabbe et al. ,
1987). The apparent tumour promoting effects of TGF-B in
these tumours may be due to an inability of the malignant
cell to progress to an advanced state of differentiation
in which it could respond to an inhibitory signal (Steel,
1989), as suggested by the poverty of oestrogen receptors
in the tamoxifen unresponsive, progressing tumours.
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Figure 12 : A diagramatic representation of the
autocrine and paracrine pathways for TGF-B.
Proteolysis
The pathway for active TGF-B production and the potential
actions of TGF-B in breast cancer tissue. TGF-B may act
by:
(i) the autocrine inhibitory pathway whereby TGF-B
produced by a breast cancer cell (as mRNA translated to
protein precursor) is activated and acts via TGF-B
receptors to inhibit the cell
and/or
(ii) the paracrine stimulation of other cells and tissues
or inhibition of immune response within the tumour.
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The data suggest that escape from hormone dependence
does not occur simply through failure of the cytokine
release pathway.
The mechanism for this escape from the autocrine
inhibitory effects of TGF-B on the breast cancer cells
(figure 12) may be due to failure to activate secreted
TGF-B (Hsaun, 1989) over 98% of which is secreted in
inactive form (Wakefield et al. , 1987) an established
control point in MCF-7 in vitro (Knabbe et al., 1987).
Alternatively cells may fail to respond to the negative
stimulus (Roberts et al., 1985) or respond weakly
(Parkinson, 1985) due to reduction or loss of receptor
function (Roberts et al., 1988, Massague et al., 1988,
Valverius et al., 1989). The tumour cells may be
resistant to the growth inhibitory effects of TGF-B as
has been demonstrated in vitro (Valverius et al., 1989)
perhaps due to a lack of functional TGF-B receptors as
occurs in retinblastoma (Kimchi et al . , 1988).
Alternatively, there may be a mechanism similar to that
observed following viral transformation of cells, where
increased TGF-B secretion is associated with
downregulation of the TGF-B receptors in the same cells
(Anzano et al., 1985). Although modulation of ligand-
receptor binding may not be an important control
mechanism in some systems (Wakefield et al . , 1987),
modulation of TGF-B responsiveness may occur at the level
of signal transduction (Valverius et al. , 1989). TGF-B
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may even directly stimulate the breast cancer cells
compatible with the jLn vi tro observation that
upregulation of TGF-B mRNA is accompanied by apparent
stimulation by the transcribed TGF-B of T-47D cells
rendered steroid insensitive (King et al., 1989).
The enhancement of stromal growth and angiogenesis
(Roberts et al., 1986, Heine et al., 1987, Massague 1987,
Sporn et al., 1987, Roberts et al., 1988) and the immuno¬
suppressive effect of TGF-B (Kerhl et al., 1986, Wrann et
al., 1987, Sporn et al., 1987, Carel et al., 1990, Torre-
Amoine et al. , 1990) may also play a crucial role. Some
combination of autocrine defect or paracrine effects on
the supporting stroma may occur, as supported by the mRNA
and protein distribution of epithelial derived TGF-B
(Akhurst et al 1988). The present study does not
distinguish between the various isoforms of TGF-B nor
address the questions of TGF-B activation and receptor
function. Neither can one exclude interactions with other
growth factors such as epidermal growth factor (Roberts
et al., 1986, Fernandez-pol et al., 1987). A further
indication that the in vivo situation may be more complex
than in vitro studies have suggested is the significant
correlation between high TGF-B mRNA expression and pre¬
menopausal status. This may be explained by the local
effects of TGF-B, actively transcribed at a high rate in
the breast tumour cells, dominating the effect of
systemically circulating oestrogens which one might
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expect from in vitro studies to inhibit TGF-B
transcription (Dickson et al. , 1986).
Sequential tumour samples
In the small group of 12 tumours with both pre-treatment
and post-treatment specimens, no distinct pattern of gene
expression was detected to relate to the clinical
behaviour of the disease. This may well be due to the
small, heterogeneous nature of the group of 12 patients
or the types of therapy administered. The measurement of
expression of the multiple drug resistance gene might be
of interest in a larger group of patients such as this.
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Conclusions
This thesis presents three types of evidence for multiple
genetic abnormalities occurring in breast cancer:
oncogene overexpression (for example c-myc, c-erbB-2 ),
tumour suppressor gene loss (YNZ allele loss, lack of p53
expression) and conversion of a tumour suppressor gene to
an oncogene (by p53 mutational activation).
The data on gene expression in the 80 patients and the
statistical correlations and associations with recognised
clinical and pathological parameters suggest that
overexpression of important genes (even of a normal
rather than mutant gene) such as c-myc or c-erbB-2 may
be significant pathogenic events in some tumours,
possibly as early rather than late steps on the
carcinogenic pathway. Furthermore, data on pS2 and TGF-B
expression suggest that direct measurement of expression
of specific genes may give useful information for the
clinical management of patients.
Those patients who do not express pS2 mRNA appear to have
a comparatively poor short term prognosis. The breast
cancer recurs at 18 months mean follow up in a
significantly higher proportion of patients who fail to
express the pS2 mRNA, even although there is no
significant association between oestrogen receptor
protein and early disease recurrence. The patients
defined in this way may therefore from a group for whom
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additional early adjuvant therapy would be particularly
appropriate. The unexpected finding that TGF-B raRNA is
high in tumours taken from premenopausal women suggests
that in vitro studies require support from direct
investigation of patient material to confirm or refute in
vitro findings.
The xenograft studies have given useful information in
terms of the changes in gene transcription (mRNA
production) in response to an oestrogenic stimulus of
oestrogen sensitive immortal human breast cancer cells.
These studies also present evidence for the selection of
a subset of increasingly tumorigenic cells from the
initial cell population, as may occur in a patient's
tumour. However, the increase in tumour TGF-B expression
in response to tamoxifen treatment of these xenograft
tumours conflicts with the observed pattern in naturally
occurring tumours in breast cancer patients, where it is
proposed that tamoxifen insmnsitive tumours may subvert
the normally autocrine inhibitory TGF-B function, promote
stromal growth and angiogenesis and suppress the local
immunocompetent cells in a paracrine fashion.
This thesis also presents strong evidence that multiple
events are involved in breast carcinogenesis. It does not
give sufficient information to determine the likely
sequence of the various genetic abnormalities in breast
tumorigenesis and this will require molecular studies of
breast tissue along the pathway from normal, through
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atypia, hyperplasia and carcinoma in situ to overtly
invasive breast cancer. The p53 oncogene/tumour
suppressor gene will be of particular interest in this
setting. The mouse xenograft model may also allow studies
of the effects on tumour growth and characteristics of
introducing normal (wild type) p53 into the MCF-7 cell
line and/or deletion of the mutant p53.
Support for the genetic basis of human breast cancer
from evidence presented in this thesis can be integrated
with epidemiological data outlined in the introduction
(figure 13). It is proposed that abnormalities in a
cancer cell lie in the DNA. Loss of one or more tumour
suppressor gene(s) and/or overexpression of oncogene(s)
may result from radiation or viral damage to DNA or
environmental interactions (including those with
hormones) with the DNA. In familial breast cancer, one or
more of these events may be inherited. The multiple DNA
alterations are reflected in mRNA and protein changes,
the gene products passing from the cell to act in an
autocrine or paracrine fashion (for example TGF-B),
lodging in the cell membrane to receive growth modifying
signals (c-erbB-2), coupling to second messenger systems
(H-ras) or interacting directly with the DNA (c-myc,
p53). Further tumour growth may then be facilitated by
hormonal and other environmental influences, promoting
the cancer cell in preference to neighbouring normal
cells, resulting in a clinically identifiable cancer.
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Figure 13: A diagramatic representation of interactions
between genetic events and factors identified by
epidemiological studies of human breast cancer.
Hormones
The underlying DNA abnormalities, resulting from damage
to the DNA by such factors as radiation and viral
material, or interaction with the DNA by other factors
results in tumour suppressor gene (TSG) loss or
overexpression or activation of oncogenes. The protein
products resulting from mRNA translation may act as a
growth signal, growth signal receptor, signal transducer
or, in a possible association with hormonal influences,
regulating transcription. The net effect of these
changes is to facilitate tumour cell growth.
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Future prospects
In future, several oncogenes may be studied from very
limited tumour material following amplification using the
polymerase chain reaction. This concept has already been
put into practice for the detection of oncogene mutation
(Gonzalez-Cadard et al., 1989) and oncogene amplification
in archival material (Frye et al. , 1989). From studies
such as that detailed in this thesis, important genes can
be selected and sequential measurements of gene
expression performed on the cells obtained by fine needle
aspiration cytology. This may yield further in vivo
information, during treatment regimes, on changes in gene
expression occurring within the viable tumour cells
which may then be used to complement clinical findings.
Thus, early indications may be gained as to how a
particular endocrine, chemotherapy or radiotherapy
treatment is working at the molecular level (or how it is
failing), or whether subsequent resistance to the
treatment is likely.
While this thesis has examined selected oncogenes, tumour
suppressor genes and growth factors, other genes such as
the multiple drug resistance genes (Goldstein et al.,
1989) also merit attention. New candidate oncogenes such
as erbB-3 (Kraus et al., 1989) and further potential
tumour suppressor loci (Devilee et al., 1989b) are
emerging.
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Future molecular studies will further address the problem
of tumour metastasis. Oncogenes may act as tumour
progression factors (Hall et al., 1989); established
oncogenes, for example H-ras (Kyprianou & Isaacs, 1990)
and novel genes such as pGM21 (Phillips et al. , 1990)
have been implicated in conferring a metastatic
phenotype.
In the next decade, molecular technology will continue to
contribute to greater understanding and improved
therapeutic intervention in human breast cancer.
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p53 gene mRNA expression and chromosome 17p allele loss in
breast cancer
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Summary p53 messenger RNA expression was examined using a cDNA probe in 76 fresh primary breast
tumour specimens, 15 of which came from patients treated with taxoxifen prior to surgery. A 2.8 kb mRNA
for p53 was expressed in 43 of the 76 specimens. In 19 tumours the levels were similar to those seen in
non-malignant (reduction mammoplasty) breast tissue, but in 24 tumours over-expression of mRNA for p53,
approaching that seen in three breast cancer cell lines, was found. The cell lines MCF-7, T-47D and
MDA-MB-231 expressed three p53 mRNA species of about 2.8 kb and a fourth of 1.6 kb. Increased mRNA
expression for p53 correlated (P <0.05) with loss of genetic material from the short arm of chromosome 17 as
demonstrated by allele loss with the VNTR probe YNZ 22.1. There was also statistically significant correlation
between increased p53 mRNA expression and low oestrogen receptor protein content in the tumours
(P <0.05), but not with other clinical parameters. The findings support the view that p53 is involved in breast
tumour biology, and suggest that its role may be complex.
p53 is a 53 kDa phosphoprotein with a short half-life
(5-45 min) (Reich & Levine. 1984; Halevy et al., 1988). The
role of p53 protein remains obscure although the p53 gene
has the structural features of a 'housekeeping' gene, including
absence of a TATA box (Reynolds et ah, 1984; Bienz-
Tadmor et al., 1985). p53 may modulate transcriptional
activation by binding to DNA in a similar way to the myc
protein (Donner et al., 1982), allowing cells to progress from
a growth arrested state to an actively dividing state or to
bypass the need for platelet derived growth factor in the
induction of competence (Oren, 1986).
Despite persuasive evidence for its role as an oncogene
(Eliyahu et al., 1984, 1985; Parada et al., 1984; Editorial,
1988; Oren, 1986) there is also reason to believe that p53 can
act as a tumour suppressor gene (Green, 1989; Wang et al.,
1989). This paradox may be resolved if rearrangements of the
p53 DNA alter the structure, expression (Masuda et al.,
1987) or stability (Jenkins et al., 1985) of the 53 kDa protein
product and if the function of a mutated p53 product differs
from that of the normal gene (Green, 1989). The p53 gene
maps to the 13.1 region of the short arm of chromosome 17
(Miller et ah, 1986). One previous study (Masuda et al.,
1987) did not find detectable changes in the p53 gene in
breast cancer. However, using the YNZ 22.1 probe
(Nakamura et al., 1988), which also maps near the tip of 17p
at 13.3, Mackay et al. (1988) found most patients had two
alleles in their constitutional (blood) DNA and 61% of these
informative patients had demonstrable loss of one allele (loss
of heterozygosity) in the tumour DNA.
p53 mRNA and p53 protein levels may (Reich et al., 1983)
or may not (Richon et al., 1989) correspond, since regulation
of p53 expression can occur at the level of mRNA abundance
or of p53 protein stability, depending on the system under
study (Rovinski et al., 1987).
While previous work on human breast cancer has
examined p53 protein expression (Cattoretti et al., 1988) or
chromosome 17p allelic loss (Mackay et al., 1988; Devilee et
al., 1989), no previous study has attempted to link the two by
relating expression of p53 mRNA to clinical parameters and/
or to deletions of chromosome 17p in breast cancer.
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Materials and methods
Seventy-six patients with fully documented history, examina¬
tion, staging investigations and follow-up, who presented with
breast cancer to the University Department of Surgery Breast
Unit at Longmore Hospital, Edinburgh, were studied. They
comprised 61 untreated and 15 tamoxifen-treated consecutive
breast cancer patients from whom sufficient material was
available for analysis. Tumour tissues (minimum 0.2 g) from
patients who underwent wedge biopsy, local excision or
mastectomy for carcinoma of the breast were frozen in liquid
nitrogen and stored at — 70°C. Tissue immediately adjacent
to that stored was fixed for histopathology and a further
piece of tumour submitted for oestrogen receptor assay. For
comparison with constitutional DNA, 20 ml of venous blood
was withdrawn for DNA extraction from white blood cells.
Breast tissue from 10 patients who underwent cosmetic
reduction mammoplasty and who did not have a personal or
family history of breast cancer was also obtained fresh and
immediately frozen.
The breast cancer cell lines MCF-7 (Soule et al., 1973),
MDA-MB-231 (Cailleau et al., 1974) and T-47D (Keydar et
al., 1979) were cultured and maintained under mycoplasma-
free (Barile, 1973) standard conditions. They were harvested
in the logarithmic phase of growth and the RNA was ex¬
tracted for comparison with that from the tumours.
Ribonucleic acid extraction
From frozen tumour, total ribonucleic acid (RNA) was ex¬
tracted using a modification of the method of Auffrey and
Rougeon (1980). Briefly, a known weight of frozen tumour
or a known number of cells washed in phosphate buffered
saline was pulverised and then disrupted in
2 ml 100 mg~' 3 m lithium chloride, 6 m urea and pre¬
cipitated at 4° C overnight. The DNA was sheared using a
Soniprep 150 ultrasonic disintegrator (MSE Scientific
Instruments, Crawley, UK) with an ice jacket, the RNA was
recovered by centrifugation at 12,000 r.p.m. and the pellet
was taken up in 6 ml of 10mM Tris buffer pH 7.0, 0.1%
sodium dodecyl sulphate (SDS). Three hundred pg of pro¬
teinase K (Boehringer Mannheim. FRG) was added and the
sample was incubated at 37°C for 20 min. Protein was ex¬
tracted using phenol equilibrated with Tris (0.1 m, pH 7) and
chloroform:isoamylalcohol (24; 1).
Following ethanol precipitation of the aqueous phase at
— 20°C, the RNA was recovered by centrifugation and dis-
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solved in autoclaved distilled water treated with diethyl
pyrocarbonate (DEPC, Sigma, USA) and stored in aliquots
at — 70°C. The quantity and purity of the RNA was assessed
by spectrophotometry at 260 nm and 240 nm.
Throughout the RNA extraction procedures, sterile dis¬
posable plastic ware was used where possible; all solutions
were made up with autoclaved DEPC-treated water using
baked glassware and gloves were worn to minimise
exogenous ribonuclease contamination (Maniatis et al.,
1982).
Electrophoresis and transfer of RNA
Twenty pg of total RNA was denatured with formamide and
formaldehyde at 55°C for 20 min; 2 pi loading buffer (50%
glycerol, 1 mM EDTA 0.4% bromophenol blue, 0.4% xylene
cyanol) and 1 pi lOpgul"1 ethidium bromide were added to
each sample. The denatured specimens were loaded on to a
1.1% agarose gel containing 0.66 m formaldehyde,
submerged beneath MOPS buffer (morpholinopropanesul-
phonic acid 0.2 M, pH 7.0, 50 mM sodium acetate pH 7.0,
5 mM EDTA) and the RNA species were separated electro-
phoretically (method modified from Fourney et al., 1988).
The gel was washed in two changes of 10 x standard saline-
citrate (1 x SSC contains 150mM sodium chloride, 300 mM
sodium citrate, 1 mM EDTA, pH 7.4) and photographed
under a UV transilluminator. The RNA was transferred to a
nylon filter (hybond-N, Amersham, UK) by capillary action
using 10 x SSC over 8h (method modified from Southern,
1975). The filter was rinsed in 2 x SSC and air-dried, and the
RNA was covalently fixed to the membrane using a UV
transilluminator. The filter and remaining gel were photo¬
graphed to check for adequate transfer of the RNA.
ethanol in the presence of salt (Steel, 1984). Precipitated
DNA was spooled from the alcohol, air-dried and redissolved
in Tris/EDTA buffer, and the concentration and purity of the
DNA were assessed using spectrophotometry at 260 nm and
280 nm. DNA was extracted from 20 ml venous blood in a
similar way, but with an additional protein extraction and
precipitation step prior to RNase treatment.
DNA (5 ng) from each patient's blood and tumour was
digested using a bacterial endonuclease (for example, Tab I),
the samples were separated electrophoretically alongside
digested lambda markers on a 0.8% agarose gel, the DNA
fragments transferred to a hybond-N membrane (Amersham,
UK) using the Southern blot technique (Southern, 1975) and
the DNA was fixed to the membrane with ultraviolet light
and baking at 80°C for 2 h.
The membrane was incubated in hybridisation buffer (5 x
Denhart's, 5 x SSC, 0.1% SDS, 10% dextran sulphate) to
which 107 c.p.m. ml-1 32P-CTP-labelled YNZ 22.1 insert was
added (Nakamura et al., 1988) and allowed to hybridise for
24 h.
Excess probe was washed from the membrane using suc¬
cessive washes of 0.1% SDS and 1 x SSC and the DNA
fragments were detected by autoradiography at — 70°C to
pre-flashed Kodak XAR film.
Oestrogen receptors
The oestrogen receptor content was measured using the
Enzyme Immunoassay (EIA; kit from Abbott Laboratories,
North Chicago, IL, USA) and expressed in fmol per mg
protein for both the tumours and the cell lines. Oestrogen
receptor protein concentrations of 20 fmol mg"1 protein or
greater were considered to be 'significant' (moderate to rich).
Probe hybridisation
Filters were pre-hybridised in 7% SDS, 0.5 M disodium hy¬
drogen phosphate (pH 7.2) and 1 mM EDTA pH 7.0 (method
modified from Church & Gilbert, 1984) for 30 min at 65°C.
To this was added 12P-cytidine triphosphate (CTP) labelled
cDNA probe, with specific activity to 107 c.p.m. ml"1 using a
random prime DNA-labelling system (Boehringer Mannheim,
FRG). 1:P-CTP incorporated probe was separated from unin¬
corporated radionucleotide using a Sephadex column (Nick
column, Pharmacia, UK) and denatured before addition to
the hybridisation solution.
To detect the p53 mRNA, the 2.1 kb cDNA clone
php53Bam of p53 protein mRNA cut from pBR322 (Zakut-
Houri et al., 1985) was used. Following 24 h hybridisation,
filters were washed to remove non-specifically attached probe
in two changes of 0.1% SDS 10 mM disodium hydrogen
phosphate wash buffer at 65°C with agitation. The filters
were blotted dry, wrapped in clingfilm and exposed to pre-
flashed Kodak XAR film at — 70°C for up to 14 days.
The extent of hybridisation of radiolabeled probe to the
mRNA species was determined from densitometry (using a
laser densitometer constructed by the Medical Research
Council Human Genetics Unit) and expressed with respect to
hybridisation to the actin probe. The size of each mRNA
species was calculated from the position of ribosomal RNA
markers.
The filters were stripped of residual probe by washing at
80°C for 60 min in 0.1% SDS and the filter was checked by
autoradiography. As a standard probe, the Pst 1 insert
cDNA of plasmid 91, detecting mouse a-actin mRNA-
specific sequences (Minty et al., 1981) was then hybridised
and washed under the above conditions to quantify
accurately the mRNA in each total RNA sample loaded.
DNA extraction
DNA was extracted from frozen tissue by disrupting finely
chopped tissue in lysis buffer containing 1 % SDS. Impurities
were removed by using RNase and proteinase K, then phenol
and chloroform, and the DNA was precipitated using
Results
A 2.8 kb p53 mRNA was detected in 43 of the 76 tumour
specimens (57%), in all three breast cancer cell lines and in
six of the 10 reduction mammoplasty specimens (Figure 1).
Low levels of this p53 mRNA (comparable to those found in
the six positive mammoplasty specimens) were also detected
in normal human tonsil, uterus and ovarian tissue (data not
shown). There were quantitative differences between the
tumour specimens and qualitative differences between the
tumours and the cell lines. Thirty-three of the 76 patients had
no detectable p53 mRNA in their tumour tissue and 19
patients had detectable p53 mRNA of 2.8 kb similar to quan¬
tity to the reduction mammoplasty specimens that gave a
positive signal. Twenty-four patients had increased levels of
the 2.8 kb p53 mRNA approaching those found in the cell
lines.
Cell line Carcinoma Reduction
MCF7 MDA T47D 0 + ++ + + + Mammoplasty
• I• llil ♦
Figure 1 p53 mRNA expression in three breast cancer cell lines
(MCF-7. MDA-MB-231 and T-47D), four representative breast
tumours with no mRNA expression (0), normal mRNA expres¬
sion ( + ) comparable to control (reduction mammoplasty) tissue
and increased mRNA expression ( + + or + + + ). In each case,
upper part of plate shows p53 mRNA species and lower part of
plate the control actin mRNA.
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The three breast cancer cell lines each yielded four p53
mRNA species. Three closely related species were of approxi¬
mately 2.8 kb, with differences between cell lines in the
amounts of mRNA for each of these species. A fourth
(1.6 kb) p53 mRNA was strongly expressed in all three lines.
There was a significant tendency for increased tumour p53
mRNA expression to be associated with clinically
insignificant levels of oestrogen receptor protein (P = 0.049,
X2 test; Table I). No statistically significant correlation was
found between p53 mRNA expression and tumour size,
spread of the tumour to lymph nodes, histolopathological
features of the tumour, patient age or menopausal status.
The 76 patients all yielded sufficient DNA for analysis
from both venous blood and tumour. Using the php53Bam
cDNA probe for p53, polymorphic bands were detected in
less than 10% of samples with BamHI, Bgl II. Sea I, Ban II,
Hinlll, EcoRI or Taq I and no rearrangements were
identified. However, with the YNZ22.1 cDNA probe and
Taq I digests, 52 of the 76 (69%) blood DNA samples were
polymorphic and the remaining 24 were not informative.
Among the 53 informative patients there was unequivocal
loss of heterozygosity (loss or marked diminution in intensity
of one allele) in 30 tumours (58%) when compared to the
constitutive (blood) DNA (Figure 2).
Loss of genetic material from the tip of the short arm of
chromosome 17, as determined by loss of heterozygosity
using the YNZ 22.1 probe, was significantly correlated with
increased p53 mRNA expression (Table II, P = 0.04, y2 test).
Allelic loss was also correlated with low levels of oestrogen
receptor protein (P = 0.024, Fisher's exact test). When the
present data are combined with those from our earlier series
(Mackay et al., 1988) the association becomes highly
significant (Table III, P<0.01).
Table I p53 mRNA expression compared to oestrogen receptor





Significant 20 14 9
(>20)
Insignificant 13 5 15
(< 20)
B T B T
Figure 2 Detection of DNA alleles using cDNA probe YNZ
22.1 following digestion of blood (B) tumour (T) DNA pairs with
the endonuclease Taql, demonstrating no allelic loss (left pair)
and loss of heterozygosity (right pair) from tumour DNA.
Table II p53 mRNA expression compared to allelic loss in 52
informative patients as demonstrated using the YNZ 22.1 probe for
the short arm of chromosome 17 (y2 6.29, P =0.04)
p53 mRNA expression
Nil Normal Increased
Allele loss 10 6 14 (30)
No allele loss 12 7 3 (22)
Table III Allelic loss in 52 informative patients with the YNZ 22.1








Allele loss 11 19
(19) (32)
No allele loss 15 7
(24) (11)
Figures in parentheses include 34 informative patients from our
previously reported data (Mackay et al., 1988; P =0.004, Fisher's
exact test).
Discussion
This study has examined p53 mRNA expression and loss of
genetic material from the short arm of chromosome 17 in 76
patients. A 2.8 kb mRNA for p53 was detected in 43 of the
76 breast cancer specimens. This corresponds to the mRNA
for p53 identified in previous studies of human tissue (Har¬
low et al., 1985; Baker et al., 1989). The quantitative
difference between tumours in p53 mRNA expression raises
the possibility that the p53 gene may fulfil different functions
in the patients with no detectable mRNA by comparison
with those in whom there was normal or increased expres¬
sion. In those tumours where no p53 mRNA was detected,
this may reflect deficiency of normal (unmutated) p53 and
hence a reduced tumour suppressor function. Deletion of one
copy of the p53 gene is compatible with increased function of
the other (abnormal) gene. Thus, where there is normal or
increased p53 mRNA expression, this may be of a mutated
form (for example a point mutation), which therefore acts as
an oncogene, promoting carcinogenesis. Alternatively, loss of
one allele may confer a minor growth advantage, with subse¬
quent mutation of the remaining p53 required to initiate or
promote carcinogenesis. If mutation were to occur first, loss
of the normal allele may be required to allow effective ex¬
pression of the mutant p53, by analogy with co-transfection
studies of normal and mutated H-rax (Spandidos & Wilkie,
1988). The step between normal and mutated p53 cannot
readily be established using the Northern blot technique,
although future use of the polymerase chain reaction (Saiki
et al., 1985) should clarify the situation.
The qualitative differences between the tumours and cell
lines may reflect reading frame differences (likely to give rise
to the 1.6 kb mRNA) or splicing, or even different
adenylated tail lengths resulting in the three messages of
about 2.8 kb in size. However, when MCF-7 cells are grown
as xenografts in immunosuppressed mice, only a single 2.8 kb
p53 mRNA species and no 1.6 kb mRNA is detected in the
tumour tissue. This finding is independent of the rate of
tumour growth (A.M. Thompson, manuscript in prepara¬
tion). A single p53 mRNA species of 1.8 kb has been noted
previously in NIH3T3 cells (Reich et al., 1983; Reich &
Levine, 1984) and this mRNA may correspond to the nuclear
mRNA regulating translation detected by Khochbin and
Lawrence (1988).
The three cell lines examined are distinguishable on
karyotype and on molecular analysis (using cDNA probes),
and they have different phenotypic characteristics; for ex¬
ample, the MCF-7 line used in these studies has on average
120 fmol mg~' total protein oestrogen receptor protein, T-
47D 40 fmol and MDA-MB-231 0 fmol. These lines also
show differing sensitivity to oestrogens and anti-oestrogens.
The consistently high level of p53 mRNA expressed in all
three lines thus implies that, in this in vitro setting, p53
mRNA expression is independent of oestrogen receptor pro¬
tein content of the cells and of hormone sensitivity. Although
we have not confirmed the correlation noted in vivo between
increased p53 mRNA expression and oestrogen poor
tumours, this may be due to a myriad of factors including
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the divergence of cell lines from the original tumour with
time.
Cattoretti et al. (1988), using an antibody PAbl801 specific
for human p53 protein in breast cancer specimens, noted a
correlation between oestrogen receptor negative tumours and
elevated p53 protein expression (/><0.05). Using this
antibody, no other significant correlation was identified.
These results therefore agree with our findings in relation to
p53 mRNA.
This study confirms that the loss of one YNZ 22.1 allele
from the short arm of chromosome 17 occurs in over half the
breast tumours studied (Mackay et al., 1988, Devilee et al.,
1989) and establishes for the first time that this allele loss
correlates with clinically insignificant levels of oestrogen
receptor protein. The tip of the short arm of chromosome 17
is thus of importance in breast as well as in colon cancer
(Lothe et al., 1988; Vogelstein et al., 1989).
Although of all the highly informative probes available for
this study, YNZ 22.1, located at 17p 13.3, was the closest to
the p53 (17p 13.1) locus, it is still several megabases telomeric
to the p53 gene. The correlation between loss of
heterozygosity for YNZ 22.1 and p53 mRNA expression
provides evidence that there may be some link between a
putative gene conferring increased susceptibility to cancer
(Mackay et al., 1988) and the oncogene or tumour suppres¬
sor gene function of p53.
Eleven of the 76 patients had tumours showing loss of
heterozygosity for YNZ 22.1, increased expression of p53
mRNA and low levels of oestrogen receptor protein. With
just 12 months mean follow-up, two of these patients have
already relapsed with metastatic disease. Continued follow-up
of the whole cohort will establish the prognostic significance
of the present findings.
The observation that, in almost a third of tumours, p53
mRNA levels were elevated while, in a comparable propor¬
tion, the message was not detectable, supports the view that
p53 is involved in breast tumour biology. Whether this is as
an oncogene or as a tumour suppressor gene (possibly as
either, depending on the individual tumour) remains to be
seen. The advent of highly polymorphic probes for the p53
gene and the application of more recent technology, such as
the polymerase chain reaction, should resolve these issues.
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Gene expression in oestrogen-dependent human breast cancer xenograft
tumours
A.M. Thompson1-2, C.M. Steel2, M.E. Foster2, D. Kerr3, D. Paterson4, D. Deane2,
R.A. Hawkins1, D.C. Carter1 & H.J. Evans2
'Department of Surgery, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW; 2MRC Human Genetics Unit,
Western General Hospital, Crewe Road, Edinburgh EH4 2XU; 3Beatson Institute, Garscube Estate, Switchback Road, Glasgow
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Summary Xenograft tumours from an oestrogen-dependent human breast cancer cell line MCF-7 have been
established and characterised in thymectomised, irradiated female CBA strain mice. There was evidence for
selection in xenografts of a subpopulation of MCF-7 cells with an altered pattern of gene expression as
measured by mRNA levels compared with the original cells in vitro. Tumorigenicity increased significantly on
repeated animal passage but oestrogen dependence was retained. Following injection of the mice with
oestrogen, mitosis was induced in the tumour cells with associated increases in thymidine uptake and
percentage of cells in S-phase. In accord with these changes, c-myc and p53 expression were increased and
TGF-beta was suppressed. Thereafter the expression of the c-myc and p53 genes fell whilst that of the
TGF-beta gene was induced as the oestrogenic stimulus declined. The oestrogen-regulated mRNA pS2 showed
a biphasic response to oestrogen and levels declined as the serum oestrogen fell to undetectable levels. This
xenograft system demonstrates that changes in transcription of oncogenes, growth factor and oestrogen-
regulated genes can be detected in vivo in response to oestrogen. It thus provides an in vivo model for studies
of the biochemical and molecular basis for therapeutic manipulation of hormone-sensitive human breast
cancer.
In studying the molecular biology of cancer cells, the
significance of in vitro observations may be uncertain due to
the absence of host factors that influence tumour behaviour
in vivo. Recent work on experimental human breast tumours
in vivo has made use, almost exclusively, of congenitally
athymic ('nude') mice (Osborne el al., 1988; Brunner el al.,
1989). We have previously reported the growth of a range of
human tumours in thymectomised, irradiated mice (Busuttil
el al., 1986) which have advantages in ease of husbandry and
cost (Steel et al., 1978; Morten el al., 1984; Hay el al., 1985).
We report here the characterization of an oestrogen-
responsive tumour derived from the MCF-7 human breast
carcinoma cell line grown in vivo in female thymectomised
and irradiated CBA mice. In addition, we have examined the
kinetics of the expression of a range of related genes (c-myc,
p53, TGF-beta and pS2) following oestrogenic stimulation in
this tumour model system.
Materials and methods
Twenty-one day old female mice from an established
breeding colony of CBA/Ca strain mice at the Institute of
Animal Technology, Western General Hospital, Edinburgh,
maintained as described in Hay et al. (1985), were anaes¬
thetised with ether and suction thymectomy performed.
Three weeks after thymectomy, 200mgkg"' arabinoside C
(Pfizer, UK) was injected by the intraperitoneal route and
48 h later the mice were irradiated to a total body dose of
7.50 Gy. Radiation was delivered from an X-ray source
(250 kv: 0.3-0.4 Gy min-1) with a Thoreus II filter. MCF-7
cells (Soule et al., 1973) were cultured in Nunclon flasks
(Nunc, Kamstrup, Denmark), fed regularly with Dulbecco's
Modified Eagle Medium (DMEM; Gibco, Paisley, UK) con¬
taining phenol red (which has an oestrogenic effect on MCF-
7 cells) supplemented with 12% fetal calf serum (FCS;
Gibco) and maintained in an atmosphere containing 5% C02
at 37°C. All cultures were persistently negative for myco¬
plasma using conventional immunofluorescence techniques
(Goding, 1983). The cells were harvested in the logarithmic
(subconfluent) phase of growth and washed twice in
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phosphate-buffered saline (PBS). A single dose of 107 viable
cells suspended in 50-100 pi PBS was injected into the fourth
right mammary fat pad 1-3 weeks after irradiation. At this
time 50 pg oestradiol benzoate (Intervet UK Ltd., Cam¬
bridge, UK) in 50 pi arachis oil was injected subcutaneously
into the nape of the neck. This injection of 50 pg oestradiol
benzoate in arachis oil was repeated every three weeks to the
same site. MCF-7 cells were also injected into 20 CBA mice
without oestrogen supplementation. A further 20 mice were
tested with a second regime: either a 1.25 mg or a 0.5 mg
oestradiol 6-week-release pellet (Innovative Research, Ohio,
USA) was placed subcutaneously. Tumours were measured
daily in two dimensions by the same author using calipers.
The volume of the tumour was calculated using the formula
pi/12 x (mean diameter)3.
Mice were killed at selected times and the tumours were
frozen immediately in liquid nitrogen or fixed for histology.
Those mice which did not develop tumours were killed 90
days from the start of the experiment. Mice which died in the
interim were examined in detail for evidence of disease.
Fragments of xenograft material arising from inocula of
MCF-7 cells were further transplanted through a dorsal
incision into additional thymectomised, irradiated mice under
anaesthetic. An injection of 50 pg 17 beta oestradiol benzoate
in arachis oil was administered as the mouse awoke.
Thereafter the transplant-bearing mice were treated as above.
Remaining tumour fragments were macerated and added to
DMEM containing 12% FCS and the tumour cells returned
to culture for 8 weeks before reinjection into mice or extrac¬
tion of total ribonucleic acid (RNA).
Two additional human breast cancer cell lines MDA-MB-
231 (Cailleau et al., 1974) and T47-D (Keydar et al., 1979)
were cultured and similarly maintained. The cells were
harvested in the logarithmic phase of growth so that the
RNA could be extracted for comparison with that from the
MCF-7 cells.
Serum oestradiol concentration
Serum was prepared from individual samples of blood
(0.3-0.8 ml) taken by cardiac puncture from each of 30 mice
at specified times following the 3-weekly oestradiol benzoate
injections. The concentration of 17 /J-oestradiol was deter¬
mined in 50 pi samples of serum using a commercially
available radioimmunoassay (Baxter Health Care, Newbury,
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rks., UK). Within assay CV was 5% and between assay
' was 6%.
Ilular DNA synthesis
rcenlage of celts in 'S' phase. A monoclonal antibody,
19, directed against the halogenated nucleotide 5-
amodeoxyuridine (5BrdU) was raised by one of the
thors (D.D.) and used for rapid S-phase measurements
onochoroff et al., 1985).
A total of 200pi of 6mgml"1 5-BrdU (Sigma) was
ected into the peritoneal cavity of each mouse under
tmination at 0, 6, 12, 18, 24, 36, or 48 h after injection of
pg 17 0-oestradiol. Each mouse was killed lh after
ministration of the BrdU and the cells were released from
: tumours by dispase digestion and fixed in 70% ethanol.
double staining procedure was used for the differentiation
human MCF-7 cells from invading host (mouse) cells,
ted cells were incubated with 10 pg of an antihuman class 1
moclonal antibody PE25 (D.D.), washed in PBS and 2 pg
phycoerythrin-labelled anti-mouse conjugate added
tuthern Biotechnology Associates Inc.). To prevent cross-
ictivity of this antibody with the BR9, the cells were then
ubated in PBS containing lOpgml-1 mouse IgG (Sigma)
• 30 min. After a wash in PBS, 10 pg of the monoclonal
tibody BR9 was added to the pellet of 106 cells and
:ubated at room temperature for 40 minutes, washed in
iS and incubated for a further 40 minutes in the presence
2 pg fluorescein isothiocyanate (FITC)-labelled goat anti-
>use conjugate (Sigma). After a final wash in PBS the cells
re analysed on a FACScan flow cytometer (Becton Dick-
t, Lincoln Park, NJ, USA) for the absolute number of
Is and the proportion of tumour cells in S phase.
ymidine incorporation Thymidine uptake was also used as
index of DNA synthesis in the isolated tumour cells. For
:h time point, intact cells were separated from the dispase/
vIEM digests by density centrifugation over 5-30% Ficoll
3 gradient (Pharmacia, Uppsala, Sweden) and 150 pi of cell
spension (106 cells ml-1 DMEM with 5% added FCS) were
ded per well of a 96-well mitcrotitre plate (Falcon 3072,
cton Dickson). One pCi 3H-thymidine (Amersham Interna-
nal, Aylesbury, UK) was added to each well and the cells
re harvested 5 h later on to glass fibre discs. The radio-
:ivity emitted from each disc was counted in 5 ml of scintil-
it (Opti-Scint, Pharmacia, Sweden) in a Packard 1600CA
alyser (Packard, Downers Grove, Illinois, USA).
stopathology
slice through the middle of each tumour was fixed in
ithacarn for 1 h then 95% ethanol and then processed
jtinely. Paraffin sections were cut and examined after
ining with haematoxylin and eosin. The mitotic index for
:h tumour was calculated from the mean number of
toses in 50 randomly chosen, high-power fields (x 400) by
e author (D.P.).
strogen receptor concentration
e soluble oestrogen receptor concentration of xenograft
sue or cells was measured following homogenisation by a
ndard method (Hawkins et al., 1981) and use of the
zyme Immuno-Assay (EIA; Kit from Abbott
boratories, North Chicago, Illinois). Both for the cells and
■ the solid tumours receptor concentration was expressed in
ol mg proteins-1 (Hawkins et aL, 1987).
traction of ribonucleic acid and northern blotting
om frozen tumour, the total ribonucleic acid (RNA) was
racted using a modification of the method of Auffrey and
iugeon (1980). A known weight of frozen tumour was
Iverised using a Mikrodismembrator II (Braun, FR Ger-
ny) and the resulting powder was finely disrupted using a
plastic pipette in the presence of 2 ml per 100 mg tissue of 3m
lithium chloride/6 M urea and left at 4°C overnight. Alterna¬
tively, cells cultured in vitro were washed in PBS and then
disrupted in 3 M lithium chloride/6M urea with a plastic
pipette. The DNA was sheared using a Soniprep 150 ultra¬
sonic disintegrator (MSE Scientific Instruments, Crawley,
UK) with an ice jacket. The RNA was recovered by cent¬
rifugation at 12,000 r.p.m. and the pellet was taken up in
6 ml lOmmol Tris buffer pH 7.0, 0.1% sodium dodecyl sul¬
phate (SDS), 300 pg proteinase K (Boehringer Mannheim,
FR Germany) were added and the tube incubated at 37°C for
20 min. Protein was extracted using phenol equilibrated with
0.1 M Tris at pH 7 and 24:1 chloroforrmisoamylalcohol. Fol¬
lowing ethanol precipitation of the aqueous phase at — 20°C,
the RNA was recovered by centrifugation and dissolved in
diethyl pyrocarbonate (DEPC, Sigma, USA) treated, auto-
claved, distilled water and stored in aliquots at — 70°C. The
quantity and purity of the RNA was assessed spectro-
photometrically at 260 nm and 240 nm. Throughout the
RNA extraction procedures, sterile disposable plastic ware
was used where possible; all solutions were made up with
autoclaved DEPC-treated water, using baked glassware and
gloves were worn to minimise exogenous ribonuclease con¬
tamination (Maniatis et al., 1982).
Twenty micrograms of total RNA was denatured with
formamide and formaldehyde at 55°C for 20 min; 2 pi
loading buffer (50% glycerol, 1 mM EDTA, 0.4% bromo-
phenol blue, 0.4% xylene cyanol) and 1 pi of lOpgpl"1
ethidium bromide were added to each sample. The denatured
specimens were loaded on to a 1.1 % agarose gel containing
0.66 M formaldehyde, submerged beneath MOPS buffer
(0.2 M morpholinopropanesulphonic acid pH 7.0, 50 mM
sodium acetate pH 7.0, 5 mM EDTA) and the RNA species
were separated electrophoretically (modified from Fourney et
al., 1988).
The gel was washed in two changes of 10 x standard saline
citrate (1 x SSC contains 150 mM sodium chloride, 15 mM
sodium citrate, 1 mM EDTA, pH 7.4), photographed under a
UV transilluminator and the RNA was transferred to a
nylon filter (hybond-N, Amersham, UK) by hydrostatic
action using 10 x SSC over 8h (Southern, 1975). The
hybond was rinsed in 2 x SSC, air-dried and the RNA was
covalently fixed to the membrane using a UV transil¬
luminator. The hybond and the remaining gel were photo¬
graphed to check for adequate transfer of the RNA.
Probe hybridisation
Filters were prehybridised in 7% SDS, 0.5 M disodium hy¬
drogen phosphate pH 7.2 and 1 mM EDTA pH 7.0 (modified
from Church & Gilbert, 1984) for 30 min at 65°C. To this
was added 32P cytidine triphosphate (CTP)-labelled cDNA
probes labelled to 1 x 10'c.p.m. ml-1 using the randomprime
DNA labelling system (Boehringer Mannheim, FR Ger¬
many). 32P-CTP incorporated probe was separated from
unincorporated radionucleotide using a Sephadex column
(Nick column, Pharmacia, UK) and denatured before addi¬
tion to the hybridisation solution.
cDNA probe inserts digested from their respective plas-
mids were used to detect messenger RNA (mRNA) species
for three oncogenes (erbB-2; p53; c-myc) three growth factors
or their receptors (epidermal growth factor receptor; trans¬
forming growth factor-beta; transforming growth factor-
alpha) and two hormone-related genes (OR3, pS2).
For c-erbB-2, the KpnI-Xbal fragment of lamda 107 was
used (Semba et al., 1985); for p53, the 2.1 kb php53Bam
cDNA (Zakut-Houri et al., 1985); and for c-myc, pSV-c-myc-
1 for exons 2 and 3 (Land et al., 1983). Epidermal growth
factor receptor (EGFR) was detected with the 3.9 kb pHER-
A64-1 probe (Ullrich et al., 1984), transforming growth
factor-alpha (TGF-alpha) with a 1.05 kb insert from Sp64-
BC1 (Derynck et al., 1984) and transforming growth factor
beta with the 1.3 kb insert from Sp65-C17N (Derynck et al.,
1985). The two hormone-related probes were the 1.6 kb OR3
oestrogen receptor cDNA (Walter et al., 1985) and the pS2
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0.56 kb cDNA for oestrogen-regulated mRNA (Masiakowski
el al., 1982). As a standard probe, the Pst 1 insert cDNA of
plasmid 91, detecting mouse alpha-actin mRNA specific
sequences (Minty et al., 1981), was used to quantify
accurately each total RNA sample loaded. It is of particular
relevance in this oestrogen-sensitive model that transcription
of actin mRNA in MCF-7 cells is not affected by oestrogen
(Saceda et al., 1988).
Following hybridisation for 24 hours, filters were washed
to remove non-specifically attached probe in two changes of
0.1% SDS lOmmol disodium hydrogen phosphate wash
buffer at 65°C with agitation. Filters were blotted dry, wrap¬
ped in cling film and exposed to preflashed Kodak XAR film
at — 70°C for up to 14 days. The extent of hybridisation of
radiolabelled probe to the mRNA species was determined
from densitometry using a laser densitometer constructed by
the Medical Research Council Human Genetics Unit and
expressed with respect to hybridisation to the actin probe.
The size of mRNA species was calculated from the position
of ribosomal RNA markers. Filters were reprobed up to six
times with different cDNA probes; before reprobing, filters
were stripped of residual probe by washing at 80°C for
60 min in 0.1 % SDS and the filter was checked by
autoradiography.
Results
One hundred and forty-five CBA strain mice were injected
with MCF-7 cells in this study (Table I). Of the 145 mice
injected, 69 received both cultured MCF-7 cells and oest-
radiol benzoate. Twelve of these 69 mice died before 90 days
leaving 57 for analysis, 30 of which (53%) grew a tumour. Of
36 mice into which tumour was transplanted, four died
prematurely and 23/32 (72%) of the remaining mice grew
tumours. The recultured cells grew as xenografts in 16 of the
18 mice injected which survived (89%). The take rate of
transplanted tumour material was significantly higher than
that of primary inocula (P = 0.04 by Fisher's exact test) and
was higher still for tumour cells that had been recultured in
vitro and then inoculated into fresh mice (P = 0.004 by
Fisher's exact test).
Tumours did not grow without oestrogen supplementation.
The 50 pg oestradiol benzoafe in arachis oil or the arachis oil
alone were well tolerated by the CBA mice and the oestrogen
delivered in this form promoted tumour growth. The use of
conventional pellets of 1.25 mg or 0.5 mg oestradiol resulted
in 20/20 deaths within 10 days. No consistent cause for these
deaths was evident at post mortem.
Histopathology
Each MCF-7 tumour was firm, pale, solid and well circum¬
scribed, not showing overt local invasion or ulceration of the
overlying skin. All the tumours were examined histologically
and were compatible with an origin from breast, although
they did not show marked adenocarcinomatous different-
iaton. There were no areas of necrosis in the smaller
Table I The fate of MCF-7 cells inoculated into immunocompromised
mice
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20 16 (89%) 2 2
tumours, although the larger tumours did have evidence of
central necrosis. No marked lymphocyte infiltration was
noted.
Microscopic and macroscopic examination of mice which
died and mice which were killed to obtain tumour showed
evidence of metastasis in only one animal. In that instance,
tumour cells were evident at the site of MCF-7 cell inocula¬
tion, as peritoneal seedlings and microscopically in the
visceral pleura of the lung. No pathological evidence of
oestrogen toxicity was found at post mortem in any animal
although there was some hair loss at the site of the oestradiol
injection.
Serum oestradiol concentration
Oestradio! was not detectable in the serum from thymec-
tomised and irradiated mice prior to injection. After injection
with 50 pg oestradiol benzoate (Figure 1), a sharp rise to a
mean 7,492 pmoll-1 (s.d. 3,374 pmol l-1) oestradiol occurred
by 24 h, declining exponentially to undetectable levels (less
than 53 pmoll-') 2 weeks after the injection.
Tumour growth
The tumours became palpable during the first 3 weeks fol¬
lowing 17 0-oestradiol injection and following the second and
third injections of oestrogen, the tumour was observed to
grow in size, but not in a uniform fashion (Figure 1). In
particular, during the first 14 days after injection, the tumour
increased rapidly in size, then from day 14 to 21 slowed
down or became static. By 3-6 weeks, all tumours were large
enough for the studies described.
Cellular DNA synthesis and mitoses
Increased thymidine uptake was noted by 18 h following the
oestrogen injection (Figure 2) and, in parallel with the
percentage of S-phase cells, reached a maximum 24 h follow¬
ing oestrogen injection, declining thereafter.
The number of mitoses per X400 field (Figure 2) showed
an increase, compared to the baseline value of 3 per x400
field, to 24 per x 400 field demonstrable 24 h following
oestrogen stimulation of the tumour. The level fell to 5
mitoses per x400 field 10 days later. The number of mitoses
showed parallel changes to the biochemical indices of cellular
DNA synthesis.
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Figure 1 Serum oestradiol and tumour volume in a mouse
xenograft model. Serum oestradiol (mean ± standard deviation)
in thymectomised and irradiated mice for 2-4 mice at each time
point following subcutaneous injection of 50 pg 17 oestradiol
benzoate. From undetectable levels (<53 pmol l-1) prior to injec¬
tion of oestradiol there is a rapid rise to a peak of 7,492 pmol-1
followed by a decline in serum oestradiol to undetectable levels
by the third week post-injection (solid dots). Tumour volume
(calculated from pi/12 x mean diameter3) for a cohort of 12 mice
(mean volume ± standard deviation) measured during weeks 3 to
6 following injection of the MCF-7 cells. Only four time points
are shown for clarity (open dots). There is a rise in tumour
volume for the 2 weeks following injection of oestrogen, with
little change in tumour volume once serum oestradiol becomes
undetectable.
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Figure 2 Three indices of cellular proliferation in xenografts of
MCF-7 cells in mice following administration of oestradiol. Cell
proliferation measured by 3H-dTr uptake (solid dots), percentage
of cells in S phase (open dots) and mitoses per x 400 field (solid
squares) showing mean value of four tumours for each time
point. The same tumours were used for all three indexes of cell
proliferation. Between 12 and 24 h following injection of 17 jl
oestradiol benzoate, MCF-7 cells are stimulated to divide, DNA
synthesis returning to prestimulation levels by 48 h and mitoses
declining within days.
Oestrogen receptors
MCF-7 cells in vitro, tumour material taken immediately
before oestradiol injection and cells cultured from xenografts
had a mean 120fmol (range 110— 135 fmol) oestrogen recep¬
tors per mg protein. There was a rise to 240 fmol trig"'
protein at 30 h, but at 7, 14 and 21 days following injection,
the level had returned to between 120 and 150 fmol mg"1
protein.
Tumour levels ofmRNA
Presence of mRNA species Messenger RNA was detected in
MCF-7 cells by seven of the nine probes (Figure 3). No
mRNA for EGFR or TGF-alpha was detected in the MCF-7
cells or xenografts, although both mRNA species were
detected in other breast cancer cell lines (MDA-MB-231 and
T47-D). While some mRNA species (c-erbB-2 and OR3)
detected in the MCF-7 cell line were not seen in the xeno¬
graft material, no mRNA species was detected in the
tumours which was not present in the original cell line
(Figure 3). The mRNA for c-erbB-2 was detected at 3.0 kb
and 1.8 kb in the original cell line but not in the xenografts.
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Figure 3 Gene expression in MCF-7 cells in vitro and in vivo
(xenografts). Representative autoradiographs of MCF-7 cells,
MCF-7 xenografts and MCF-7 cells re-cultured from the xenog¬
rafts after probing with cDNA probes for c-erbB-2, p53, pS2,
c-myc and TGF-beta (details in text) In each case the actin-
probed control for each lane is shown. Two c-erbB-2 species are
evident in the cell line but are not seen in the xenografts. Four
p53 mRNA species are demonstrated in the cell line but only one
in the xenografts and re-cultured cells. Similarly, three species
detected with the pS2 probe are seen in the cell line but only one
species in the xenografts and cells cultured from those xenografts.
The c-myc and TGF-beta probes detect identical species in both
the MCF-7 cell line and the xenograft tumours.
Four mRNA species for p53 (three at 2.8 kb, one at 1.8 kb)
were identified in the original cell line but only a single
mRNA for p53 was found in tumours or in re-cultured cells.
Similarly, three mRNA species were detected with the pS2
probe in the original cell line but only the single 0.6 kb
mRNA in the tumours. Other cDNA probes such as those
for TGF-beta and c-myc detected only a single mRNA
(2.5 kb in each case) present in both the cell line and xeno¬
grafts. There were no differences in any mRNA species
detected between xenografts, transplanted tumours and
tumour cells recultured for periods of up to 56 days.
Changes in gene expression after oestrogen stimulation (Figure
4). Densitometry permitted detection of changes in the
levels of mRNA for c-myc, p53, TGF-beta and pS2 with
respect to alpha-actin mRNA, following stimulation of the
xenograft by oestrogen. The mRNAs for c-myc and p53 both
increased then fell back towards the unstimulated level within
the first 24 h while that for TGF-beta was rapidly sup¬
pressed, rising only as the oestrogen stimulus declined after 1
week. pS2 expression showed a biphasic response with an
initial increase to 24 h, then suppression for 12 h, a less
substantial increase by 48 h and finally a decline as the
expression of TGF-beta increased.
Discussion
General characteristics
We have established the MCF-7 breast cancer cell line as
xenografts in CBA mice immunocompromised by thymec¬
tomy and whole body irradiatfon. Tissue from these tumours
can be transplanted to similar mice, and cells cultured from
the xenografts can be re-implanted to grow tumours. This
model therefore yields a large renewable supply of tumour
material passaged in vivo and permits the study of tumours
during hormonal manipulation. These MCF-7 tumours were
clearly adenocarcinomata, with necrosis in only the larger
tumours as in nude mice (Osborne, 1988) and metastasis, as
previously noted, a rare event (Busuttil et al., 1986).
As in nude mice, oestrogen supplementation is a pre¬
requisite for MCF-7 tumour growth (Shafie & Grantham,
1981; Osborne et al., 1985; Gottardis et al., 1988). The
absence of detectable serum oestrogen in female mice prior to
injection confirmed that the mice had been 'oophorectomised'
I Peak serum oestradiol
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Figure 4 Changes in mRNA following oestrogenic stimulation
of MCF-7 xenografts. Host animals were injected with 17/1 oest¬
radiol benzoate at time 0. The changes shown are for c-myc, p53,
pS2 and TGF-beta mRNA species in xenografts, as detected by
densitometry of autoradiographs, with respect to that for actin as
a control. The percentage at each time point is the mean of six
tumours. mRNA expression for the same four species is shown
for the original MCF-7 cells and cells recultured from xenograft
tumours. Levels of c-myc (open squares) and p53 (solid dots)
mRNA reach a peak within 12 h and decline to prestimulation
levels by the second week. pS2 mRNA (solid squares) shows a
biphasic response, with a peak at 12 h, apparent suppression of
this peak to coincide with the peak serum oestradiol at 24 h and
then a further substantial rise and then gentle decline to pres¬
timulation values by the second week. In contrast to the other
three species, TGF-beta is slightly suppressed in the first 24 h and
peaks at day 7, returning gradually to prestimulation levels by
day 21 (open dots).
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by the irradiation. The serum oestrogen profile following a
single subcutaneous injection of oestradiol benzoate in
arachis oil (Figure 1) gave very high and possibly even
inhibitory serum levels of oestradiol between 12 and 36 h.
From day 2 to day 8, levels of oestradiol were within the
physiological range for non-pregnant premenopausal women
(110-1,630 pmol 1"', data from Baxter Health Care, New¬
bury, UK) and they remained sufficient to sustain oestrogen-
dependent tumour growth for 21 days. Serum oestradiol
levels in surgically oophorectomised nude mice which have
received the implantable pellet also fall within the same range
(Shafie & Grantham, 1981; Blumenthal et al., 1988). We have
no explanation for the intolerance of our experimental mice
to the implantable pellet, although the findings reported here
confirm our previous experience with this strain (M.E.F. and
C.M.S., unpublished data).
DNA synthesis and mitotic activity of the tumour cells was
evident in respone to oestradiol (Figure 2). The increase in
mitoses from a mean of 3 per x 400 field to 24 per field is in
keeping with observations in nude mice (5 and 25 mitoses per
x400 field respectively; Osborne et al., 1985). Similarly, des¬
pite possible influences on the thymidine pool by oestradiol,
thymidine uptake and the % S phase cells confirmed the
histological observation that, following oestrogen administra¬
tion, there was an increase in cell proliferation, which
preceded the increase in tumour volume.
The slight rise in oestrogen receptor protein following
oestrogen stimulation of the tumour, from 120fmolmg"'
protein to 240 fmolmg_l protein, and its subsequent return
to basal level is consistent with the view that oestrogen can
stimulate the synthesis of its own receptor.
mRNA species
The ntRNA species detected, particularly in the MCF-7 cells
in vitro, merit comparison with published data. Using the
oncogene probes to study the RNA from MCF-7 grown in
vitro, two distinct mRNAs of 1.8 and 3.0 kb were identified
hybridising to the c-erbB-2 probe, both smaller than the
single 4.8 kb mRNA species previously described (Semba et
al., 1985) and identified in breast tumours and normal
human tissues (data not shown). An amplified and rear¬
ranged epidermal growth factor receptor in epidermoid car¬
cinoma cells generating a Aruncated 2.8 kb mRNA that
encoded only the extracellular EGF binding domain has been
reported previously (Ullrich et al., 1984). Just as the c-erbB-2
gene may be rearranged in the MCF-7 cells studied, trun¬
cated transcription may occur. Certainly, alternative trans¬
cription mechanisms have been proposed for the c-erbB-2
gene (Tal et al., 1987).
It is well recognised that a single gene can give rise to a
variety of mRNA transcripts: the three p53 mRNA species of
circa 2.8 kb similar to the 2.8 kb mRNA in human breast
tumours (Thompson et al., 1990) may result from such
mechanisms as different transcription initiation sites,
differential splicing or other post-transcriptional modific¬
ation. Certainly, the mean size observed corresponds well to
published data for the human p53 mRNA (Zakut-Houri et
al., 1985; Harlow et al., 1985), and the additional 1.8 kb
mRNA identified is probably still large enough to encode a
53 kDa protein. The c-myc mRNA of 2.5 kb corresponds to
that previously reported in MCF-7 cells (Zajchowski et al.,
1988). The 2.5 kb mRNA for TGF-beta was of the expected
size (Derynck et al., 1985; Travers et al., 1988).
Although mRNA for the epidermal growth factor receptor,
and the mRNA for TGF-alpha, which acts upon it, have
been reported in MCF-7 cells (Dickson et al., 1986, Arteaga
et al., 1988), none was evident in the MCF-7 cell line tested
here, suggesting that the MCF-7 cells in use in our
laboratory may be variants of those used in some previous
studies.
OR3, the probe for oestrogen receptor mRNA detected
two messages of 3.0 and 1.7 kb, but no 6.2 kb mRNA. As in
this study, Henry et al. (1988) were unable to demonstrate
oestrogen receptor mRNA in the MCF-7 cell line using the
OR3 cDNA clone, but demonstrated hybridisation to a
6.2 kb mRNA using their radionucleotide labelled RNA
probe. While mRNA of 6.2 kb (Walter et al., 1985), 4.2 kb
(Pari et al., 1987) and 3.7 kb (Barrett-Lee et al., 1987) has
been reported in human tumour tissue and in the MCF-7 cell
line, the species identified here do not correspond to any of
these. It is therefore possible that the probe used did not
detect the oestrogen receptor mRNA (perhaps due to the
experimental conditions) or alternatively that the MCF-7
cells used in this study produce oestrogen receptor mRNA
smaller in size than that previously identified. However, the
translated oestrogen receptor protein was certainly present
when assayed by enzyme immunoassay.
The pS2 probe appears to cross-hybridise to the same 3 kb
and 1.7 kb mRNA as the OR3 probe but hybridises most
strongly to a small mRNA of about 600 base pairs (Figure
3), corresponding to the oestrogen induced mRNA of
Masiakowski et al. (1982). The biphasic change in pS2 sug¬
gests that the role of pS2 as a marker for oestrogen action
may not be as simple as originally proposed.
mRNA differences in vitro and in vivo
The original MCF-7 cells grown in vitro expressed several
mRNA species not evident in the xenografts or in cells of
these xenografts recultured for some time in vitro. These
findings may indicate in vivo selection for a subpopulation of
cells within the MCF7 culture.
The MCF-7 cells re-cultured from xenografts had an iden¬
tical pattern of gene expression to the xenografts and did
not, over an 8-week period, revert to the original MCF-7 cell
line pattern. Serious consideration was given to the pos¬
sibility that these findings could be due to a contaminant in
the original cell line (such as mycoplasma) expressing the
gene concerned or to contamination (perhaps by a plasmid)
at some point in the RNA extraction or electrophoresis. Both
these explanations are unlikely since tests on the MCF-7
culture (Barile, 1973) were persistently negative for myco¬
plasma, and no evidence of plasmid contamination was
found in these or any other northern-blot RNA studies.
Moreover, a range of different plasmids was used as vectors
for the cDNA probes.
mRNA changes following oestrogen stimulation
Oestrogen-induced stimulation of c-myc expression,
previously noted in breast cancer cells in vitro (Dubik et al.,
1987), was confirmed. The expression of c-myc and p53 at
elevated levels in the xenograft tumours in response to oest¬
rogen suggest that in vivo the expression of these two nuclear
genes may be involved in cell cycling (Kelly & Seibenlist,
1985; Lamb & Crawford, 1986). In vitro work (Brown et al.,
1984) identified an increase of pS2 mRNA in response to
oestrogen which was attributed to increased transcription.
The biphasic response of pS2 mRNA noted in this study may
reflect initial oestrogenic stimulus then, as the oestrogen
achieves a peak, inhibition of pS2 transcription, with subse¬
quent pS2 stimulation as the serum oestrogen returns to
more physiological levels.
Similarly, a decrease in TGF-beta transcription has been
noted in vitro in response to oestrogen treatment of MCF-7
cells (Dickson et al., 1986). Both these effects were noted in
vivo in response to oestrogen. In the present xenograft
system, TGF-beta transcription increased as the mitogenic
stimulus of oestrogen declined, compatible with the anti¬
proliferative effects noted on oestrogen receptor-positive
breast cancer cell lines in vitro (Kerr et al., 1989).
Clinical implications
Gene expression in the breast cancer cells, as detected by
mRNA analysis, obviously changes when cells cultured in
vitro grow as tumours in vivo. The physiological and clinical
significance of in vitro observations have on occasion been
controversial and may be difficult to interpret due to lack of
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host-related determinants that affect tumour behaviour in
vivo (Shafie & Grantham, 1981). Certainly, different effects
on cell kinetics have been observed using MCF-7 cells in vitro
compared to nude mouse xenografts (Brunner et al., 1989).
The model we describe here provides information com¬
plementary to that obtained from in vitro work and from
clinical studies, particularly in examining host-tumour cell
interactions and in determining the role of gene expression in
oestrogen-dependent breast tumour growth.
The MCF-7 xenografts in thymectomised and irradiated
CBA strain mice therefore present a useful model for examin¬
ing the in vivo behaviour of oestrogen-dependent breast
cancer and has considerable potential for the study of the
actions of therapeutic agents in vivo.
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